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ABSTRACT 
A Systems-Level Approach to Understand the Seasonal Factors of Early Development with 
Clinical and Pharmacological Applications 
 
Mary Regina Boland 
 
Major developmental defects occur in 100,000 to 200,000 children born each year in the United 
States of America. 97% of these defects are from unidentified causes. Many fetal outcomes (e.g., 
developmental defects), result from interactions between genetic and environmental factors. 
The lifetime effects from prenatal exposures with low impact (e.g., air pollution) are often 
understudied. Even when these exposures are studied, the focus is often placed on immediate 
effects of the exposure (e.g., fetal anomalies, miscarriage rates) leaving lifetime effects largely 
unexplored. This makes prolonged (or lifetime) effects of low-impact exposures an understudied 
research area. Included in this set of low-impact exposures is seasonal variance at birth.  
This thesis measures the effects of seasonal variance at birth on lifetime disease risk at both the 
population-level and molecular-levels. Four aims, comprising this thesis study, were conducted 
that utilize data from pharmacology, clinical care (Electronic Health Records) and genetics. 
These aims included: 1.) Development of an Algorithm to Reveal Diseases with a 
Prenatal/Perinatal Seasonality Component (described in chapter 2); 2.) Investigation of 
Climate Variables that Affect Lifetime Disease Risk By Altering Environmental Drivers 
(described in chapters 3 and 4); 3.) Discovery of Genes Involved in Birth Season – Disease 
Effects (described in chapter 5) and 4.) Investigation of Pharmacological Inhibitors As 
Phenocopies of the Birth Season – Disease Effect (described in chapters 6 and 7). Knowledge 
gained from these four areas, through seven distinct studies, establishes that birth season is a 
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Since antiquity (Hippocrates and Galen, 1952), the relationship between disease and birth 
seasonality was described, pondered and studied. The Ancient Egyptians, some 5,500 years ago, 
were known to apply different treatments for a given condition depending on the season of the 
year, which was noted by specially labeled treatment jars (Allen, 2005). Hippocrates wrote down 
and recorded tomes of health information from the Ancients. He described a connection between 
seasonality and disease nearly 2,500 years ago, “for knowing the changes of the seasons…how 
each of them takes place, he [the clinician] will be able to know beforehand what sort of a year is 
going to ensue…for with the seasons the digestive organs of men undergo a change” 
(Hippocrates and Adams, 460BCE).  
Not only was seasonality deemed of vital importance to the Ancients, but also climate factors – 
wind, water, air quality – were viewed as critical to human health. Hippocrates described the 
vital connection between climate factors and overall health and surgical outcomes. The position 
of cities was important because of the city’s exposure to these climate factors. He wrote “cities 
that are exposed to winds between the summer and the winter risings of the sun and … those 
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which lie to the rising of the sun are all likely to be more healthy than such as are turned to the 
North, or those exposed to the hot winds.” (Hippocrates and Galen, 1952) 
Childbirth and fertility were a main focus of Ancient medicine with fertility seasons being noted 
in many Ancient cultures. Traditionally, fertility seasons were often seen as ways to promote the 
survival of the offspring by planning the child’s birth in a mild season (thereby increasing the 
child’s chances for survival). In modern times, the effect of birth season on infant mortality is 
less pronounced except in some Northern European countries where season of conception is still 
associated with increased infant mortality (Melnikov et al., 2007). Conception during the 
summer months in Novosibirsk, Siberia was associated with increased adverse pregnancy 
outcomes (Melnikov et al., 2007). A June or July conception (the worst observed in their study) 
would result in a predicted birth month of February or March (i.e., the middle of the winter) 
(Melnikov et al., 2007). Also some African countries experience season-of-birth increases in 
infant mortality due to increases in infectious diseases that are driven by the season, including 
malaria and cholera (Becher et al., 2004). In those countries, being born during the rainy season 
was associated with increased risk of infant mortality (rate ratio of 1.21) (Becher et al., 2004).  
1.1 Literature Review 
1.1.1 Epidemiological Review 
Prenatal exposure to infectious disease is known to increase the risk of adverse fetal outcomes. 
The classic example is rubella exposure during pregnancy (Hill, 1965), which results in fetal loss 
and intellectual / communication problems in offspring born following prenatal rubella exposure 
(Hardy et al., 1969). A large study of a rubella outbreak in 1964 was conducted on prenatal 
exposure to rubella and the various outcomes of offspring (Sever et al., 1965). Surprisingly, they 
found that for first-trimester rubella exposure: 84.4% of conceptions were live-born healthy (519 
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/ 615), 7.2% (44 / 615) were lost during the prenatal period, 2.0% were born with a congenital 
rubella syndrome / malformation (12 / 615), and 6.5% were lost to follow-up (40 / 615) (Sever et 
al., 1965). The rubella outbreak and Sever et al. study was conducted prior to the legalization of 
abortion in the USA, which occurred in 1973. This explains why elective termination / induced 
abortion is not present in the statistics for rubella exposure. 
According to the Centers of Disease Prevention and Control (CDC), the current background rate 
of fetal loss during the prenatal period is 17% (CDC et al., 2012; Ventura et al., 2012). This is 
three times the reported rate of fetal loss experienced by the rubella-exposed mothers in 1964 as 
reported by Sever et al.. Currently, only 62.6% of conceptions are live-born healthy when all 
outcomes are accounted for including the 18.4% of conceptions that end in legal termination 
(CDC et al., 2012; Ventura et al., 2012). This is without any known prenatal exposures. 
Although with a known exposure (e.g., a pharmacological drug), the risk to the fetus can increase 
dramatically (Boland and Tatonetti, 2016a). 
Recently, the Zika virus has gained notoriety in the media. While not proven, there is some 
evidence to suggest that prenatal exposure to the Zika virus results in microcephaly in the 
offspring (Rasmussen et al., 2016). Some researchers believe that the detrimental effects of Zika 
virus on the offspring may be exacerbated by other confounder variables, e.g., nutrition. No prior 
outbreaks of Zika virus (in the Pacific Islands) were linked with microcephaly in prenatally 
exposed fetuses (Duffy et al., 2009; Ioos et al., 2014). This suggests that other factors may be 
behind the sudden increase in microcephaly in Zika exposed areas. Whatever the true cause of 
the rise in microcephaly, this recent outbreak does underscore the importance of prenatal 
exposures on fetal outcomes and the large variability that exists for a given exposure both among 
the women exposed and also their offspring. 
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Prenatal exposures resulting in immediate adverse outcomes that are easily observable at birth 
(e.g., microcephaly) are studied more often in the literature. However, exposures (even high-
impact exposures) with effects that occur much later in life are more difficult to study 
(Boekelheide et al., 2012). Sever et al. also noted that while 84.4% of rubella-exposed 
conceptions were live-born healthy, there was not sufficient time to study the long-term 
outcomes from prenatal rubella exposure (i.e., a baby may appear healthy at birth but may 
develop a disease later in life due to rubella exposure) (Sever et al., 1965). 
Several low-impact exposures have been linked with lifetime disease risk including arsenic and 
lead exposure in water. The immediate outcomes following prenatal exposure are easier to 
capture. The immediate effects following prenatal exposure to arsenic in water included an 
increased risk of spontaneous abortion (i.e., “miscarriage”), stillbirth and neonatal death (Milton 
et al., 2005). Others found that prenatal exposure to arsenic resulted in low birth size including 
reduced head size (i.e., “microcephaly”) and chest size (Rahman et al., 2009). However, while 
lifetime effects from prenatal exposure to arsenic may be difficult to quantify, the effects from 
general exposure on disease risk were easier for researchers to quantify. Arsenic exposure in 
drinking water has been linked to increased rates of various cancers, including lung, kidney, skin, 
bladder and liver cancers (Chiou et al., 1995; Hopenhayn-Rich et al., 1998). In Taiwan, 
researchers found a link between arsenic exposure and cardiovascular diseases (Navas-Acien et 
al., 2005) and mortality from ischemic heart disease (Chen et al., 1996). However, in other 
settings and locations the findings were less clear suggesting that the mechanism connecting 
arsenic exposure and cardiovascular disease may require further elucidation (Navas-Acien et al., 
2005). 
Another study found that both lead and arsenic exposure in drinking water could affect the 
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neurodevelopment of children (Calderón et al., 2001). They found that arsenic influenced verbal 
abilities and long-term memory functioning while lead exposure affects the attention processes 
(Calderón et al., 2001). Lead exposure was linked with neurological development in children in 
studies containing data from around the world (Lanphear et al., 2005). Additionally, a causal 
relationship has been identified between lead exposure and hypertension (Navas-Acien et al., 
2007). Hypertension is a common risk factor for severe cardiovascular disease. 
Clearly, infectious disease exposure along with exposures to heavy metals during the prenatal 
period can have a critical impact on fetal outcomes. Many of these factors (especially infectious 
diseases) vary seasonally, leading modern researchers to investigate the relationship between 
developmental seasonality (using birth month as a proxy) and disease risk. Several recent studies 
have linked birth month with neurological (Halldner et al., 2014; McGrath et al., 2010; Willer et 
al., 2005), reproductive (Huber et al., 2008; Huber and Fieder, 2009; 2011; Huber et al., 2004; 
Kemkes, 2010), endocrine (Kahn et al., 2009) and immune / inflammatory disorders (Disanto et 
al., 2012), and overall lifespan (Doblhammer and Vaupel, 2001). Each of these studies uses birth 
month as a proxy for birth season. 
Major radiation exposures – such as Chernobyl and Fukushima-Daiichi – are also studied using 
various climate models to accurately capture the spread of radioactive particles over large areas 
(Møller and Mousseau, 2006; Steinhauser et al., 2014). Most models incorporate wind speed and 
current, and precipitation patterns (Liu et al., 2001). Many of these climate factors are shown to 
be important when birth month  - disease patterns are compared across countries (chapter three 
of this dissertation) Correlating each birth month – disease pattern with some known climate 
factors (e.g., precipitation patterns) per region will allow for meaningful comparisons of results. 
This will reveal the underlying climate factor driving the birth month - disease association. 
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1.1.2 Genetics Review 
1.1.2.1 Learning from High-Impact Exposures: The Importance of Prenatal Regulation of 
Vitamins  
Birth season – disease relationships are thought to exist due to some seasonal change in climate 
or pollutant exposure, which thereby alters disease risk. The mechanisms underlying these 
relationships involve some ‘gene-environment’ relationship (Boland et al., 2013b; Boland and 
Tatonetti, 2016c; Burga and Lehner, 2012). The field of ‘epi-genetics’ focuses on elucidating 
genetic changes that occur due to environmental contaminants (Egger et al., 2004). Typically 
these changes take the form of DNA methylation changes, or histone modifications, which can 
be passed on to offspring (Egger et al., 2004). Some traditionally ‘genetic’ conditions, such as 
Down’s syndrome increased dramatically exactly nine months following the Chernobyl nuclear 
disaster (Scherb and Voigt, 2007). These increases were observed in Berlin, Germany and 
Belarus (Scherb and Voigt, 2007) indicating that some chromosomal instability conditions are 
related to radiation exposure.  
A look at several ‘high-impact’ prenatal exposures reveals a common theme of sex-ratio 
disturbances. Table 1 depicts a summary of well-studied exposures and their resulting fetal 
outcomes. A variety of exposures resulted in sex-ratio disturbances. Data from the Seveso 
Herbicide plant explosion demonstrated that fathers exposed to dioxin yielded more female 
offspring. Contrastingly, fathers exposed to radiation yielded less female offspring as 
demonstrated in Hiroshima, Nagasaki, and Chernobyl. The chronic sex disturbances observed in 
Europe (principally Northern Europe) are believed to be due to abnormalities in sperm 
production that were observed in wildlife in the surrounding region following the Chernobyl 
nuclear disaster. Barn swallows were found to have abnormal sperm with observed reductions in 
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vitamins A and E (Møller et al., 2005). Increased blood oxidation levels of lipids were observed 
in Chernobyl children with rates higher in girls then in boys (Ben-Amotz et al., 1998).  Beta-
Carotene (pro-vitamin A) supplementation lowered these oxidation levels in the Chernobyl 
children leading researchers to conclude that irradiation increases lipids’ susceptibility to 
oxidation and that Beta-Carotene supplementation may act as a lipophilic antioxidant or 
radioprotector (Ben-Amotz et al., 1998). 
Vitamin supplementation can potentially mitigate many adverse effects following exposure to 
catastrophic events (Table 1). Many vitamins have been linked to prenatal outcomes. A lack of 
folate (vitamin B9) during prenatal development has been causally linked to spina bifida and 
neural tube defects in the fetus. Increased folic acid (the synthetic form of vitamin B9) 
supplementation in pregnant women resulted in a reduction in neural tube defects outcomes in 
offspring (Czeizel and Dudas, 1992). Furthermore, folate is known to vary seasonally in humans 
as observed in Gambia, and China (Bates et al., 1994; Hao et al., 2003). Therefore, variance in 
prenatal exposure to various critical vitamins (e.g., folate) resulting from seasonal changes may 
be responsible for some birth season – disease effects.  
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Table 1. Summary of High-Impact Prenatal Exposures And Their Effects On Offspring 
Disaster Name, Location, Date Adverse Fetal Outcomes  
Immediate Prolonged Refs. 
Hiroshima and Nagasaki, Japan, 
Aug. 6 and 9, 1945 
 
Neurological damage:  
• Severe neurological impairment and / 
or lowering of intelligence 
• Risk: 7 - 26 weeks after fertilization 
Microcephaly: 
• Risk: 0-18 weeks after fertilization  
Sperm Effect:  
• Irradiated fathers yield less 
female offspring  
Egg Effect (?): 
• Irradiated mothers yield less male 
offspring  
(Green, 1968; Otake et 
al., 1988; Scherb and 
Voigt, 2007; Schull et 
al., 1988; Yamazaki 
and Schull, 1990) 
Agent Orange and United States 
Service Men and Women Serving in 
Vietnam Area, 1960-1968  
 
None  
• No Pregnancies Reported During 
Vietnam Deployment 
Male or Female Exposure:  
• Spina Bifida 
Female Service in Vietnam (not tied to any 





(VA, 2015a; b) 
Seveso Herbicide Plant Explosion, 
Italy, July 10 1972 
 
Spontaneous Abortions: 
• 67.7% increase 
Chloracne  
• Present in children (not a prenatal 
effect)  
Sperm Effect:  
• Fathers exposed to TCDD or 
dioxin yielded more female 
offspring  
(Clapp and Ozonoff, 
2000; Hay, 1977; 
Mocarelli et al., 1996; 
Mocarelli et al., 2000) 








• Excess loss of 400 male fetuses – 
Czech Republic exposed during end 




• Peaked in Germany (Berlin) and 
Belarus, 9 months afterwards  
Sex Ratio Disturbances: 
• Throughout Northern Europe 
Thyroid cancer:  
• Increased 
Barn Swallows:  
• Experienced abnormal sperm and 
reductions in Vitamins A and E  
(Jacob et al., 1998; 
Møller and Mousseau, 
2006; Møller et al., 
2005; Peterka et al., 
2004; Scherb and 
Voigt, 2007)  
Fukushima-Daiichi Nuclear 
Disaster, Japan, March 16, 2011 
Fetal Loss / Anomalies: 
• No Observed Change  
To Early To Determine (Fujimori et al., 2014) 
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1.1.2.2 Understanding the Evolutionary Gradient for Genes that Regulate Seasonally 
Varying Biofactors 
Evolutionary gradients involved in seasonally varying processes have been described in many 
species including birds (Porlier et al., 2009), insects (Hoffmann and Weeks, 2007), snails 
(Trussell and Etter, 2001) and various plant species (Etterson et al., 2016; Kay and Sargent, 
2009). In some species, these changes have been tied to latitude as well (Schemske et al., 2009). 
Climate variation has been shown to drive evolution in human genes generally speaking (i.e., 
without the seasonal aspect) (Piazza et al., 1981). The specific climate-driver involved varies by 
species. For example, in snails an evolutionary gradient was observed in genes that corresponded 
to snails adaption to water temperature (Trussell and Etter, 2001).  
Two types of evolutionary gradients are described in the literature based on the direction of the 
change: co-gradient variation (co-vary in the same direction) and counter-gradient variation 
(co-vary in opposing directions) (Trussell and Etter, 2001). The importance of both co-gradient 
variation and counter-gradient variation depends on the particular climate variable of interest. 
These types of variation can enable insights into populations of patients at increased risk for an 
adverse prenatal outcome through perturbation of a seasonal mechanism. 
1.2 Problem Statement  
Developmental defects occur in 100,000 to 200,000 children born each year in the United States 
of America. 97% of these defects are from unidentified causes. These causes are believed to be 
due to unidentified prenatal/perinatal environmental exposures. Many outcomes (e.g., 
developmental defects), result from interactions between genetic and environmental factors. The 
literature describes a wide-variety of prenatal / perinatal environmental factors and the resulting 
outcomes on the offspring. However, previous research focuses heavily on high-impact 
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catastrophic events. These catastrophic events include the Hiroshima and Nagasaki explosions 
and subsequent radiation exposure, and more recent events such as the Fukushima-Daiichi 
nuclear disaster. However, the lifetime effects from prenatal exposures with low impact (e.g., 
lead paint) are often understudied. Even when these lower impact exposures are studied, the 
focus is often placed on immediate effects of the exposure (e.g., fetal anomalies, miscarriage 
rates) leaving lifetime effects largely unexplored. Thus, making prolonged (or lifetime) effects of 
low-impact exposures an understudied research area. Included in this set of low-impact 
exposures is seasonal variance at birth. A body of literature exists focusing on seasonal 
exposures at birth and conception and the effects that these seasonal birth exposures can have on 
risk for diverse diseases including asthma, attention deficit hyperactivity disorder (ADHD) and 
various reproductive conditions among others. The studies comprising this dissertation assert 
that the effect of seasonal variance at birth on lifetime disease risk is an under-studied 
research area (literature gap) that is worthy of systematic investigation on both population-
level and mechanistic-levels. 
1.3 Purpose of the Study  
The purpose of this study is to systematically explore the relationship between seasonal 
exposures at birth (perinatal) and during the gestational period (prenatal) and their disease-
related effects later in life. As previously stated, the bulk of prior research focuses on 
environmental effects from high-impact exposures, such as Hiroshima and Nagasaki. When 
research on low-impact exposures is conducted, it is typically focused on immediate effects such 
as miscarriage rates and fetal anomalies.  Seasonal variance at birth (a type of low-impact 
exposure) and the effect on lifetime disease risk (a prolonged outcome) is an understudied 
research area.  
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A systems-level approach is needed to understand the seasonal factors driving the relationship 
between season and lifetime disease risk. Important information can be gleaned from genes 
involved in evolutionary gradients based on geographic location. These genes have been dictated 
by evolution as being important in the climate-survival relationship and therefore are likely to be 
important for key seasonally dependent factors (e.g., Vitamin D). 
A conceptual schema detailing the relationship between different factors that affect prenatal / 
perinatal outcomes following exposures is shown in Figure 1. Certain genetic variants exist in 
evolutionary gradients that are based on the geographic locations of the inhabitants. Information 
on these genes and the proteins perturbed by these genetic variants along with the immediate 
prenatal outcomes that result (e.g., miscarriage rates, fetal anomalies) could be utilized to help 
understand the birth season – lifetime disease risk effects that are observed at the 
epidemiological level. This is represented in Figure 1 by the orange in-direct relationship arrow 
that connects the gene’s evolutionary gradient and related associations between season and 
disease (i.e., prolonged adverse effect). 
The goal of this dissertation work is to develop a systems-level approach to understand the 
seasonal factors of early development with clinical and pharmacological applications. My overall 
approach is informatics-driven while harnessing methods from Earth Science, Pharmacology, 
Genetics, and Epidemiology when appropriate. 
1.4 Research Questions and Hypotheses   
This research consists of three main research questions with their associated hypotheses. The 
questions are as follows: 
Q1: Does a patient’s birth month (as a lower-level proxy for season) affect their lifetime disease 
risk? If so, what types of diseases (i.e., disease categories) correspond with each season? 
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• H1: Undetected developmental birth defects occurring during the prenatal / perinatal 
period can manifest themselves later in life as chronic diseases 
Q2: What biologically important factors (i.e., biofactors) vary seasonally in humans? Of the 
known seasonally varying biofactors, which biofactors are expressed during the prenatal period? 
Which of those biofactors are potential modulators of birth season – disease effects? 
• H2: Seasonally varying factors (e.g., vitamin D, folate) during the prenatal period can 
affect development 
Q3: Can birth month be used as a proxy for undetected environmental exposures that affect 
disease risk? How do these effects vary by climate, region, and country? Are the seasonally 
varying factors (e.g., low sunlight) correlated with the disease risk experienced at each 
site/climate/region/country? 
• H3: Birth month is a proxy for undetected environmental exposures that affect personal 
disease risk later in life. These effects are also tied to the climate at birth; therefore being 
born in October in New York City is very different from being born in Taiwan in 
October. However, the disease-associated mechanism (e.g., low vitamin D at birth and 
adjustment disorders) should be generalizable across countries even if the specific month 
when vitamin D is low varies by country. This holds if and only if the variance in the 
exposure truly confers disease susceptibility. 
To address these questions, this dissertation focuses on four aims. Table 2 lists each aim, its 





Table 2. Dissertation Aims, Corresponding Studies, and Chapter Reference Information  
Aim  Description Ch. Ref. 
Section I: Population-Level Insights 
1 Develop an Algorithm to Reveal Diseases with a 
Prenatal/Perinatal Seasonality Component 
  
 • Season-Wide Association Study (SeaWAS) 
algorithm development and results from 
Columbia University Medical Center  
2 (Boland et al., 
2015b) 
 • Validation of novel cardiovascular disease – 
birth month associations from SeaWAS at Mt 
Sinai Medical Center 
2 (Li et al., 2016) 
2 Investigate How Climate Variables Can Affect Lifetime 
Disease Risk By Altering Environmental Drivers 
  
 • Large-scale exploration of Climate-Hospital 
Performance Effects Using Medicare’s 
Hospital Compare Dataset (over 4,700 
hospitals from 15 climates) 
4 (Boland et al., 
2017b) 
 • Multi-Site / Multi-Country SeaWAS to Find 
Environmental Drivers Correlated With Birth 
Month Associations 
3 (Boland et al., 
2015a; Boland 
et al., 2017c) 
Section II: Mechanistic Insights 
3 Uncover Genes Involved in Birth Season – Disease 
Effects 
  
 • Construct Month-of-Birth (MOB) – Gene Map 5 (Boland and 
Tatonetti, 
2016c) 
4 Use Pharmacological Inhibitors As Phenocopies of the 
Birth Season – Disease Effect 
  
 • Systematic exploration of a gene – DHCR7– 
under evolutionary pressure due to geographic 
location reveals that pharmacological inhibition 
results in adverse effects in similar body 
systems, but much more severe, to those 






 • Assess whether pharmacological inhibition of 
identified genes results in adverse outcomes 




1.5 Significance  
“On relatively small evidence we might decide to restrict the use of a drug for early-morning 
sickness in pregnant women. If we are wrong in deducing causation from association no great 
harm will be done. The good lady and the pharmaceutical industry will doubtless survive….but 
we should need very strong evidence before we made [make] people burn a fuel in their homes 
that they do not like or stop smoking the cigarettes and eating the fats and sugar that they do 
like.” -Hill 1965 
Figure 1. A Conceptual Schema Detailing The Relationship Between Different 
Factors that Affect Prenatal / Perinatal Exposures Outcomes. This Knowledge 
Is Integrated In The Studies Comprising This Dissertation To Inform Our 
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In 1965, Dr. Hill outlined several important steps in determining whether an association was 
causal or not (Hill, 1965). He also noted an important facet of causality in epidemiology – to 
error on the side of increased safety to mothers and their offspring. This is of vital 
importance and remains a hallmark to this day. My dissertation seeks to embrace this approach 
and error on the side of increased safety to mothers and their children while learning as much as 
possible about the birth season  - disease effect to provide insights into the scale of the issues, 
and the severity of the risk faced by exposed children. 
Major developmental defects occur in 100,000 to 200,000 children born each year in the United 
States of America (USA). However, a much larger concern in the USA remains the children 
afflicted with learning disabilities such as Attention Deficit Hyperactivity Disorder (ADHD). 
The number of those afflicted with ADHD continues to grow. Estimates from the Department of 
Education (DOE) report that 6.4 million children and youth ages 3-21 received special education 
services representing 13% of all public school students nationally (NCES, 2016). This represents 
a massive public health issue. In aim one, ADHD was found to be associated with fall birth 
(November was the peak risk month) in NYC. If this study can identify shed light on the 
mechanisms behind the ADHD – season of birth issue this could be of great importance to the 
DOE and funding agencies. 
Asthma is another common disease of childhood. In 2014, asthma was responsible for 439,435 
inpatient hospital discharges (CDC, 2016). Among children under the age of 18, 8.6% are 
afflicted with asthma (CDC, 2016). This makes asthma another major public health problem for 
children. Asthma was found to be linked with season of birth in aim one, which was validated in 
the literature by a study published in 1983 in Denmark (Korsgaard and Dahl, 1983). The climate 
driver was peak sunshine exposure, which was related to high temperature and humidity. High 
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temperature and humidity provide an ideal breeding ground for microscopic dust mites. 
Exposure to these dust mites during the first few months of birth (i.e., perinatal / post-natal 
exposure) increases the likelihood that the child will develop dust mite allergies later in life. This 
also contributes to an increased risk of asthma. Aim two seeks to understand this relationship 
more deeply by uncovering how disease risk for asthma varies across various sites throughout 
the world.  
Asthma is primarily a disease of the poor - 10.4% of children below the poverty level were 
afflicted with asthma vs. 6.3% of those in the richest group (i.e., 450% of poverty level or 
higher) (CDC, 2016).  Finding and identifying the key drivers behind the birth season – asthma 
relationship will be tremendously helpful to this traditionally underserved population. 
Additionally, this dissertation seeks to understand not only the drivers of these diseases at the 
epidemiological level, but also at the genetic level to uncover the mechanistic reasons for these 
occurrences (e.g., dust mite prevalence, air pollution, sunshine exposure). This will lend critical 
insights into additional genetic risk factors that may play a role in increasing an individual’s risk 
for an adverse effect of birth season.  
1.6 Contributions  
This dissertation as a whole asserts that the effect of seasonal variance at birth on lifetime disease 
risk is an under-studied research area (literature gap) that is worthy of systematic investigation 
on both epidemiology and genetic levels. The first two aims seek to identify the diseases with 
birth season/month relationships and the climate drivers (e.g., sunlight, rainfall) responsible for 
the increased disease risk. These aims focus on providing deep knowledge on the relationship 
between birth month and disease risk.  
The last two aims focus on uncovering the mechanistic drivers of the birth month – disease 
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relationship. This includes identifying the genes involved in seasonally varying compounds that 
are important in the birth month disease relationship. Further it seeks to find subsets of the 
population at increased risk for adverse effects of birth season by investigating genetic variants 
among hypertension patients. Knowledge can also be gleaned from pharmacological inhibitors of 
genes and can be used as phenocopies of the birth month  - disease relationship. This is 
especially important for genes known to be involved in an evolutionary gradient tied with 
climate or geographic region. 
This dissertation utilizes a two-pronged approach (epidemiological and mechanistic) to provide a 
‘deep’ understanding into the prolonged outcomes following prenatal/perinatal seasonal 
exposure. Prior to this research, a literature gap existed for low-impact exposures (such as 
season) and prolonged outcomes (i.e., lifetime disease susceptibility). Seasonal variance during 
the prenatal and perinatal period represents an important low-impact exposure that is currently 
understudied. This dissertation addresses this particular type of low-impact exposure. 
Several important steps were outlined by Dr. Hill regarding determining if an association is 
causal or not (Hill, 1965). These nine criteria became known as the Hill’s criteria for causality. 
The different aims in this study address different criteria outlined by Hill. Figure 2 illustrates the 
literature gap that exists in the epidemiology literature (Figure 2A) and how each aim addresses 
a different set of Hill criteria (Figure 2B). 
This dissertation contributes a thorough in-depth analysis of seasonal factors that affect fetal 
outcomes upon prenatal or perinatal exposure. Each aim focuses on a different set of Hill’s 
Criteria to identify the factors that are causal in the birth season – disease relationship. By 
applying this systematic approach, spurious factors will also be identified that cannot be directly 
tied to a biological mechanism. This allows us to tease out mechanisms that are related to true 
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birth season effects from spurious effects. This delineation is useful both to other researchers 
interested in studying prenatal epi-genetic mechanisms and other outcomes following prenatal 
exposures.  
1.7 Overall Limitations  
There are several limitations to this dissertation as a whole. Aims one and two (chapters 2-4) rely 
heavily on data derived from Electronic Health Records (EHRs), which were not collected for 
research purposes but rather for billing. While a rich data source, there are many biases that exist 
within EHR data. Data completeness is often an issue, as many patients will have diseases, 
medications and surgeries that are not recorded in the EHR because those procedures, diagnoses, 
and so forth were made at another facility. Therefore, patients that are listed as not having a 
particular diagnosis may in fact have that diagnosis. By testing SeaWAS at multiple sites, many 
of these biases are minimized. Additionally, Hospital Compare data is used in chapter 4 to assess 
the relationship between climate and various hospital performance metrics. This contributes 
valuable information that is free from some of the aforementioned biases. 
Figure 2. State of the Literature Regarding Environmental Exposures and Their 
Adverse Outcomes Following Fetal Exposure (Figure 2A) and An Illustration Depicting 








































Aims three and four (chapters 5–7) utilize existing data from PubMed and DisGeNET on disease 
– gene associations and also seasonally varying biofactors in humans. A lot of this information is 
incomplete, and represents the various disease selection and publication biases endemic in the 
scientific community. Many genes are poorly understood and studied with effects that are 
completely unknown. Additionally, this dissertation focuses on genes that are expressed during 
development – as annotated by the Gene Ontology. The annotations in the Gene Ontology are 
also incomplete and this affects the results slightly. Additionally, the fetal-maternal barrier 
warrants further investigation as the placenta is known to be susceptible to environmental effects 
(Nelissen et al., 2011). Incorporating knowledge on the epigenetics of the placenta could help 
with understanding the underlying disease mechanism (Nelissen et al., 2011). For the purposes of 
this dissertation, I focus on population-level insights gleaned from EHR-data and Hospital 
Compare data. I couple this with mechanistic insights gleaned from pharmacological data and 
genetics. However, placenta gene information is not specifically investigated and represents 



























Development of an Algorithm for 
Conducting Birth Season-Wide 
Association Studies (SeaWAS)  
 
2.1 Abstract 
An individual’s birth month has a significant impact on the diseases they develop during their 
lifetime. Previous studies reveal relationships between birth month and several diseases 
including atherothrombosis, asthma, attention deficit hyperactivity disorder, and myopia, leaving 
most diseases completely unexplored. This retrospective population study systematically 
explores the relationship between seasonal affects at birth and lifetime disease risk for 1,688 
conditions. I developed a hypothesis-free method that minimizes publication and disease 
selection biases by systematically investigating disease-birth month patterns across all 
conditions. The initial dataset includes 1,749,400 individuals with records at New York-
Presbyterian/Columbia University Medical Center born between 1900-2000 inclusive while the 
external replication site - Mount Sinai Hospital - included 1,169,599 patients. I modeled 
associations between birth month and 1,688 diseases using logistic regression. Significance was 
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tested using a chi-squared test with multiplicity correction. I found 55 diseases that were 
significantly dependent on birth month. Of these 19 were previously reported in the literature 
(p<0.001), 20 were for conditions with close relationships to those reported, and 16 were 
previously unreported. Distinct incidence patterns across disease categories were observed. 
Individuals born in birth months with higher cardiovascular disease incidence (February-June) 
were also associated with decreased life expectancy in the literature corroborating the findings. 
Neurological diseases, pregnancy conditions and asthma associations revealed by my method 
were validated by European studies in the literature. Novel cardiovascular conditions associated 
with birth month were validated externally using Mount Sinai Hospital data. Overall, individuals 
born in May and July had the lowest overall disease risk. Lifetime disease risk is affected by 
birth month and seasonally dependent early developmental mechanisms may play a role in 
increasing lifetime risk of disease. 
2.2 Introduction 
The recent adoption of Electronic Health Records (EHRs) allows meaningful use (Jha, 2010) of 
data recorded during the clinical encounter for high-throughput or ‘phenome-wide’ exploratory 
analyses (Boland and Tatonetti, 2015; Denny et al., 2010; Jensen et al., 2012; Roque et al., 2011; 
Shah, 2013). Using EHR data requires overcoming problems with definition discrepancies 
(Boland et al., 2013b), data sparseness, data quality (Weiskopf and Weng, 2013), bias (Hripcsak 
et al., 2011), healthcare process effects (Hripcsak and Albers, 2013) and privacy issues 
(Loukides et al., 2010). Informatics methods can overcome these challenges, for instance: 
standardized ontologies minimize definition discrepancies (Elkin et al., 2006), concordance 
measured across integrated datasets allows for data sparseness and quality assessment (Weiskopf 
and Weng, 2013), and statistical methods can minimize bias and healthcare process effects 
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(Dickersin, 1990; Hripcsak et al., 2007; Stern and Simes, 1997). Using informatics approaches, 
EHR discovery methods (Jensen et al., 2012) were developed with successful applications in 
diverse areas including: dentistry (Boland et al., 2013a), genetics (Crawford et al., 2014; Denny 
et al., 2010; Kohane, 2011), and pharmacovigilance (Haerian et al., 2012; Wang et al., 2009). 
Novel disease association patterns (Doshi-Velez et al., 2014; Holmes et al., 2011), drug-drug 
interactions (Tatonetti et al., 2012) and seasonal dependencies (Cohen et al., 2014; Melamed et 
al., 2014; Randolph, 2014) have also been established using EHRs. 
Previous birth month – disease studies investigated the relationship between one single disease 
and birth month. They did not employ high-throughput or ‘phenome-wide’ approaches (Denny et 
al., 2010). In many studies, birth month was used as a lower-level proxy for season. However, 
some studies used the season variables themselves converting the month-day attributes to a birth 
season variable (Pantazatos, 2014), or in some cases binning months (e.g., Jan-Mar = winter). 
The most common statistical method used by prior studies was chi-square analysis (35.8%, 
19/53) followed closely by regression. However, the countries conducting these studies were 
more diverse. Only 26.4% of studies were conducted in the United States of America (i.e., 
14/53). These statistics are presented in Table 3. Countries with only one study were not 
included in Table 3. When grouped together, Northern European countries in general (e.g., 
Germany, Denmark, Ukraine, Sweden) were responsible for 15 studies or 28.3% of the sample – 
greater than any other region in the world. 
Methods that were seldomly used include Cosinor analysis, and various forms of temporal 
analysis including time series spectral analysis and Knox clustering (Kulldorff and Hjalmars, 
1999). The prior methods focused on already established birth month – disease relationships and 
the developed models were tailored to those specific diseases using additional model parameters. 
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The researchers sought to tease out some of the nuances within their datasets to establish what 
drivers were important in the birth month – disease mechanism.  
Table 3. Statistics for Birth Month Studies Methods and Locations: Prior to SeaWAS 




Location Number of Studies 
At Given Location 
(N=53 studies) 
Chi-square 19 USA 14 
Regression 14 Sweden 5 
ANOVA 6 Australia 3 
Ratios 4 Japan 3 
Binomial p 1 Israel 2 
Cosinor analysis 1 Spanish Language 2 
Temporal Analysis:  
     Knox clustering 1 Turkey 2 
     Time series using 
spectral analysis 1 United Kingdom 2 
 
Unlike prior methods that focused on one disease at a time, SeaWAS is a high-throughput 
method that explores all diseases’ potential association with birth month at a given location. 
SeaWAS investigates all diseases without preselecting certain “interesting” diseases to be robust 
to disease selection bias (i.e., only studying ‘popular’ diseases) and publication biases 
(Dickersin, 1990; Easterbrook et al., 1991; Stern and Simes, 1997; Vawdrey and Hripcsak, 
2013).  
This dissertation focuses on data-driven approaches that seek to learn birth month – disease 
relationships from the data in a ‘phenome-wide’ manner across a wide-variety of diverse 
diseases (Denny et al., 2010). In this study, I developed a high-throughput, hypothesis-free 
algorithm that mines for disease-birth month associations across millions of records. The 
approach is called SeaWAS: Season-Wide Association Study as it finds all conditions associated 
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with birth month. I show that SeaWAS detects diseases with seasonal components related to 
early development. The novel cardiovascular disease findings were then validated at a separate 
EHR in NYC (same city, demographics and climate). 
2.3 Methods 
2.3.1 Population 
I used Columbia University Medical Center (CUMC)’s health record data, previously converted 
to the standardized Common Data Model (CDM) developed by the Observational Medical 
Outcomes Partnership (now the Observational Health Data Sciences and Informatics, OHDSI) 
(Overhage et al., 2012). CUMC data was initially recorded using International Classification of 
Diseases, version 9 (ICD-9) codes. These ICD-9 codes were mapped to Systemized 
Nomenclature for Medicine-Clinical Terms (SNOMED-CT) codes according to the CDM v.4 
(Overhage et al., 2012). SNOMED-CT captures more clinical content then ICD-9 codes 
(Campbell and Payne, 1994) making it ideal for phenotype classification. Additionally, using a 
standardized CDM increases the portability of the method across institutions enhancing data 
sharing (Margolis et al., 2014).  
All individuals were extracted if they were born between 1900-2000 inclusive (N=1,749,400 
individuals) and were treated at CUMC (between 1985-2013), demographics given in Table 4. 
The median age of the population was 38 years (interquartile range IQR: 22, 58). I performed a 
fisher-exact test between the birth month distributions for each sex vs. the average birth month 
distribution. Likewise the birth month distributions by birth decade (e.g., 1900-1909, 1990-1999) 
were compared to the overall average birth month distribution. No statistically significant 
differences were found (p=1 for all comparisons). Therefore, yearly and sex-based variation in 
the birth month distribution is minimal and should not affect the analyses. 
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Monthly birth rate data for CUMC was consistent with known New York City (NYC) births 
using data from the Centers of Disease and Control (CDC) for 1990-2000 inclusive (CDC, 
2014b). CUMC data were highly correlated with CDC birth rates from Bronx (r=0.833, 
p=0.001), New York (r=0.796, p= 0.002) and Queens (r=0.791, p=0.002) counties. I performed 
this verification check because confirming the place of birth for individuals can be complex 
(Duncan et al., 2014), and was not possible for the CUMC dataset. Subsequently, for the 1990-
2000 period I was able to obtain data regarding the number of babies admitted to CUMC on the 
day of their birth for the 1990-2000 period and found that the proportion (no. of patients 
admitted to CUMC on their day of birth / no. of patients included in SeaWAS) ranged from 
17.97%-31.28% by birth year with the average proportion being 22.98%. CUMC’s Institutional 
Review Board approved this study. 
2.3.2 Algorithm 
My method investigated associations with birth month across all recorded conditions. A 
condition was defined as any SNOMED-CT code mapped using the CDM (Overhage et al., 
2012). For controls, individuals were randomly sampled from the same EHR population without 
the disease ensuring that the control sample size was 10 times the size of the case population. 
The association between birth month (as an integer) and each condition was modeled using 
logistic regression with significance assessed using chi-square (R v.3.1.0). Therefore, the 
monthly birth rate was compared between the case and control populations for each condition 
adjusting for monthly birth month variation effects. For multiplicity correction, only conditions 
passing the Benjamini-Hochberg adjustment that controls for the false discovery rate (FDR) were 
selected (Benjamini and Hochberg, 1995). To ensure sufficient sample size across all 12 months, 
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only conditions having at least 1000 individuals born between 1900-2000 inclusive were 
included in the study (i.e., 1,688 distinct conditions). 
To evaluate SeaWAS, all articles from PubMed with the term “birth month” were extracted 
along with an additional article referenced by a located article (N=156). I manually reviewed all 
abstracts and removed articles related to non-humans (N=8), breeding (N=7), sports (N=10), or 
where birth month was used for another purpose, e.g., for matching controls (N=34), 
perspective/meta-analysis papers (N=2), papers not available in English (N=2), and one paper 
with a statistical error noted in PubMed. This process identified 92 relevant articles. I then 
manually classified each paper by the disease studied and whether they found or failed to find an 
association. Some conditions associated with birth month in the literature, e.g., height, were not 
extractable from the EHR (36 diseases were not extractable). In total, 19 diseases reported in the 
literature could be mapped to EHR conditions. Of those diseases, 16 were positively associated 
(>50% of literature supported an association) and 3 were not associated (<=50% of literature 
failed to find an association). I extracted all relevant EHR codes for each of the 16 positive 
associations (N=172 codes). These literature associations were used for quality assessment of 
SeaWAS results. 
I used the following internal evaluation technique to evaluate novel associations discovered by 
SeaWAS. I ran the SeaWAS algorithm on a restricted sample comprising 80% of the original 
sample, randomly chosen. Results were corrected for multiplicity using the Benjamini-Hochberg 
adjustment that controls the FDR. I took all novel associations (i.e., not reported in the literature) 
revealed in the restricted sample, and then validated them using the validation set (containing 
20% of the original population). 12 of the 16 discovered associations were validated in this 
manner.  
 28 
Permutation analysis was also used for empirical evaluation of SeaWAS. My algorithm 
randomly selected 55 diagnosis codes from the set of 1,688 codes included in the study. The 
algorithm then set all codes in this randomly derived set as ‘positive’ associations. Next, the 
number of positive literature results in each random sample was measured. This was done for 
1,000 random samples. The overall distribution of these random samples was compared to 
SeaWAS results. This allowed for the assessment of the true positive rate (TPR), false positive 
rate (FPR), positive predictive value (PPV) and the total number of confirmed literature 
associations obtained from SeaWAS.  
For all significant associations, my algorithm calculated the proportion of individuals having the 
condition using their birth month and day out of all individuals with the same birth month and 
day. This generated a set of proportions for every day in the year (366 days). My algorithm then 
used a 2-month window (Kahn et al., 2009) to smooth the daily proportion rate (1 month before 
the date and one month after the date). The weekly and monthly averages were then computed. 
An overview of the algorithm is shown in Figure 3. 
All SeaWAS results were compared to the literature in a binary manner to ascertain if the 
association was previously reported. Afterwards, the disease-birth month risk plots from the 
literature were analyzed. I used three criteria to select studies, namely: 1) published raw data; 2) 
raw data includes some adjustment for natural variation in birth month depending on study 
region; and 3) disease-birth month data were at a similar granularity level to allow for effective 
comparisons (e.g., this criterion would exclude studies that grouped multiple diseases together or 
removed certain disease subtypes). I sought to include pattern data for at least one study per 
disease category to compare with SeaWAS.  
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Table 4. Demographics of Patients Included in SeaWAS: CUMC and Mt Sinai 
Demographic CUMC N (%), 
N=1,749,400 
Mt Sinai M (%),  
M=1,169,599 
Sex 1   
   Female 956,465 (54.67%) 678,717 (58.03%) 
   Male 791,534 (45.25%) 490,600 (41.95%) 
   Other/Unidentified 1,401 (0.08%) 282 (0.02%) 
Race   
   White 665,366 (38.03%) 424,803 (36.32%) 
   Other 1 456,185 (26.08%) 165,423 (14.14%) 
   Unidentified / Unknown 386, 533 (22.10%) 256,819 (21.96%) 
   Black 189,123 (10.81%) 166,950 (14.27%) 
   Declined 29,747 (1.70%) NA 
   Asian 20,746 (1.19%) 45,596 (3.90%) 
   Native American / Indian 1,511 (0.09%) 2,447 (0.21%) 
   Pacific Islander 189 (0.01%) 1,094 (0.09%) 
   Hispanic / Latino NA 106,467 (9.10%) 
Ethnicity   
   Non-Hispanic 590,386 (33.75%) 761,535 (65.11%) 
   Unidentified 458,071 (26.18%) 208,899 (17.86%) 
   Hispanic 361,123 (20.64%) 199,165 (17.03%) 
   Declined 339,820 (19.42%) NA 
Other Attributes  Median (1st, 3rd 
Quartile) 
Total SNOMED-CT codes per patient 6 (1, 32) 7 (3, 22) 
Distinct SNOMED-CT codes per patient 3 (1,8) 5 (2, 10) 
Age (year of service – year of birth) 38 (22, 58) 53* (36, 66) 
Treatment Year Range 1985-2013 1979 - 2015 
1 Other (includes Hispanics not otherwise identified) 
* Computed in days, age in years  = age in days / 365.25 
 
2.3.3 Mount Sinai Replication Methods 
To perform a proper replication study, the original SeaWAS study was followed as closely as 
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possible (Boland et al., 2015b). EHR data was obtained from Mount Sinai Hospital (MSH) 
located in NYC. Both CUMC and MSH are urban medical centers located in NYC and were 
expected to be subject to similar climate conditions (Boland and Tatonetti, 2016c). EHR data at 
MSH is represented using a different schema and data model than was used in the original 
SeaWAS study at CUMC. Therefore the locally obtained International Classification of 
Diseases, version 9 (ICD-9) codes used at MSH were mapped to the Systemized Nomenclature 
for Medicine-Clinical Terms (SNOMED-CT) using the mapping table from the CDM v.4 
(Overhage et al., 2012). Approval for this study was obtained from the Institutional Review 
Board at MSH. 
All individuals born between 1926 and 2000 inclusive (1,169,599 patients) who were treated at 
MSH (between 1979 - 2015) were included in this replication study, demographics given in 
Table 4. The median age of the MSH population was 53 years (interquartile range, IQR: 36-66), 
which skews older than the original CUMC population (median=38 years, IQR: 22-58). Race 
and ethnicity demographics are represented slightly differently between the MSH and CUMC 
datasets. Overall sex, race, and ethnicity distributions did not differ significantly between the two 
institutions (p > 0.05, Table 4).  
The CUMC-only SeaWAS study found novel cardiovascular condition-birth month associations 
(Boland et al., 2015b), therefore this was the focus of the MSH replication. Also at both 
institutions (CUMC and MSH) essential hypertension (associated with birth month at CUMC) 
was the most prevalent disease, signifying the clinical importance of this association. Therefore, 
only circulatory system conditions (as defined using the ICD-9 codes) that were present in both 
the MSH and CUMC datasets (i.e., having at least 1000 patients at both MSH and CUMC) were 
selected. This represented a set of 108 conditions. 
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In the MSH replication, the SeaWAS algorithm was modified slightly from the public domain 
(code available here: https://github.com/maryreginaboland/SeaWAS) to fit the database schema 
of MSH. First a phenome-wide exploration of all birth month – disease associations for 
conditions with at least 1000 patients (1433 conditions) was performed. I employed the 
Benjamini-Hochberg method to correct for multiple hypotheses and control for the false 
discovery rate (FDR) (Benjamini and Hochberg, 1995) similar to the original study. 
Next, I performed a post-hoc analysis, using Pearson’s correlation, to compare the birth month - 
disease risk curves between the two institutions (CUMC, MSH). I assessed statistical 
significance by comparing the actual correlation between the two institutions to an empirically 
derived null distribution. My algorithm generated empirical null distributions for each condition 
by randomizing the birth month–disease risk curve from MSH. It then computed the Pearson 
correlation for the random curve and CUMC’s birth month-disease risk curve. This procedure 
was repeated 1000 times producing 1000 random correlation results. The empirically derived p-
value was determined as the proportion of random correlations greater than the actual correlation 
between true MSH data and true CUMC data divided by 1000. If this value is zero then the p-
value is reported as “p < 0.001.” 
To place the findings in the context of biological mechanisms deemed important in birth month 
associations, I obtained peak flu season data obtained from the Centers for Disease Prevention 
and Control (CDC) data on flu activity from 1982-83 through 2013-14 (CDC, 2014a). I also 





Figure 3. Schematic Overview of Season-Wide Association Study Method. SeaWAS was 
performed using the Common Data Warehouse (CDW) at Columbia University Medical 
Center (CUMC). 1,688 conditions had at least 1000 patients and were tested for possible birth 
month associations. Logistic regression was performed to assess the relationship between 
birth month (modeled as a numeric variable) and disease. 55 conditions were associated with 
birth month after false discovery rate correction. Results were compared to relevant PubMed 












































































































2.3.4 Analysis of Potential Confounders in Cardiovascular – Birth Month Findings 
My algorithm revealed a novel relationship between cardiovascular diseases and birth month. 
Since this finding was novel, I decided to investigate the relationship between the cardiovascular 
disease – birth month relationship and other known demographic confounders, including 
ethnicity and income (Cooper, 2001). Therefore, I analyzed the ‘Essential Hypertension’ (the 
most common cardiovascular disease - birth month association) in greater depth. Specifically I 
investigated the relationship between ethnicity and income and the birth month – disease 
relationship. Patients were separated into ‘Poor’ and ‘Rich’ using the IRS 2012 zip code income 
information (IRS, 2015). Patients were classified as being ‘Poor’ if the most popular income 
bracket for their zip code was the lowest IRS income bracket ($1 - $25,000) and patients were 
classified as being ‘Rich’ if the most popular income bracket was the highest reported ($200,000 
or more) for their zip code.  
2.4 Results 
2.4.1 EHR mining of 1,688 conditions reveals 55 conditions dependent on birth month 
I used SeaWAS to mine birth month associations for 1,688 SNOMED-CT conditions with at 
least 1,000 individuals recorded at CUMC. After multiplicity correction using FDR (α=0.05, 
N=1688 conditions), 55 conditions were found associated with birth month. All reported p-
values are FDR adjusted (q-values). 
2.4.2 Literature validation of SeaWAS results 
Using the curated reference set of 16 conditions (that mapped to 172 SNOMED-CT codes), I 
found 19 SeaWAS results (7 distinct diseases) were supported by the literature, representing a 
significant enrichment with OR=3.4 (95% CI: 1.9-6.0, p<0.0001). SeaWAS successfully ruled-
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out associations between birth month and disease risk for all ‘true negatives’ in the reference set. 
The algorithm compared SeaWAS results for known and closely related diseases to help 
elucidate gaps in the literature. Some diseases, e.g., reproductive performance, featured 
prominently in both the literature and SeaWAS results, whereas, other diseases featured heavily 
in the literature but not as strongly in my results, e.g., asthma/allergy and rhinitis. A potential 
literature gap exists for respiratory syncytial virus (2 publications, Figure 4), which had many 
SeaWAS known or highly related associations (8 total associations). A Manhattan plot visualizes 
results by disease category showing that some categories including, circulatory, and respiratory 
diseases appear prominently in the results.  
The algorithm found 20 conditions associated with birth month that were similar to those in the 
reference set and 16 that were completely novel (Table 5). Nine of these 16 associations were 
cardiovascular conditions including: atrial fibrillation (p<0.001), essential hypertension 
(p<0.001), congestive cardiac failure (p<0.001), angina (p=0.001), cardiac complications of care 
(p=0.027), mitral valve disorder (p=0.024), pre-infarction syndrome (p=0.036), cardiomyopathy 
(p=0.009), and chronic myocardial ischemia (p=0.022). Seven discovered associations were non-
cardiovascular: primary malignant neoplasm of prostate, malignant neoplasm of overlapping 
lesion of bronchus and lung, acute upper respiratory infection, non-venomous insect bite, 
venereal disease screening, bruising and vomiting. 
2.4.3 Internal evaluation of discovered associations 
All novel associations found using SeaWAS were internally validated. The SeaWAS algorithm 
was run on a dataset containing an 80% restricted sample and then validated using the novel 
associations in the validation set (20% original sample size). 12 of the 16 novel associations were 
validated including 6 out of 9 novel cardiovascular conditions. Table 5 denotes the discovered 
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conditions that passed the internal validation. Four conditions were not significant after 
correction in the restricted sample including: mitral valve disorder, pre-infarction syndrome, 
chronic myocardial ischemia, and vomiting.  
2.4.4 Evaluation using permutation analysis 
The algorithm uses permutation analysis to assess the concordance between SeaWAS results and 
what was reported in the literature.  It randomly selects 55 codes from the set of 1,688 codes 
included in the study and set them as ‘positives’. The algorithm then measured the number of 
positive literature results in random samples and compared to SeaWAS. This was run for 1,000 
random samples. SeaWAS consistently and significantly (p < 0.001) outperformed random for 
TPR, FPR, and PPV at finding more literature validated associations.  
2.4.5 SeaWAS replicates established birth month trends: Asthma, Reproductive 
Performance and ADHD 
I calculated smoothed birth month proportions for all 55 SeaWAS birth month associations. I 
then compared conditions with known associations to birth month and their published trends. 
The smoothed weekly and monthly proportions are shown in Figure 5 for three established 
associations: asthma, ADHD and reproductive performance and three discovered associations: 
atrial fibrillation, mitral valve disorder and chronic myocardial ischemia. To compare results 
with the published proportions from other studies, I used an asthma study from Denmark 
(Korsgaard and Dahl, 1983), reproductive performance study from Austria (Huber et al., 2004) 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. SeaWAS Results Show Enrichments for Literature Associations. Figure 4a 
shows the breakdown of SeaWAS results by number of publications demonstrating a 
relationship. Figure 4b shows the number of SeaWAS associations known to be related to 
disease from the literature (solid black), and those that are closely related to known diseases 
(curvy lines). Figure 4c depicts all birth month-disease associations in a Manhattan plot 
organized by their respective ICD-9 disease categories (x axis). A significant SeaWAS 
association is a disease-birth month association remaining significant after FDR adjustment. 
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Table 5. Birth Month-Disease Associations Discovered Using SeaWAS (N=16) 








Birth Month Risk 
 Validation?  High Low 
Cardiovascular (N=9)       
Atrial fibrillation 48961 Yes <0.001 
 
Mar Oct 
Essential hypertension 269913 Yes <0.001 
 
Jan Oct 
Congestive cardiac failure 61448 Yes <0.001 
 
Mar Oct 
Angina 20741 Yes <0.001 
 
Apr Sept 
Cardiac complications of 
care 
13653 Yes 0.027 
 
Apr Sept 
Cardiomyopathy 17873 Yes 0.009 
 
Jan Sept 





10010 No 0.022 
 
Apr Nov 
Mitral valve disorder 22966 No 0.024 
 
Mar Nov 
Other (N=7)       
Acute upper respiratory 
infection 
112487 Yes <0.001 
 
Oct May 
Bruising 8904 Yes 0.015 
 
Dec Apr 
Nonvenomous insect bite 7435 Yes 0.001 
 
Oct Feb 




neoplasm of prostate 
20353 Yes 0.002 
 
Mar Oct 
Malignant neoplasm of 
overlapping lesion of 
bronchus and lung 
2714 Yes 0.014 
 
Feb Nov 
Vomiting 30495 No 0.029 
 
Sept Jan 






















































































































































































































































































































Comparing results with Denmark’s asthma study (Korsgaard and Dahl, 1983) showed highly 
similar seasonal patterns. They found two large peaks in May and August, with two smaller 
peaks in June and July (Korsgaard and Dahl, 1983). My results were shifted by 2-months with 
large peaks in July and October and smaller peaks in August and September. I extracted data on 
the average monthly sunshine exposure for NYC and Denmark (2014a; 2014b) for comparison 
(Figure 5). For reproductive performance, I compared the results to an Austrian study (Huber et 
al., 2004) (Figure 5). I validated a dip in births among females born in May through September 
as this was also found in the Austrian study. I compared the ADHD smoothed proportions to 
odds ratios reported by a Swedish study and found a similar upward trend towards the later part 
of the year peaking in November (Halldner et al., 2014) (Figure 5).  
I sought to include at least one seasonality comparison for each disease category (N=7) of known 
associations to those found by SeaWAS. This includes: allergy/asthma/rhinitis, reproductive 
performance, ADHD, eye conditions/problems, respiratory syncytial virus, otitis media and 
colitis. Literature studies on eye conditions/problems failed the three criteria for inclusion as data 
was presented at different disease granularity levels (e.g., mild myopia was excluded) preventing 
effective comparisons. I found data for conditions in the three remaining categories, otitis media, 
colitis and respiratory syncytial virus (data not shown). I found many similarities among these 
data, but the exact mechanistic relationship between these conditions and birth seasonality 
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Figure 5. Birth Month Distribution Plots for Three Literature Validated SeaWAS 
Results and Three Discovered SeaWAS Associations. I selected 3 well-known literature 
associations: asthma, ADHD and reproductive performance to compare with SeaWAS birth 
month trends. I compared my results to findings published in articles for each of these 
diseases: 1) asthma data from a Denmark study by Korsgaard et al. 1983 (Korsgaard and 
Dahl, 1983); 2) reproductive performance data from an Austrian study by Huber et al. 2004 
(Huber et al., 2004), which I compared to Full-Term Normal Delivery (i.e., general birth 
code); and 3) ADHD data from a Swedish study by Halldner et al. 2014 (Halldner et al., 
2014). To facilitate comparison between asthma studies from different locales, I used data on 
the average monthly sunshine exposure for New York, USA and Skagen, Denmark obtained 
from World Weather and Climate Information (2014a; 2014b). I also found three interesting 
new associations: atrial fibrillation, mitral valve disorder and chronic myocardial ischemia.  
 
 40 
2.4.6 Discovered Associations: Cardiovascular Conditions and Birth Month 
My algorithm found 16 birth month – disease associations with no prior literature, I highlight 
three of these in Figure 5, including: atrial fibrillation, mitral valve disorder and chronic 
myocardial ischemia. For illustration purposes, I selected cardiovascular conditions whose 
pattern of association between birth month and disease risk differs. Mitral valve disorder 
demonstrates a clear bimodal seasonal pattern with a major disease risk peak among those born 
in March and a second smaller disease risk peak for those born in August. Whereas, risk for 
atrial fibrillation is unimodal and peaks among those born in March with a trough between 
September and November.  
2.4.7 Patterns of birth-month dependencies cluster by disease type 
Of nine discovered cardiovascular associations, six had high-risk birth months in March or April 
suggesting that high-risk birth months may cluster by disease category. I examined the disease 
category-birth month relationship and found that individuals born in March were at increased 
risk for cardiovascular diseases, but they had greater protection against respiratory illnesses and 
neurological conditions. Contrastingly, individuals born in October were at increased risk for 
respiratory conditions with increased protection against developing cardiovascular conditions. 
Overall, some months, namely May and July, had zero at risk diseases.  
2.4.8 Cardiovascular Disease Risk-Birth Month And Lifespan-Birth Month 
I compared the cardiovascular disease findings (N=10) from SeaWAS to published data relating 
overall lifespan and birth month (Doblhammer and Vaupel, 2001), see Figure 6. Months with 
lower cardiovascular disease risk corresponded with months having longer life expectancies 
from Doblhammer et al.’s previous study (Doblhammer and Vaupel, 2001). Six of the 10 
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cardiovascular conditions were significantly anti-correlated with life-expectancy data. The 
strongest anti-correlation was cardiac complications of care (Denmark: r=-0.815, p=0.001; 
Austria: r=-0.863, p<0.001); followed by chronic myocardial ischemia  (Denmark: r=-0.810, 
p=0.001; Austria: r=-0.826, p<0.001); pre-infarction syndrome (Denmark: r=-0.712, p=0.009; 
Austria: r=-0.918, p<0.001); coronary arteriosclerosis (Denmark: r=-0.617, p=0.030; Austria: r=-
0.773, p=0.003); atrial fibrillation (Denmark: r=-0.615, p=0.033; Austria: r=-0.763, p=0.004); 
and angina (Denmark: r=-0.611, p=0.035; Austria: r=-0.771, p=0.003).  
2.4.9 Cardiovascular Result Replication at Mount Sinai Hospital 
In addition to validating known birth month disease relationships, SeaWAS revealed nine 
circulatory system conditions were associated with birth month. Specifically winter births (Jan-
Mar) were related to increased risk of developing circulatory system conditions later in life. 
Because this finding was novel, I sought to validate the findings externally using another EHR 
system also in New York City (NYC). In this way, I was able to test if the relationship between 
circulatory system conditions and birth month held when exposed to the same climate and 
seasonal factors. 
I performed pattern analysis of the birth month – disease risk curves for the circulatory system 
conditions between MSH and CUMC (set of 108 conditions). This was done to ascertain whether 
or not the birth month – disease relationship was the same between the two institutions. Seven of 
nine CUMC findings had significantly similar patterns at MSH (Figure 7, Table 6). In Figure 7, 
I show the seasonal risk patterns at birth obtained from MSH and CUMC for all nine circulatory 
system conditions. Four of these nine circulatory system conditions were also significant at the 
phenome-wide level at MSH. Two associations, congestive cardiac failure and mitral valve 
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Figure 6. SeaWAS Cardiovascular Condition-Birth Month Proportions Correlate with 
Published Lifespan-Birth Month Results from Doblhammer et al. 2001. All 10 (9 novel) 
cardiovascular disease-birth month associations found by SeaWAS were compared to 
Doblhammer et al.’s lifespan-birth month dependencies for Denmark and Austria (Doblhammer 
and Vaupel, 2001). The lifespan-birth month associations are shown in Figure 6a. Six of the ten 
were anti-correlated (i.e., months with low cardiovascular disease risk were also months with 
longer life expectancies from Doblhammer et al.’s study (Doblhammer and Vaupel, 2001). The 
top three anti-correlated cardiovascular diseases are shown in Figure 6b, cardiac complications 
of care (Denmark: r=-0.815, p=0.001; Austria: r=-0.863, p<0.001); chronic myocardial 
ischemia  (Denmark: r=-0.810, p=0.001; Austria: r=-0.826, p<0.001); and pre-infarction 
syndrome (Denmark: r=-0.712, p=0.009; Austria: r=-0.918, p<0.001). In Figure 6b, ** denotes 






Figure 7. Cardiovascular Condition Risk vs. Birth Month Results from CUMC and MSH. 
Figure 7A shows results from all nine cardiovascular conditions from both MSH (red line) and 
CUMC (blue line).  Seven of nine cardiovascular conditions were correlated at a statistically 
significant level with MSH data (i.e., the birth month – condition patterns were correlated) using 
Pearson’s correlation. A significant pattern across the two institutions indicates that the birth 
month – condition relationship is the same. Figure 7B shows the most correlated result between 
MSH and CUMC was coronary arteriosclerosis (r=0.83, p<0.001). Figure 7C shows the 
comparison with the peak flu season month using CDC data on flu activity from 1982-83 through 
2013-14 (URL: http://www.cdc.gov/flu/about/season/flu-season.htm). Serum vitamin D levels 




I overlaid data on seasonal variation in vitamin D levels and flu diagnosis levels to identify 
trends that could imply a biological rationale for observed cardiovascular – birth month 
association patterns. Figure 7D shows the seasonal variation in vitamin D levels (Meier et al., 
2004) along with the birth month – coronary arteriosclerosis risk curves from MSH and CUMC. 
Low vitamin D months correspond to high coronary arteriosclerosis risk birth months (Figure 
7B). In Figure 7C, I also included data from the CDC (http://www.cdc.gov/flu/about/season/flu-
season.htm) containing the number of times each month was the peak month for a given flu 
season. This data was aggregated from 1982-83 through 2013-14 (CDC, 2014a). 
2.4.10 Investigating Other Potential Confounders in Cardiovascular – Birth Month 
Findings 
The relationship between birth month and cardiovascular disease was assessed in several 
stratified populations for ‘Essential hypertension’ – the most common cardiovascular disease 
(Figure 8). Two common ethnicities – White and Black– were compared. I found that blacks had 
a slightly higher proportion of hypertension, but the overall birth month – hypertension curve 
was the same. For income status, I found the poor population to be at greater risk of hypertension 
overall then the rich population. The rich population was much smaller in size (a little over 11 
thousand with hypertension), and the birth month – disease risk curve showed greatly variability. 
The overall trend for hypertension – birth month was similar across the sexes (female and male). 
In general, the trends for hypertension– birth month were the same across the stratified 
populations shown (Figure 8). 
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Table 6. Replication Results for Circulatory System Conditions Between MSH and CUMC: Phenome-Wide P-values 









MSH CUMC MSH CUMC Pearson 
Corr. 




P* P * P** 
Atrial fibrillation Symptom 11 2 9 3 1.050 1.056 0.226 2.1X10-10 0.007 
Coronary 
arteriosclerosis 
Disease 9 1 9 4 1.070 1.039 2.46X10-15 3.1X10-8 <0.001 
Essential 
hypertension 
Symptom 10 1 9 1 1.029 1.020 0.003 1.3X10-5 0.005 
Congestive 
cardiac failure 
State 11 8 9 1 1.042 1.030 0.760 2.2X10-4 0.222 
Angina Symptom 9 1 9 4 1.091 1.070 0.002 6.5X10-4 0.003 





11 2 9 4 1.069 1.084 0.834 0.022 0.031 
Mitral valve 
disorder 
Disease 9 7 12 3 1.057 1.063 0.562 0.024 0.445 
Pre-infarction 
syndrome 
Symptom 9 1 10 6 1.058 1.051 0.022 0.036 0.036 
* Phenome-Wide P-value, FDR adjusted (1688 conditions for CUMC, 1433 for Mt. Sinai) 
** Empirically Derived P-value Using Random Permutations of Mt Sinai’s birth month distribution 






















































































































































































Figure 8. SeaWAS Hypertension-Birth Month Proportions By Ethnicity, Income and 
Sex. ‘Essential hypertension’ – birth month curves show the same trends across rich and poor 
and white and black populations. Males and females also showed similar trends. Larger 
differences were observed between rich and poor income groups then black and white 
ethnicities. However, the overall trends were the same indicating greater risk for hypertension 
in the winter months (Dec-Mar) and lower risk in the fall months (Sept-Nov). The blue line 




While the first ‘SeaWAS’ (SeaWAS: Season-Wide Association Study) study of its kind (Boland 
et al., 2015b), it was not the first study to investigate the role of climate on human health. The 
relationship between climate and climate factors on human health and disease is well known and 
studied (Dell et al., 2012; 2013; Epstein, 1999; Pöschl, 2005). Informatics researchers previously 
overlaid geospatial air quality data with human disease patterns to learn relationships between air 
quality and disease (Marinoni et al., 2015). 
Many diseases demonstrate birth month dependencies with known mechanistic etiologies, 
including: asthma (Korsgaard and Dahl, 1983), ADHD (Halldner et al., 2014), reproductive 
performance (Huber et al., 2004), and myopia (Mandel et al., 2008). In these studies birth month 
was used as a proxy for seasonal variations in physiological state or changes in environmental 
exposures. Understanding dependencies between diseases and these variations is an important 
and challenging research task. My novel algorithm, SeaWAS uses a hypothesis-free method that 
does not relying on a priori hypotheses and makes use of large-scale population-level data 
obtained via EHRs. 
2.5.1 SeaWAS Confirms Known Disease-Birth Month Associations 
SeaWAS confirmed a literature-validated association between asthma (hyper-reactive airway 
disease) and birth month reported by studies from Denmark (Korsgaard and Dahl, 1983) and 
Sweden (Åberg, 1989). When I compared my findings to the Denmark study, I found a two-
month shift in the birth month-asthma pattern that corresponds with a shift in the peak sunshine 
(a factor in asthma complicated by dust mite allergies) between Denmark and NYC (2014a; 
2014b).  
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Likewise, comparing the reproductive performance results to an Austrian study (Huber et al., 
2004) revealed that the dip in births among females born in May through September was 
observed in both studies (Huber et al., 2004). Importantly, the female reproductive system, 
unlike males, is established early with females being born with their lifetime maximum number 
of oocytes (Baker, 1963; Morita and Tilly, 1999). Oocyte count is thought to be linked to fertility 
(Tilly et al., 2009). Many studies show a link between maternal birth month and number of 
offspring supporting the belief that prenatal and early developmental effects can alter female’s 
lifetime fertility (Huber et al., 2008; Huber and Fieder, 2009; 2011; Huber et al., 2004; Kemkes, 
2010). SeaWAS findings bolster this body of literature. 
I compared the ADHD results to those reported by a Swedish study and found a similar upward 
trend towards the later part of the year peaking in November (Halldner et al., 2014). The 
rationale for their findings that they reported was that relative age/immaturity (born later in the 
year) may result in increased ADHD detection (Halldner et al., 2014). This occurs because more 
immature children (i.e., younger in age) face higher demands early on in their school years 
making them more susceptible to ADHD diagnosis. The age cutoff for schools in Sweden is 
December 31st, which is the same for NYC public schools. Another alternative explanation is 
that the relationship between Vitamin D and ADHD and learning patterns has been established in 
rats (Becker et al., 2005; Burne et al., 2004) and Vitamin D deficiency in early development (in 
utero or shortly after birth) could be related to ADHD. 
2.5.2 Discovered Cardiac Condition-Birth Month Relationship 
SeaWAS revealed nine cardiovascular conditions associated with birth month. In the literature 
there are reports of a connection between perinatal flu exposure and increased risk of 
cardiovascular diseases later in life. Most notably, a study on children born to survivors of the 
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H1N1 1918 subtype who were associated with a >20% excess risk of cardiovascular disease 
(Mazumder et al., 2010). They also investigated the maternal malnutrition hypothesis and found 
that the maternal infection and cardiovascular disease risk relationship was independent of 
maternal malnutrition (Mazumder et al., 2010). Therefore, maternal infection during the winter 
months (Jan-Mar) could contribute to the increased cardiovascular disease risk among children 
born in those months that I observed in NYC. 
Looking at all ten (nine novel) cardiovascular conditions revealed that individuals born in the 
autumn (September-December) were protected against cardiovascular conditions while those 
born in the winter (January-March) and spring (April-June) were associated with increased 
cardiovascular disease risk. Interestingly, a study found that people born in the autumn (October-
December) lived longer than those born in the spring (April-June) (Doblhammer and Vaupel, 
2001). Furthermore the relationship between cardiovascular disease risk and lifespan is 
established (Stamler et al., 1999). I compared the results to the Doblhammer et al. study 
investigating lifespan’s dependency on birth month and found six cardiovascular diseases were 
significantly anti-correlated. This indicates that birth months with low risk for six cardiovascular 
diseases were also associated with longer lifespan in Doblhammer’s study (Doblhammer and 
Vaupel, 2001) (Figure 6). The findings suggest that the relationship between lifespan and birth 
month (Doblhammer and Vaupel, 2001) could possibly be explained by increased cardiovascular 
disease risk.  
The relationship between cardiovascular disease and birth month could be mediated through a 
developmental Vitamin D-related pathway. Serum 25-hydroxyvitamin D levels are lower and 
parathyroid hormone levels are higher during the winter when no supplementation is given 
(Dawson-Hughes et al., 1991).  Even with maternal supplementation, seasonally dependent 
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Vitamin D deficiency has been observed among breastfed infants (Halicioglu et al., 2012) and 
newborns (Lee et al., 2007). This is important because levels of parathyroid hormone and 
Vitamin D are associated with cardiovascular disease (Lee et al., 2008; Wang et al., 2008). 
Specifically elevated parathyroid hormone is correlated with increased heart failure in elderly 
males (Wannamethee et al., 2014). Studies focusing on adolescents found that Vitamin D 
deficiency resulted in an increased likelihood of hypertension (a SeaWAS discovered 
association) (Kumar et al., 2009; Reis et al., 2009) and high-density lipoprotein cholesterol 
(Kumar et al., 2009), both risk factors for cardiovascular disease. 
2.5.3 Replicating Novel Cardiovascular Disease – Birth Month Relationships at Mount 
Sinai Hospital 
Coronary arteriosclerosis, essential hypertension, angina and pre-infarction syndrome were all 
significantly associated with birth month at the phenome-wide level at both MSH (after adjusting 
for 1433 tests) and CUMC (after adjusting for 1688 tests). Their seasonal patterns were also 
significantly correlated (Table 6, Figure 7) supporting the connection between these conditions 
and birth month. While the patterns were highly correlated, in some instances the birth month 
with the max Relative Risk (RR) differed between the two institutions. For example, angina and 
coronary arteriosclerosis both experienced maximum RR’s in April using CUMC data versus 
January for the MSH data. However, the patterns for both of these conditions were highly 
correlated (coronary arteriosclerosis, r = 0.830; angina, r = 0.715). This underscores the 
importance of analyzing the entire pattern (Figure 7) versus merely selecting maximum or 
minimum birth months to avoid misleading results.  
Three conditions, atrial fibrillation, cardiomyopathy, and chronic myocardial ischemia, were 
significantly correlated between CUMC and MSH but were not significantly associated with 
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birth month at the phenome-wide level at MSH. These conditions could be associated with birth 
month through their common comorbidities, namely essential hypertension, angina, coronary 
arteriosclerosis and pre-infarction syndrome (Benjamin et al., 1998). However, it could also be 
the effect of sample size between the two institutions and the effects of stringent phenome-wide 
p-value adjustment. Many of these conditions had lower maximum RRs at MSH. For example, 
chronic myocardial ischemia had a maximum RR of 1.069 (0.973, 1.174) at MSH vs. 1.084 
(1.011, 1.162) at CUMC. The significant correlation of the patterns between the two institutions 
supports the hypothesis of an underlying birth month effect for these conditions. 
There are several additional reasons why results from CUMC and MSH may differ. Firstly, many 
of these circulatory system conditions are comorbid with one another (e.g., atrial fibrillation 
often occurs with other conditions such as essential hypertension) (Benjamin et al., 1998). 
Conditions that replicated across institutions were ‘core’ heart conditions, such as essential 
hypertension, that often occur in the presence of other cardiac ailments (Blair et al., 1996). These 
conditions may actually be driving the disease risk – birth month association. If this is the case, 
then they remain significant across institutions (provided the climate is the same). While both 
hospitals are located in NYC, they may serve patients with different socioeconomic 
demographics. These differences could play a role in the accessibility of certain healthcare 
options. Importantly, in spite of these issues, seven of nine CUMC circulatory system findings 
had statistically significant patterns at MSH. 
2.5.4 Proposed Biological Mechanisms Underlying Cardiovascular Disease – Birth Month 
Relationships  
Several mechanisms have been proposed previously that could explain the relationship between 
cardiovascular conditions and birth month, first described in (Boland et al., 2015b). Vitamin D 
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deficiency is known to increase cardiovascular disease risk, this is especially true for patients 
who already have essential hypertension (Lee et al., 2008). Furthermore, vitamin D levels have 
been shown to vary seasonally in women (Meier et al., 2004). Vitamin D levels in babies also 
depends on maternal vitamin D (Lee et al., 2007).  Another hypothesis to explain cardiovascular 
– birth month relationships is maternal flu infection. Researchers found that children born to 
survivors of the H1N1 1918 subtype had a >20% excess risk of cardiovascular disease later in 
life (Mazumder et al., 2010). Maternal infection tends to be higher in the winter months (January 
– March) therefore this could contribute to increased risk among children born in those months.  
Figure 7 shows that low vitamin D months correspond to high coronary arteriosclerosis risk 
birth months. However when vitamin D is low (Figure 7D), the risk for flu infection is also high 
(Figure 7C). It is unclear which mechanism (maternal flu infection and vitamin D) is potentially 
responsible for the birth month association. It could also be a combination of both mechanisms. 
Flu infection is high during the birth months with the highest risk, but vitamin D levels are also 
at their lowest during this same period (Figure 7C, 7D). Also vitamin D plays a role in immune 
response (Cantorna et al., 2004; Mora et al., 2008), which could indicate that peak flu season and 
low vitamin D occur together for a mechanistic reason (and are not independent of each other). 
My work confirmed a link between cardiovascular conditions and birth month across two 
institutions – MSH and CUMC – in the same climate (NYC) (Boland et al., 2015b). This 
supports the hypothesis that a biological mechanism tied to climate and seasonality could explain 
this increase in disease risk.  
Birth months that were high in serum vitamin D (Jul-Oct.) appeared ideal for lower coronary 
arteriosclerosis risk. Additionally, birth months with a high flu burden (Jan – Mar.) were high-
risk birth months for coronary arteriosclerosis. This does not indicate that being born in flu 
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season causes coronary arteriosclerosis later in life nor does it indicate that being born in a high 
vitamin D season lowers risk of coronary arteriosclerosis. These findings merely show support 
for proposed biological mechanisms, which require further validation from biologists, including 
more systematic examination in chapter 3 of this dissertation.  
2.6 Limitations  
Study limitations include the lack of condition independence (conditions rarely occur in 
isolation) potentially affecting multiplicity correction. Also, the algorithm cannot rule out 
indirect mechanisms (e.g., depression affects fertility, and learning ability) behind associations 
between disease risk and birth month. Some conditions associated with birth month may be 
associated because the infant was born in a high-risk period, e.g., acute bronchiolitis-autumn 
births. These associations differ from lifetime disease effects, however this algorithm does not 
distinguish between them because both are presented in the literature as birth month-disease 
associations (chapter three does address some of this effect). Another limitation is the exclusive 
use of EHR data, which is affected by the healthcare process (Hripcsak and Albers, 2013) and 
can introduce bias (Hripcsak et al., 2011), e.g., sick patients tend to be over-represented in EHR 
populations (Weiskopf et al., 2013). The potential affect of this bias is minimized in my findings 
because the birth month by year data at CUMC correlated with CDC data on individuals born in 
NYC counties. This indicates that CUMC’s EHR population adequately represents the ‘true’ 
NYC-born population (which includes healthy people) with respect to birth month.  
An issue with this version of the SeaWAS algorithm is that birth month is modeled as a 
numerical variable and not an ordinal variable. This can result in an over-estimation of the p-
value for birth month – disease relationships with certain non-linear shapes. This would result in 
those shapes being determined as not dependent on birth month when in fact there is a non-linear 
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dependency. Therefore, there might be more than 55 conditions associated with birth month at 
NYC then those found by this initial SeaWAS algorithm. Importantly, another algorithm 
presented in chapter three of this dissertation, correlates specific exposures with birth month – 
disease risk dependencies curves. Therefore the algorithm in chapter three is not affected by this 
numerical modeling of birth month issue. 
2.7 Conclusion 
This work presents my high-throughput algorithm called SeaWAS that uncovers conditions 
associated with birth month without relying on a priori hypotheses. SeaWAS confirms many 
known connections between birth month and disease including: reproductive performance, 
ADHD, asthma, colitis, eye conditions, otitis media (ear infection) and respiratory syncytial 
virus. The algorithm revealed 16 associations with birth month that have never been explicitly 
studied previously. Nine of these associations were related to cardiovascular conditions 
strengthening the link between cardiac conditions, early development, and Vitamin D. 
Seasonally-dependent early developmental mechanisms might play a role in increasing lifetime 
disease risk. 
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Birth month and climate are known to impact lifetime disease risk while the underlying 
exposures remain largely elusive. The purpose of this study is to uncover distal causal risk 
factors underlying birth month – disease relationships. This global birth month – disease study 
includes data from ten and a half million individuals from six sites, three countries, and four 
distinct climates to probe the relationship between exposure variance across sites and disease risk 
variance by birth season. My method couples Electronic Health Records (EHRs) with the 
seasonality of climate factors, pollutants, and influenza-like illness to uncover the most 
informative birth season exposures. Correlations are performed between each birth month - 
disease risk curve and a host of identified exposures at each study site. A meta-analysis of these 
correlations determines the most significant birth month – exposure relationships across all six-
study sites. The algorithm adjusts for multiplicity using Bonferroni’s method to select only the 
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most robust relationships. My method also successfully distinguishes relative age effects (a 
cultural effect) from environmental exposures. The only identified relative age association was 
Attention Deficit Hyperactivity Disorder. First trimester exposure to carbon monoxide was 
linked with increased risk of depressive disorder. I also found first trimester exposure to fine air 
particulates increased atrial fibrillation risk. Decreased exposure to sunlight during the third 
trimester increased the risk of type 2 diabetes mellitus. Global study of birth month – disease 
relationships reveals distal causal risk factors underlying these relationships. Important 
biological hypotheses can be formed only when the distal factors have been identified. 
3.2 Introduction 
Seasonality and climate together play an important role in human health and disease, which has 
been studied for millennia (Hippocrates and Galen, 1952). Geographic location alone alters the 
exposure to many diverse environmental exposures (Jarup, 2004). Variance in these exposures is 
important in understanding differences in disease risk among populations. Prenatal or perinatal 
exposure to many environmental variables has been tied with increased disease risk later in life. 
This includes climate factors such as reduced sunlight (Waldie et al., 2000) and high humidity 
(Crowther, 1985). Flu, or influenza-like illness (ILI) exposure during pregnancy is also tied to 
increased disease risk in offspring (Bánhidy et al., 2005). Furthermore, exposure to pollutants 
during pregnancy can increase risk of disease among the offspring. Such pollutants include 
carbon monoxide (Raub et al., 2000), nitrogen dioxide (Maroziene and Grazuleviciene, 2002; 
Singh, 1987), ozone (Salam et al., 2005), and sulfur dioxide (Rogers et al., 2000). These 
exposures are also known to vary seasonally because of changes in atmospheric boundary layer 
depth, changes in emission rates and changes in wind and advection. Therefore it is reasonable to 
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hypothesize that seasonal variations in these factors could modulate birth month – disease risk 
patterns observed in epidemiology studies. 
Electronic Health Records (EHRs) are currently used throughout the world to record and store 
health information collected during the clinical encounter. These EHRs represent a rich data 
source for high-throughput explorations of birth season – outcome relationships. A 
comprehensive analysis should shed light on the exposures driving the underlying birth season – 
disease effects. 
My algorithm, described in chapter two, called SeaWAS for Season-Wide Association Study, 
systematically investigates birth month - disease dependencies across all diseases having 
sufficient prevalence in EHRs where birth month serves as a proxy for seasonal variance at birth. 
Initial studies were conducted using data from New York City (NYC). Novel cardiovascular 
findings were validated in a separate EHR system with increased disease risk being observed in 
winter months (Jan-April) (Li et al., 2016). This EHR was also in NYC and thereby subjected to 
similar climate constraints (Li et al., 2016). Previous studies did not identify environmental 
factors behind the associations because they were conducted in a single climate. Separately, 
researchers from North Russia (Northern Kola Peninsula) found that males born in the summer – 
fall had increased elasticity of blood vessels, which could be protective against cardiovascular 
disease later in life. Additionally, their results point to differences in cardiovascular physiology 
that appear birth month/season dependent (Melnikov et al., 2016). They also found that females 
who died from acute myocardial infarction (AMI) were found to have a significant birth season 
relationship in the Sakha Republic, Russia (Melnikov, 2003). 
In this study, I develop another algorithm to investigate the relationship between developmental 
stages (first, second, third trimester, perinatal or pregnancy-wide) and seasonal environmental 
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exposures (climate, pollution, flu) for birth month – disease relationships.  The algorithm 
delineates birth month – disease relationships due to differences in school cutoff dates across 
sites indicating the effect of relative age on human health and disease. I present results obtained 
using data from six distinct institutions, over three countries, spanning five cities, and four 
distinct climates.   
3.3 Methods 
3.3.1 Clinical Data 
Birth month – disease risk data were obtained from six different hospitals or study sites. A 
version of the SeaWAS algorithm was published on GitHub (Boland, 2015) that conforms to the 
Common Data Model (CDM) adopted by the Observational Health Data Sciences and 
Informatics (OHDSI) consortium (Overhage et al., 2012) allowing my code to be shared among 
the OHDSI community. A SeaWAS was performed at three OHDSI collaborator sites using 
OHDSI-formatted R scripts that were run locally on each site’s EHR databases. Three study sites 
were not OHDSI participants at the time of the study. Therefore code was formatted to meet their 
individual institution’s data schemas. Permission was obtained from each institution’s local 
Institutional Review Board (IRB), which conforms to each country’s, and in some cases state’s, 
laws and guidelines.  
A call for members of the Observational Health Data Sciences and Informatics (OHDSI) group 
was put together to solicit collaborators from within the OHDSI community that already have 
data conformed to the OMOP CDM (Boland et al., 2015a). The call for collaborators began in 
September 2015. Initially, 15 sites (not including CUMC) agreed to participate in some way 
including 6 non-OHDSI member sites (total: 9 OHDSI collaborator sites, 6 non-OHDSI 
collaborator sites). Table 7 shows the success-in-obtaining-data rates for OHDSI vs. non-OHDSI 
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collaborators when running SeaWAS. Typically, higher rates of engagement were seen among 
non-OHDSI members because these individuals were excited and personally motivated to 
participate in the research. Soliciting interest within the OHDSI community was a challenging 
issue and many hurdles were encountered due to differences among various institutions’ methods 
for handling IRBs. This represents one of the challenges of collaborating on a global scale 
(Boland et al., 2017a). Issues that resulted in studies dropping out completely were usually 
centered on institution-specific data privacy restrictions that were insurmountable. For example, 
some institutions only permitted de-identified data to be mapped to the OMOP CDM. Birth 
month is a protected health data element meaning that any database containing birth month is 
considered to be potentially re-identifiable. This seemingly nuanced legal distinction resulted in 
the final exclusion of several sites.  
Table 7. Success and Failure Rates in Obtaining Data for the Extended SeaWAS Study  
Status of Data OHDSI member? % Rate 
Data Submitted to Study – 
Success 
3 OHDSI sites 30.00% OHDSI 
 3 non-OHDSI collaborator site 50.00% non-OHDSI 
Stuck in IRB/Other Issue 4 OHDSI sites 40.00% OHDSI 
 3 non-OHDSI collaborators 50.00% non-OHDSI 
Dropped out of Study 
Completely Before IRB 
3 OHDSI sites 30.00% OHDSI 
Total 16 (10 OHDSI, 6 non-
OHDSI) 
37.50% Success Rate (6/16) 
 
The algorithm maps International Classification of Diseases, version 9 (ICD-9) codes to the 
Systemized Nomenclature for Medicine – Clinical Terms (SNOMED-CT) codes using the 
Common Data Model (Boland et al., 2015b; Overhage et al., 2012). Only the first instance of a 
diagnosis for each patient was included in the algorithm (for full algorithm details see Boland et 
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al.) (Boland et al., 2015b). Hereafter, I refer to distinct medical SNOMED-CT diagnoses as 
diseases realizing that some may be indicative of medical conditions. 
First, site characteristics were obtained, including, patient demographics, setting (climate, in-
patient/out-patient) and CDM version number (if an OHDSI data partner). For climate, the 
Köppen-Geiger climate classification system (Köppen, 1884; Kottek et al., 2006) was used to 
describe the high-level climate of each region.  
The SeaWAS algorithm returns birth month – disease risk curves for all diseases with at least 
1,000 patients at a given site. These disease risk – birth month curves were then used as input 
into the developmental time point – exposure – disease model described below in the Statistical 
Modeling section. 
3.3.2 Exposure Data 
To study the relationship between exposure and birth season relationships, a dataset was required 
containing seasonal variance in exposures across a variety of exposure types and locations. I 
investigate 6 climate variables (mean sunshine hours, minimum temperature, maximum 
temperature, rainfall in inches, relative humidity, days of precipitation), 5 pollutant variables 
(fine particulate matter (PM 2.5 micrometers in diameter), ozone (O3), carbon monoxide (CO), 
nitrogen dioxide (NO2), and sulfur dioxide (SO2)), and flu / influenza-like illness (ILI) in this 
study. Figure 9 illustrates the variation in seasonal exposure to each of the 12 factors (climate, 
pollution and influenza) across all sites. Exposure data were assembled from the Centers for 
Disease Prevention and Control (CDC), Environmental Protection Agency (EPA) and the 
National Oceanic and Atmospheric Administration (NOAA). For Taiwanese and Korean data, I 
obtained data from the Korean Meteorological Administration, the Taiwanese Central Weather 
Bureau, and the Korean CDC (KCDC) Virological Surveillance data. When data was unavailable 
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in a freely accessible public dataset, I used published literature to obtain the required seasonality 
in pollutant or flu exposure information.  
3.3.3 Statistical Modeling 
Because cultural/sociological effects of birth month are fundamentally different from 
environmental effects, I first determined those diseases with significant relative age effects 
(Musch and Grondin, 2001). Relative age was defined as an individual’s age relative to the 
individual’s peers in the same school grade. Next, I investigated the relationship between 
seasonal environmental exposures and birth month – disease risk.  
3.3.4 Delineating Culture Effects from Seasonal Environmental Effects 
The first step in modeling the relationship between birth month – disease risk and various 
exposures, was to distinguish birth month effects that were driven by purely cultural elements 
from those due to exposure to environment, pollution or some other factor. For instance, in 
sports, the age of each child athlete relative to their peers determines their ability to succeed. 
This has been demonstrated in multiple cases (Helsen et al., 2005; Musch and Grondin, 2001) 
and has been characterized as the ‘relative age effect’. Children that are ‘older’ relative to their 
peers are more likely to succeed in athletics, whereas children ‘younger’ then their peers are at 
increased risk of being victims of bullying (Mühlenweg, 2010). To study the ‘relative age effect’, 
the public school cutoff dates were collected for each study site. Data were adjusted from each 
institution using the cutoff dates from that region. Therefore, curves ranged from 6 months older 
than the average child (i.e., just after the cutoff date) versus 6 months younger than the average 
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Figure 9. Seasonal Variance in Exposure to Twelve Different Factors. Six climate factors are included: 
mean sunshine hours, low temperature, high temperature, rainfall in inches, relative humidity, days of 
precipitation. Five pollutant factors included in this study: fine particulate matter (PM 2.5 micrometers in 
diameter), ozone (O3), carbon monoxide (CO), nitrogen dioxide (NO2), and sulfur dioxide (SO2) and 




A regression model for the relationship between relative age (+6 months vs. average…-6 months 
vs. average) and disease risk was used to compute the significance of relative age for each 
disease at each site. Diseases that were nominally significant across all 6 sites were considered to 
have significant cultural effects.  
3.3.5 Modeling Seasonal Environmental Exposures Occurring During Developmental  
Twelve seasonally varying environmental exposures were identified as potential factors involved 
in birth month – disease relationships (Figure 10). To model the relationship between exposures 
and birth month – disease risk, I first modeled the exposure level for each critical developmental 
time point. The trimester of an exposure is vital in determining the effects on the offspring 
(Bérard et al., 2007; Goldstein, 1995), therefore I examined the cumulative exposure for each 
factor across each of the three trimesters. In addition, I investigated pregnancy-wide exposure 
(cumulative exposure across the entire pregnancy) and perinatal exposure (exposure at birth) as 
these also represent critical developmental periods. 
The average gestation period in weeks was obtained for each country: USA, South Korea and 
Taiwan. The mean gestation was 38.5 weeks in Taiwan (Hsieh et al., 2006), 39.17 weeks in 
South Korea (Lim et al., 2010) and 38.6 weeks in the USA according to the CDC (CDC, 2015). 
These average gestation periods were used to compute the typical conception month for each 
birth month. 
Next the cumulative exposure for each developmental stage (e.g., first trimester) for each factor 
(e.g., sunlight, rainfall) was calculated for a given birth month. These calculations were made 
using the midpoints of each month. For example, an October birth month would have a typical 
first trimester period from mid-January – mid-April; a typical second trimester period of mid-
April – mid-July; and a typical third trimester period of mid-July – mid-October. Therefore first 
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trimester sunlight exposure for an October birth month would include the sunlight exposure from 
mid-January through mid-April and so on. 
3.3.6 Meta-Analysis Across All 6 Sites Using Random Effects Modeling 
First, I correlated each exposure - developmental stage (e.g., first, second, third trimester) with 
the disease relative risk by birth month per site. Each disease was compared against each 
developmental time point for each factor (e.g., sunlight, rainfall, etc.). Pearson’s correlation was 
determined for the relationship between the exposure during a certain period (e.g., first trimester) 
and disease risk. Because the seasonality of exposures varied widely across sites, these 
correlations were performed for each study site. 
Next, I employed a meta-analysis approach to harness all data from the diverse sites. I used the 
DerSimonian-Laird (DSL) random-effect meta-analytical approach (DerSimonian and Laird, 
1986) to determine an overall ‘site-wide’ correlation coefficient representing the effect of an 
individual exposure (e.g., sunlight) on a given disease (e.g., depression) during a specific 
developmental stage (e.g., first trimester).  The DSL method transforms each site-specific 
correlation coefficient to a Fisher Z value with a standard error determined by the site-specific 
sample size. This weighs correlations from sites with a larger sample size for a given disease 
higher than correlations from sites with lower sample sizes. A summary correlation coefficient 
can then be computed from these ‘sample-size adjusted’ correlations. This summary statistic 
represents the overall correlation obtained from the meta-analysis across the 6 sites. The DSL 
method was implemented based on Schulze (Schulze, 2004) and incorporated in the R ‘metacor’ 
library (Laliberté and Laliberté, 2015) with widespread use among the research community 











































Figure 10. Factors that Could Influence Birth Month – Disease Relationships. This 
includes the cultural effect of relative age and 12 ‘traditional’ exposures including flu / 
influenza-like illness, 6 climate variables (3 sunlight and 3 moisture-related), fine air 
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Figure 11. Schema Depicting the Model that Captures the Environmental Exposures’ Effect At Various 
Developmental Time Points During Prenatal / Perinatal Development. Results are integrated across multiple 
sites using the DerSimonian-Laird Random Effects Meta-Analytical Approach. 
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Hence, my method determines the correlation between each of 12 exposures across 133 diseases 
during 5 different developmental stages (i.e., three trimesters, pregnancy-wide and perinatal). 
Therefore, multiple comparisons must be accounted for in the analysis. To remain as stringent as 
possible, and bias ourselves against finding disease – exposure relationships, I used Bonferroni’s 
method of p-value correction that adjusts for all comparisons, including all 133 diseases, 12 
exposures and 5 developmental stages (133x12x5=7980 tests). This stringent threshold allows 
me to state that exposure X during stage Y is associated with increased or decreased risk of 
disease Z. Figure 11 illustrates the overall method to find significant exposure-disease 
relationships for a given developmental stage. 
3.4 Results  
3.4.1 Data 
Data were obtained from six study sites including Columbia University (CU) in New York City, 
New York; Mount Sinai Hospital (MSH) in New York City, New York; Vanderbilt University 
(VU) in Nashville Tennessee; University of Washington (UW) in Seattle, Washington; Ajou 
University in Suwon, South Korea and the Taiwan National Health Insurance program, which 
contains data from each of Taiwan’s four geographic regions. Table 8 contains a breakdown of 
the patient demographics from each study site. Overall, patients were middle aged ranging from 
a median of 35 years old in Taiwan to 53 years old at MSH in NYC. However, most datasets had 
a median age in the 40s. Race and ethnicity varied by site due to differences in local populations. 
Both datasets from Asia: Taiwan and South Korea did not collect race/ethnicity data and 
therefore only nationality was used with the assumption that the majority of patients were Asian. 
The percent of Hispanic patients also varied across sites with 2-4% at UW and VU versus 17-
21% Hispanic at both NYC sites.  
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School of Medicine  
N (%) 
Location New York City, 
New York 
New York City, 
New York 
Nashville, Tennessee Seattle, Washington Taiwan (99.99% 





No. of Patients 1,749,400 1,169,599 3,051,997 1,770,510 909,689 1,848,692 
Sex 1       
   Female  956,465 (54.67%) 678,717 (58.03%) 1,558,550 (51.07%) 895,351 (50.57%) 464,576 (51.07%) 892,178 (48.26%) 
   Male 791,534 (45.25%) 490,600 (41.95%) 1,278,939 (41.90%) 874,618 (49.40%) 445,113 (48.93%) 956,514 (51.74%) 
   Other 1 1,401 (0.08%) 282 (0.02%) 214,508 (7.03%) 541 (0.03%) - - 
Race       
   White 665,366 (38.03%) 424,803 (36.32%) 1,653,093 (54.16%) 990,209 (55.93%) NA NA 
   Other 2 456,185 (26.08%) 165,423 (14.14%) NA 82,656 (4.67%) NA NA 
   Unidentified 386, 533 (22.10%) 256,819 (21.96%) 1,123,369 (36.81%) 367,100 (20.73%) NA NA 
   Black 189,123 (10.81%) 166,950 (14.27%) 241,978 (7.93%) 110,007 (6.21%) NA NA 
   Declined 29,747 (1.70%) NA 5,638 (0.18%) 16,976 (0.96%) NA NA 
   Asian 20,746 (1.19%) 45,596 (3.90%) 24,109 (0.79%) 122,839 (6.94%) NA NA 
   Native 
American  
1,511 (0.09%) 2,447 (0.21%) 3,074 (0.1%) 16,408 (0.93%) NA NA 
   Pacific Islander 189 (0.01%) 1,094 (0.09%) 736 (0.02%) 3,085 (0.17%) NA NA 
   Hispanic  (See Ethnicity) 106,467 (9.10%) (See Ethnicity) 61,230 (3.46%) NA NA 
   Korean NA NA NA NA NA 1,848,692 (100%) 
   Taiwanese NA NA NA NA 909,689 (100%) NA 
Ethnicity       
   Non-Hispanic 590,386 (33.75%) 761,535 (65.11%) 713,853 (23.39%) NA NA NA 
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   Unidentified 458,071 (26.18%) 208,899 (17.86%) 2,280,039 (74.71%) NA NA NA 
   Hispanic 361,123 (20.64%) 199,165 (17.03%) 44,527 (1.46%) NA NA NA 
   Declined 339,820 (19.42%) NA 13,578 (0.44%) NA NA NA 
Other Attributes Median (IQR)     
Total SNOMED-
CT codes per 
patient 
6 (1, 32) 7 (3, 22) 8 (3, 26) 9 (3, 24) 186 (98, 338) 4 (2, 12) 
Distinct 
SNOMED-CT 
codes per patient 
3 (1,8) 5 (2, 10) 5 (2, 14) 4 (2, 11) 49 (33, 70) 4 (2, 12) 
Age (year of 
service – year of 
birth) 
38 (22, 58) 53* (36, 66) 44 (25, 61) 48 (34, 64) 35 (20, 50) 42 (28, 57) 
Treatment Year 
Range 








Cfa Cfa Cfa Csb Aw Dwa 
 
In- / Out- Patient In-patient Both Both Both Both Both 
CDM** Version V.4 None None None V.5 V.4 
1 Other (includes individuals of unidentified gender); 2 Other (includes Hispanics not otherwise identified); * Computed in 
days, age in years  = age in days / 365.25; ** CDM: Common Data Model
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I obtained the birth month – disease risk curves for each disease with at least 1000 patients at 
each study site. In total, 133 diseases had at least 1000 patients at all 6 sites and I focused on this 
intersection set for the remainder of the analyses. Disease-specific sample sizes varied across 
sites. ‘Essential hypertension’ was the most common disease at all four USA sites. Both Asian 
sites showed increased prevalence of gastrointestinal issues and lower incidence of 
cardiovascular disease.  
3.4.2 Statistical Modeling 
I first investigated the relationship between relative age –as determined by school cutoff dates– 
and the birth month – disease risk relationship. Out of 133 diseases, only one disease was 
significantly associated with relative age across all 6 sites – Attention Deficit Hyperactivity 
Disorder (ADHD). The result both before relative age adjustment (i.e., unadjusted birth month) 
and after is shown in Figure 12. The average difference in ADHD risk due to relative age was 
17.97% (average peak of 1.084 vs. average trough of 0.904) with children younger then their 
peers experiencing greater ADHD risk. No other diseases were significantly correlated with 
relative age. 
Next, the relationship between exposures at certain developmental stages (e.g., a given trimester) 
and disease risk were investigated. My method determines the correlation between each of 12 
exposures across 133 diseases at five different developmental stages. Therefore, multiple 
comparisons must be accounted for in the analysis. Figure 13 shows the Manhattan plot for each 
developmental stage. Results are reported as significant if they pass the Bonferroni correction 
threshold for multiple comparisons across all analyses (i.e., 133 diseases *12 exposures* 5 time 
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Figure 12. Method to Detect the Existence of a Relative Age Effect In Birth Month – 
Disease Associations and Results. Figure 1A illustrates the method of adjusting birth month 
– disease associations by school cutoff dates to calculate the relationship between relative age 
and disease risk. Taiwan and Seattle, Washington are grouped together because the school 
cutoff date is the same at both locations (Aug. 31). Figure 1B shows the only significantly 
associated disease found across all 6 sites between relative age and disease risk – Attention 
Deficit Hyperactivity Disorder (ADHD). The average difference in Relative Risk (RR) by 
relative age was calculated resulting in a difference of 17.97% in peak vs. trough months. 
Peak risk was observed in the -5 month and trough (lowest risk) was observed in the +4 
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Figure 13. Manhattan Plot Showing Relationship Between Disease Risk and 
Exposures Occurring During Certain Developmental Time Points. Individual 
diseases are colored by their respective ICD-9 disease categories. The different 
Bonferroni adjusted demarcations are noted. Note that Acne is extremely associated 
with second trimester sulfur dioxide exposure (-log(p)>300). I reported results as 
significant if they pass the most stringent Bonferroni correction threshold (133 
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Figure 14. Depressive Disorder and First Trimester Exposure to Carbon Monoxide Figure 14A Depressive 
Disorder and First Trimester Exposure to All Environmental Factors. Larger squares in Figure 14A indicate 
correlations with larger confidence intervals, which typically occurs when the number of patients at a given site is 
low for a particular disease. Fi ur  14B. Relationship Between Depressive Disorder and First Trimester 
Carbon Monoxide Exposu e At Each Study Sit .  E ch site has its own s bplot in Figure 14B, the colored line 
is the relative risk of depr ssive disorder at th t site by birth m nth. The solid black lines indicate the first trimester 
exposure to Carbon Monoxide at each site. Figure 14C. Connec ing the Literature on First Trimester Carbon 
onoxide (CO) Exposure and Offspring’s Risk of Depressive Disorder and Our Current Study. A solid 
black arrow denotes each literature link with directionality being denoted by up or down red arrows. The major 
link in my study is the link between first trimester CO exposure and increased risk of depressive disorder (thick 
dashed green line). I also found a lower correlation between GAD and first trimester exposure to CO suggesting 
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Current'Study'Zhang%et%al.%2008%
Third*Trimester*Exposure*and*Type*2*Diab tes* llitus* Mechanis-c*Pathway*C D"
Figur  15. Atr al Fibrillation and Fi st Trim ster Exposure to Fine Particulate Matter (PM 2.5) and Type 2 
Diabetes Mellitus and Third Trimester Exposur  to Sunl ght. Figure 15A. Atrial Fibrillation and First 
Trimester Exposure to Fine Particul te Matt r PM 2.5) At Each Study Site. The colored line is the relative 
risk of atrial fibrillation by birth month per site. Solid black lines indicate the first trimester exposure to PM 2.5 per 
site. Figure 15B. First Trimeste  PM 2.5 Exposure an  Offspring’s Risk of Atrial Fibrillation: the Literature 
and Our ur ent Study. A solid black arrow denotes each literature link with increase/decrease in risk depicted 
by up or down red arrows. I found a distal cause: prenatal exposur  to PM 2.5 increases the risk of atrial 
fibrillation; wher as, ot ers report find ngs of proximal causes i  the s me causal pathway. Figure 15C. Type 2 
Diabetes Mellitus (T2DM) and Third Trimester Exposure to Sunshine At Each Study Site. The colored line is 
the relative risk of T2DM by birth month per site. Solid black lines indicate third trimester exposure to mean 
sunshine hours per site. Figure 15D. Third Trimester Exposure to Sunshine and T2DM: the Literature and 
Our Current Study. A solid black arrow denotes each literature link with increase/decrease in risk depicted by up 
or down red arrows. Low sunlight lowers vitamin D levels in the blood stream. My study is denoted by the green 
dashed arrow, which connected third trimester sunlight levels with T2DM risk later in life. Note that I uncovered 
the distal causal risk factors versus proximal causes. 
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A total of 56 distinct diseases were significantly associated with at least one exposure during at 
least one developmental stage. These 56 diseases were involved in 150 distinct disease-exposure-
developmental stage tuples. Twenty-seven diseases were significantly associated across multiple 
exposure-stages. This was expected due to the inherent correlation among exposures. One 
disease – Dysuria – was involved in 14 tuples (disease-exposure-stage).  
Several first trimester exposures were significantly correlated or anti-correlated with increased 
risk of depressive disorder later in life (Figure 14A), including low sunlight and temperature. 
However, the most significant association was a positive correlation between first trimester 
carbon monoxide (CO) exposure (R=0.725, Confidence Interval (CI): 0.529 – 0.847) and 
increased risk of depressive disorder. The relationship is shown in Figure 14B for all six 
individual sites.  
Atrial fibrillation was positively correlated with PM 2.5 exposure during the first trimester 
(Figure 15A). Taiwan and South Korea both had fewer patients with atrial fibrillation (10,476 
patients in Taiwan and 2,241 in S. Korea vs. US sites that ranged from 36,837 – 58,771 patients) 
and the relationship was not as strong in those locations (i.e., Taiwan and S. Korea). Further, lack 
of sunlight during both the third trimester and the perinatal period increased risk of T2DM later 
in life. The connection between low sunlight and increased risk of T2DM in the offspring was 
stronger during the third trimester (R=-0.816, CI: -0.5767 – -0.929) then during the perinatal 
period (R=-0.580, CI: -0.420 – -0.705). The individual site breakdown for the relationship 
between exposure to low amounts of sunlight during the third trimester and later risk of T2DM is 





This study provides a global understanding of birth month - disease risk relationships and allows 
for systematic investigation of a number of different possible mechanisms. Results were 
integrated from over ten million unique individuals across three countries, two continents, and 
five distinct climates. This enabled successful discrimination between birth month – disease 
relationships driven by relative age (a cultural effect) versus seasonal environmental exposures, 
including climate factors, pollution and influenza. ADHD was found to be significantly 
dependent on relative age with an average difference in disease risk of 17.97% due to relative 
age with younger children experiencing greater risk of diagnosis than their peers. Several 
exposures were found to occur during the prenatal period (i.e., maternal exposures) that 
influenced risk of disease in the offspring and also perinatal exposures (i.e., direct exposure to 
the offspring) that influence lifetime disease risk.  
3.5.1 Culture Effects Can Induce Birth Month – Disease Dependencies: The Tale of 
Relative Age 
The ‘relative age effect’ is the phenomenon whereby children are preferentially selected based 
on their age relative to their peers (Helsen et al., 2005; Musch and Grondin, 2001). This is 
commonly studied among athletes where the slight advantage due to age including size, mental 
agility and timing of the onset of puberty provides slightly older children with a distinctive edge 
over their classmates. Sociologists have also looked into the effect and found that children that 
are ‘younger’ relative to their peers are at increased risk of being victims of bullying 
(Mühlenweg, 2010). Each of these relative age effects could alter an individual’s risk of disease 
later in life. Therefore, my algorithm explicitly investigated the relationship between relative 
age, calculated using birth month distributions, and lifetime disease risk of all diseases in this 
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study. Of the 133 tested, only one disease – ADHD – was found to have a significant 
dependency due to relative age (Figure 12). 
A study among Taiwanese children also found a significant relationship between relative age and 
ADHD (Chen et al., 2016). This effect was also found in Iceland, where in addition to finding a 
connection between relative age and ADHD, they also describe a relationship between academic 
performance and relative age (Zoëga et al., 2012). Other researchers have also studied the 
connection between academic performance, ADHD, and relative age finding increased risk for 
adverse outcomes among younger children (Evans et al., 2010). 
While individual countries and sites have described the relationship between relative age and 
ADHD, this is the first comprehensive study to investigate relative age and disease across three 
distinct countries, six sites, and four distinct school cutoff dates. This increases the robustness of 
the findings while validating other site-specific studies, by establishing increased confidence in 
this dependency and the increased need for provider awareness of this issue when prescribing 
stimulants for the treatment of ADHD. This study establishes a relationship between ADHD and 
relative age, however the cause for this could be either a.) younger children are at increased risk 
of being a victim of bullying (which could result in traumatic brain injury, thereby affecting 
neurological functioning) or b.) over-diagnosis of younger children with ADHD (when they are 
otherwise healthy). 
Note for the next three sections, all prenatal exposures affecting the offspring’s lifetime disease 
risk are mediated through the fetal-maternal barrier. Therefore, all prenatal exposures are 
referred to as maternal exposures that influence the offspring’s disease risk and all perinatal 
exposures are referred to as direct exposures on the newly born offspring. 
3.5.2 Sunlight During Third Trimester and Risk of Type 2 Diabetes Mellitus in Offspring 
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Sunlight was inversely correlated with T2DM during the third trimester (R=-0.816) and the 
perinatal period (R=-0.580). Low vitamin D exposure during pregnancy has been linked to 
increased risk of gestational diabetes (Zhang et al., 2008), which is diabetes of the mother during 
pregnancy. Gestational diabetes is shown to increase the risk of T2DM among offspring with a 
reported odds ratio of 7.76 (Clausen et al., 2008). In this study, sunlight exposure during the third 
trimester of pregnancy was linked to changes in T2DM risk among offspring later in life.  
The link between prior work described in the literature and results from my study is highlighted 
in Figure 15D. Each of the links details one small piece of the larger puzzle. In causal terms, 
these prior studies found the proximal causes whereas I reveal the distal factor that can explain 
the smaller steps in the proximal pathway (Laland et al., 2011; Scott-Phillips et al., 2011). 
Mechanistically, my results also fit into the ‘thrifty phenotype hypothesis’, which states that 
inadequate early nutrition impairs development of the pancreas, which in turn greatly increases 
the susceptibility of the offspring to T2DM (Hales and Barker, 2013; Hales and Barker, 1992). 
Maternal gestational diabetes is often an indicator of impaired prenatal nutritional status. My 
work links a distal factor – low sunlight exposure during third trimester – to increased risk of 
T2DM in offspring. By uncovering a distal factor in this mechanism, this work opens the door 
for evolutionary biologists to delve into this relationship further to elucidate a fitness benefit. 
3.5.3 First Trimester Exposures and Risk of Depressive Disorder in Offspring 
Risk of depressive disorder and birth month is an association that is studied often in the literature 
(Joiner Jr et al., 2002). An Australian study investigated the relationship between birth month in 
both Southern and Northern hemispheres found that flu peak was important in explaining the 
birth season – depression/suicide relationship (Joiner Jr et al., 2002). 
Figure 14A shows that first trimester exposure to influenza-like illness (ILI) was a significant 
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factor in depressive disorder with a slightly lower correlation value (R=0.612, CI: 0.384 – 0.770) 
than CO exposure (R=0.725, CI: 0.529 – 0.847). Depressive disorder was also significantly anti-
correlated with sunlight (R=-0.625, CI: -0.452 – -0.753) and temperature (high temperature, R=-
0.645, CI: -0.462 – -0.779; low temperature, R=-0.651, CI: -0.446 – -0.790) indicating that lack 
of sunlight during the first trimester also appeared to be related to depressive disorder. Because 
the strongest factor was CO exposure, I focused on the mechanisms underlying a relationship 
between first trimester CO and depressive disorder. Additionally, prior studies investigated a 
connection between ILI/flu and sunlight with depressive disorder without investigating pollutant 
variables such as CO that are often correlated with sunlight. 
Generalized anxiety disorder (R=0.404, CI: 0.264 – 0.528) was also significantly associated with 
first trimester CO exposure although the relationship was weaker. Importantly, generalized 
anxiety disorder was only significantly associated with variance in CO exposure and no other 
variable (such as flu, sunlight, etc.). This further bolstered the hypothesis of a mechanistic link 
between both depressive disorder and generalized anxiety disorder and first trimester exposure to 
CO. Additionally, a study by Moffitt et al. found that generalized anxiety disorder (GAD) and 
major depressive disorder (MDD) often occur together with no apparent sequential pattern 
suggesting that GAD+MDD may be a disease of its own (Moffitt et al., 2007). Therefore, finding 
that both GAD and depressive disorder were significantly correlated with first trimester CO 
exposure suggests that this study may be uncovering a link between GAD+MDD and first 
trimester CO. 
Chronic CO poisoning exhibits itself clinically as chronic fatigue, depression and often a 
diagnosis of influenza infection (either due to the patient’s weakened immune system or due to 
the ‘flu-like’ symptoms that patients often present with) (Knobeloch and Jackson, 1999) 
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underscoring the importance of CO exposure on depression. Prenatal exposure to CO was shown 
to cause learning and memory deficits indicating that maternal exposure to CO crosses both the 
fetal-maternal and the blood-brain barriers (Mactutus and Fechter, 1984). First-trimester 
exposure to CO was shown to cause intrauterine growth retardation (IUGR) (Salam et al., 2005) 
and disrupts hippocampus functioning (Mereu et al., 2000). Shrinking of the hippocampus is one 
of the critical hallmarks of depression (Sapolsky, 2001). The link between first trimester CO and 
both GAD and depressive disorder may be mediated through a shrinking of the hippocampal 
structures caused by prenatal CO exposure. The link between this study and prior studies on 
prenatal CO exposure and depression from the literature is shown in Figure 14C. The major link 
in this study is the link between first trimester CO exposure and increased risk of depressive 
disorder (thick dashed green line). A lower correlation between GAD and first trimester exposure 
to CO was found suggesting that it could be patients afflicted with both diseases as described by 
Moffitt et al. (Moffitt et al., 2007) that were exposed to CO. 
3.5.4 Fine Particulate Matter During First Trimester and Risk of Atrial Fibrillation in 
Offspring 
A positive correlation was found between atrial fibrillation and PM 2.5 exposure during the first 
trimester (Figure 15A). Taiwan and South Korea both had very low incidence of atrial 
fibrillation and the relationship was not as strong in those locations suggesting the possibility that 
an additional factor may mediate the relationship. In adults, PM 2.5 exposure has been associated 
with adverse cardiovascular outcomes including increased heart failure admissions and mortality 
(Dominici et al., 2006; Ito et al., 2011; Zhou et al., 2011). Exposure to PM 2.5 in adults was also 
associated with increases in systolic blood pressure (Brook et al., 2010). Children of mothers 
with gestational hypertension were found to have higher blood pressure, and elevated cholesterol 
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and apolipoprotein B levels (Miettola et al., 2013). High blood pressure is a risk factor for later 
development of atrial fibrillation (Psaty et al., 1997). Exposure to fine air particulates increased 
the risk of gestational hypertension in pregnant women (Vinikoor‐Imler et al., 2012). I propose a 
mechanism that connects atrial fibrillation and first trimester exposure to fine particulate matter 
by elevating maternal blood pressure and inducing gestational hypertension. The link between 
the prior literature on this topic and prenatal fine particulate matter and increased risk of atrial 
fibrillation is depicted in Figure 15B. The uncovered link between first trimester exposure to 
fine air particulates and increased risk of atrial fibrillation later in life represents a distal cause 
with the proximal causes all outlined together in Figure 15B. 
3.5.5 Perinatal Exposures and Later Risk of Disease 
Some diseases were tied to exposures during the perinatal period (i.e., the environment the baby 
is born into). One such relationship is perinatal flu exposure and lifetime risk of anemia 
(R=0.660, CI: 0.467 – 0.793). Some regions such as NYC and South Korea illustrated near 
perfect correlation between flu exposure and lifetime risk of anemia while other sites showed a 
lower correlation. Newborns are at increased risk from influenza and other viruses due to their 
developing immune system (Levy, 2007). This increases their risk of developing an infection due 
to the viruses. Anemia often results as part of the body’s innate immune system to fight 
infections (Frickhofen et al., 1990). The uncovered link between perinatal flu exposure and 
anemia may be mediated through an immune pathway.  
3.6 Limitations 
My method investigates the presence or absence of correlations between exposures during 
different developmental stages and lifetime disease risk. The DSL meta-analysis method was 
used to uncover only correlations that were consistent across all study sites (i.e. robust). While 
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this study deeply probed into how specific exposures can affect lifetime disease risk, there are 
other exposures (e.g., diet) that this study was unable to investigate due to lack of available data.  
Importantly, if a co-varying environmental factor exists that was not included in this analysis and 
was perfectly correlated with one of the exposures in this analysis then my algorithm may be 
uncovering an association that is due to this other unmeasured factor. For example, if seasonal 
smoking patterns were perfectly correlated with CO seasonality at all six sites, then this would 
be a confounder. This is not likely given the number of sites (and perfect correlation of an 
environmental exposure across multiple sites is unlikely) and the diversity of the sites (e.g., 
Asian vs. USA). However, it remains a limitation of this study. Importantly, the phrase ‘causal 
risk factors’ is only used in instances where this study reveals the distal causal risk factor in an 
already established pathway. In other instances, further testing would be required to clearly state 
if this study’s findings were causal factors or strongly correlated with another untested causal 
factor. Another limitation is unknown cultural differences between sites in my study. I 
investigated the relationship between relative age and birth month dependent diseases because 
the effect of relative age is possible to capture (i.e., through use of school cutoff dates). Other 
cultural differences may be difficult to identify and tease out (e.g., mandatory military 
conscription). Therefore, associations that are not found across all sites may be true birth month 
– diseases relationships where a cultural factor modulates the exposure. I focus only on those that 
are significant using the DSL method across all six sites.  
3.7 Conclusion 
In conclusion, this comprehensive study of factors involved in birth month – disease risk used 
data from over 10 million patients, three countries, two continents, and five climates. This study 
was able to distinguish the cultural effect of relative age from seasonal environmental exposures 
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that both affect birth month – disease dependencies. It also identified both the seasonal 
environmental exposure and the stage that resulted in increased disease risk. Others in the 
literature have identified the proximal causes behind these relationships, whereas this study 
identified distal causal risk factors. Several important findings include a link between both 
depressive disorder and generalized anxiety disorder and first trimester exposure to carbon 
monoxide. Lack of sunlight exposure during the third trimester was correlated with increased 
Type 2 diabetes mellitus risk. Finally, increased risk for atrial fibrillation occurred with first 
trimester exposure to fine air particulates. By identifying the distal causal risk factors in these 
disease pathways, this study allowed for the identification of areas that may require season-
dependent dosing of prenatal supplements. 
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Climate is a known modulator of disease, but its impact on hospital performance metrics remains 
unstudied. The relationship between Köppen-Geiger climate classification and hospital 
performance metrics was assessed in this study. Specifically, 30-day mortality was obtained from 
Hospital Compare, and collected for the period July 2013 through June 2014 (7/1/2013 – 
06/30/2014). A hospital-level multivariate linear regression analysis was performed while 
controlling for known socioeconomic factors to explore the relationship between all-cause 
mortality and climate. Hospital performance scores were obtained from 4,524 hospitals 
belonging to 15 distinct Köppen-Geiger climates and 2,373 unique counties. Model results 
revealed that hospital performance metrics for mortality showed significant climate dependence 
(p<0.001) after adjusting for socioeconomic factors. Climate is a significant factor in evaluating 
hospital 30-day mortality rates. These results demonstrate that climate classification is an 
important factor when comparing hospital performance across the United States. 
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4.2 Introduction 
The relationship between climate and human health and disease is well known (Dell et al., 2012; 
2013; Epstein, 1999; Hippocrates and Galen, 1952; Pöschl, 2005). Recently, variation in 
temperature related to climate variability and extreme weather events has been linked to hospital 
admission rates for heart disease (Schwartz et al., 2004). Air humidity is also an important health 
factor (Sherwood and Huber, 2010). Pollutants, including both carbon monoxide and fine air 
particulates have been associated with increased admissions for a number of conditions 
(Dominici et al., 2006; Schwartz, 1999). In contrast to the evidence (Lee et al., 2008), outcome-
based quality of care assessments ignore hospital location when comparing hospitals and 
explicitly state the assumption that ‘global location of the hospital should not affect the outcome’ 
(Lacour-Gayet et al., 2004).  
Hospital performance statistics are often reported while ignoring regional climate information. 
Location is usually only mentioned as a confounding factor in determining the fiscal cost of 
services (Hargraves and Brennan, 2016) while ignoring the quality of the result (i.e., the 30-day 
mortality rate). Many climate variables (e.g., temperature, humidity) and other climate-
dependent pollutants (e.g., air particulates, water contaminants) may be responsible for some of 
the variation in hospital performance metrics. The total number of relevant climate variables to 
consider can be large. Therefore, the Köppen-Geiger climate classification system was selected 
(Köppen, 1884; Kottek, 2015 ) as a proxy for a high number of intertwined climate variables. 
The Köppen-Geiger climate classification uses precipitation and temperature to describe a 
region’s climate and has been widely used in various fields such as hydrology(Peel et al., 2007) 
and ecology(Smith et al., 1992). In addition to climate, adjusting for socioeconomic factors is 
important when studying climate effects as prior studies have shown significant geographic 
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gradients in hospital services that are economic-dependent and not climate-dependent (Mercier et 
al., 2015). 
Hospital performance statistics and 30-day mortality rates for many hospitals across the United 
States of America (USA) are readily available in the Hospital Compare dataset. Hospital 
Compare is maintained by the Centers for Medicare and Medicaid Services (CMS) with the 
purpose of providing the general public with information to make informed decisions on their 
healthcare (www.hospitalcompare.hhs.gov). 
In this study, hospital-level variation in 30-day mortality measures reported in Hospital Compare 
and their relationship with hospitals’ Köppen-Geiger climate classification were examined. 
4.3 Methods 
4.3.1 Data  
4.3.1.1 Köppen-Geiger climate classification 
This study used the Köppen-Geiger climate classification system (Köppen, 1884; Kottek et al., 
2006) to compare hospitals’ climates. The Köppen-Geiger classification is a classical climate 
classification used by researchers (Zanobetti and Schwartz, 2009) throughout the world including 
members of the World Health Organization (Polack et al., 2005). Each county in the United 
States of America (USA) is assigned a category using three axes: broad climate type, as well as 
precipitation and temperature characteristics (Köppen, 1884; Kottek, 2015 ). Each of these three 
factors is combined to produce the overall climate designation. For example, the New York City 
(NYC) climate is designated Cfa meaning that its climate is warm temperate (‘C’), fully humid 
(‘f’) with a hot summer (‘a’). Köppen-Geiger climates at the US-county level were obtained 
(Kottek, 2015 )  and linked it to Federal Information Processing Standard (FIPS) codes. In some 
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instances, multiple climate classes were mapped to the same county with proportions for each 
climate within that county (this occurs when counties contain data from across two climate 
boundaries). Therefore, the climate with the highest proportion for each county (i.e., the 
dominant climate) was used in this study’s analysis. 
4.3.1.2 Hospital Compare 
Thirty-day mortality data from Hospital Compare were obtained by downloading the entire 
release of Hospital Compare (2015 Annual Files released on July 16, 2015) (CMS, 2015 ). The 
‘readmissions, complications and deaths’ file was used to obtain 30-day mortality rates for all 
conditions reported (a total of 6 conditions, obtained from file: 
HOSArchive_Revised_FlatFiles_20150716/Readmissions and Deaths-Hospital.csv). Data for 
these measures were collected for the period from July 2011 through June 2014 (7/1/2011 – 
6/30/2014). This study did not investigate patient-reported outcomes (Boulding et al., 2011). 
Each hospital included in Hospital Compare contains zip code information, which can be used to 
link the hospital to the county-level Köppen-Geiger climate data source (described above).  
4.3.1.3 Census Bureau’s American Community Survey (ACS) 
Socioeconomic factors are known confounders in quality-of-care comparisons across hospitals 
(Das and Mohpal, 2016). Therefore, data on six different potentially confounding variables for 
hospital performance were obtained, including: income, race, English-speaking ability, insurance 
coverage, renter-occupied status, and total number of households. The American Community 
Survey (ACS) collected by the U.S. Census Bureau, 5-year data from the 2014 release was used.  
These six potential confounders were selected because they have been linked to hospital 
performance (either readmission or mortality) metrics and are known to vary regionally. 
Socioeconomic status (specifically median household income and race) are well-known 
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independent risk factors for hospital readmissions related to heart failure (Philbin et al., 2001).  
Patients who owned their own homes had significantly fewer hospital readmissions for COPD 
(Coventry et al., 2011) indicating that the percent of renters per county is a potential confounder. 
English fluency is another potential confounder as non-English speaking individuals were at an 
increased risk for 30-day readmissions even after adjusting for other socioeconomic variables 
(Karliner et al., 2010). Insurance status also altered risk for hospital readmissions (Kangovi and 
Grande, 2011).  
4.3.2 Statistical Methods 
I extracted all six mortality metrics for each hospital provided by Hospital Compare. Each score 
was reported in percentages. For example, a hospital score of 14.6 for ’Heart Failure (HF) 30-
Day Mortality Rate” indicates that 14.6% of patients with a heart failure diagnosis died within 
30-days. Raw mortality counts were used along with the counts of patients sampled for each 
hospital instead of the raw mortality rates. I mapped the Hospital Compare data to their 
corresponding FIPS codes using the zip codes provided in the original data file using the R 
package noncensus (Ramey, 2015).   
The Köppen-Geiger climate classes were mapped to hospital county information contained in the 
Hospital Compare data. All scores that were reported as ‘Not Available’ by the CMS were 
removed. The CMS lists data as ‘Not Available’ if 1) the number of cases does not meet the 
minimum required for public reporting, 2) the number of cases is too small to reliability report 
the data, or 3) to protect personal health information. The CMS may also restrict access to 
mortality rates if 1) a hospital elected not to submit data for a particular reporting period, 2) a 
hospital had no claims data for a particular measure or 3) a hospital elected to suppress a 
measure from being publicly reported. Since the CMS chose to restrict these data, they were 
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unavailable for analyses. I also removed four hospitals belonging to a unique climate (i.e., with 
no other hospital in that climate) to avoid any biases due to low-sample size. The final dataset 
contained 4,524 hospitals belonging to 15 distinct climates. The F-test was used to determine 
overall significance for the various measures and confounders vs. climate.  
A linear hierarchical regression model was constructed that pools data from all six 30-day 
mortality rates reported in Hospital Compare. This model was implemented using the Stan 
software in R (Carpenter et al., 2016). The model then automatically captures the relationship 
between size of the hospital and natural sampling fluctuations. The model was fitted using the 
open-source Bayesian inference engine, running at the default settings of 2000 iterations for 4 
chains. Parameters for hospital size, and hospital-specific variability in mortality were used in 
the model as these factors could skew the results (Gelman and Price, 1999). In addition, 
parameters for each of the six-socioeconomic confounder variables were used. These 
socioeconomic factors included: income, total number of households, % renter, % un-insured, % 
speak English ‘very well’, and % white alone. Data for each socioeconomic variable were 
obtained from the ACS using the county-level FIPS codes. Therefore, hospitals were assigned 
their corresponding socioeconomic variables based on the geographic location of the hospital 
(i.e., all hospitals in the same county received the same set of socioeconomic variables). 
4.4 Results 
The final dataset contained 4,524 hospitals from 15 distinct climates and 2,373 unique counties 
(Figure 16). All six mortality measures varied by climate as illustrated in Figure 17 and the six 
socioeconomic confounder variables also varied across climates and by USA county (Figure 
18). Each confounder was significant across different climates, which motivated the addition of 




Figure 16. Hospital Compare Data By County with Major Climate Designations: A Map 
of the United States Showing Hospital Compare Data Mapped to Köppen-Geiger Climate 
Classifications. Map of the United States was generated using the following R libraries: 
choroplethr (version: ‘3.5.2’, URL: https://cran.r-
project.org/web/packages/choroplethr/index.html), ggplot2 (version: ‘2.1.0’, URL: 
https://cran.r-project.org/web/packages/ggplot2/index.html), noncensus (version: ‘0.1’, URL: 
https://cran.r-project.org/web/packages/noncensus/index.html), zipcode (version: ‘1.0’, URL: 
https://cran.r-project.org/web/packages/zipcode/index.html), grid (version: ‘3.3.0’, URL: 
https://stat.ethz.ch/R-manual/R-devel/library/grid/html/00Index.html) and gridExtra (version: 
‘2.2.1’, URL: https://cran.r-project.org/web/packages/gridExtra/index.html). The map itself 




























































































































































































































































































































Figure 17. Raw Mortality Boxplots For All Six Mortality Measures By Köppen-Geiger 
Climate Classification System. The relationship between climate and individual disease varies 
somewhat. A near linear relationship is observed for 30-day heart failure mortality (lower center 
plot). A pooled-mortality statistic (across all 6 diseases) was used in the model. Köppen-Geiger 
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Figure 18. County-Level Variance of Six Known Confounders: income, total number of 
households, % renter occupied housing, % uninsured persons, % English-fluent and % 
white. Map of the United States was generated using the following R libraries: choroplethr 
(version: ‘3.5.2’, URL: https://cran.r-project.org/web/packages/choroplethr/index.html), ggplot2 
(version: ‘2.1.0’, URL: https://cran.r-project.org/web/packages/ggplot2/index.html), noncensus 
(version: ‘0.1’, URL: https://cran.r-project.org/web/packages/noncensus/index.html), zipcode 
(version: ‘1.0’, URL: https://cran.r-project.org/web/packages/zipcode/index.html), grid 
(version: ‘3.3.0’, URL: https://stat.ethz.ch/R-manual/R-devel/library/grid/html/00Index.html) 
and gridExtra (version: ‘2.2.1’, URL: https://cran.r-
project.org/web/packages/gridExtra/index.html). The map itself utilized the choroplethr library 





































































































































































Pooled All−Cause Mortality ModelA" B"
Figure 19. Climate’s Impact on Hospital Performance Mortality Statistics After Adjustment for Confounders: Map 
of the United States of America. Model coefficients for climate’s impact on 30-day mortality are displayed by climate 
classification in Figure 19A. A map of the USA illustrating the results of the model is shown in Figure 19B. Map of the 
United States was generated using the following R libraries: choroplethr (version: ‘3.5.2’, URL: https://cran.r-
project.org/web/packages/choroplethr/index.html), and ggplot2 (version: ‘2.1.0’, URL: https://cran.r-
project.org/web/packages/ggplot2/index.html). The map itself utilized the choroplethr library version 3.5.2. 
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The linear regression model revealed distinct relationships between climate and mortality 
statistics. The mortality data was pooled across all six conditions and found that equatorial 
climates (light orange Figure 19A) had lower climate coefficients after adjustment for 
confounding. Hospitals located in equatorial dry climates (Aw climate) were found with the 
lowest risk of mortality (blue in Figure 19B) indicating that wetter climates are more debilitating 
a finding also reported by Sherwood et al.’s model (Sherwood and Huber, 2010). The subarctic 
snow climate (Dfc climate) had the highest pooled mortality rate (red in Figure 19B). Another 
climate with high mortality is the snowy warm summer climate (orange in Figure 19B, Dsb 
climate). Both the subarctic snow climate (Dfc) and the snowy warm summer climate (Dsb) are 
centered in the northwest region of the USA. 
4.5 Discussion 
This study’s results suggest the importance of considering climate-induced impact in hospital 
performance statistics. Pooled 30-day mortality rates were found to vary significantly by climate. 
In general, equatorial climates had improved mortality rates after adjusting for socioeconomic 
confounders. Further, subarctic and heavy snow climates had worse mortality rates. The model 
adjusted for known confounders, including, % insured, % renters, household income, % speak 
English well, % white and total number of households. The model found a significant climate 
effect after adjusting for these factors. The model’s results fit well with the literature. For 
example, cold, dry air (i.e., low temperature and low humidity) is known to increase the risk of 
influenza-related mortality (Barreca and Shimshack, 2012; Davis et al., 2012) and my model 
found that colder climates tended to have higher mortality rates while warmer, milder climates 
had lower mortality rates. Additionally, Sherwood et al. demonstrate that peak heat stress for 
humans and animals occurs in wet climates indicating that dry climates may be the ideal 
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environment while high temperature and relative humidity can be debilitating (Sherwood and 
Huber, 2010). 
4.5.1 Policy Implications Of Climate – Performance Relationship 
Government agencies, such as CMS, are making tremendous strides to provide more data to 
patients to allow patients to make informed healthcare choices. The CMS designed Hospital 
Compare as a patient-facing tool to allow patients to ‘compare’ hospitals using a set of hospital 
performance metrics. This allows patients to decide where they want to receive medical 
treatment. 
Some researchers have questioned the usefulness of Hospital Compare’s performance metrics 
(Halasyamani and Davis, 2007). They note a discrepancy between “Hospital Compare” quality 
measures and “Best Hospitals” (Halasyamani and Davis, 2007). However, researchers have 
shown that the reported conditions (heart attack, pneumonia, heart failure) that Hospital Compare 
highlights account for 16% of Medicare discharges from acute care hospitals and 16% of 
Medicare hospital payments (Kahn et al., 2006). This makes the Hospital Compare performance 
metrics vital for a large cohort of Medicare patients. 
Additionally, alternative metrics such as “Best Hospitals” have not proven to be informative in 
predicting outcomes such as 30-day mortality. One study investigated surgical outcomes 
following radical cystectomy using “Best Hospitals” performance metrics from the US News & 
World Health Report (Lascano et al., 2015). The researchers found either no correlation or an 
inverse correlation between the quality of the hospital (using one of these “Best Hospitals” 
metrics) and mortality 90 days following surgery (Lascano et al., 2015) making those metrics not 
informative for measuring mortality-related hospital performance. Others found that admission 
to one of “America’s Best Hospitals” was associated with lower 30-day mortality among elderly 
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patients with acute myocardial infarction (Chen  et al., 1999). Although, those researchers did 
not mention adjusting for other socioeconomic confounders (e.g., insurance status) that would 
bias their results (Chen  et al., 1999).  
Hospital Compare performance measures have been used successfully by many researchers to 
learn more about hospital care through the United States (Werner and Bradlow, 2006). Using 
these data, this study demonstrates that climate matters when choosing a hospital even after 
adjusting for many other known socio-economic factors (Figure 19B). These results have 
important implications for patients as well as policy makers.  
4.5.2 Proposed Climate-Based Performance Adjustment 
Originally, hospitals’ mortality rates were compared against a national rate. However, due to 
unfair penalization of hospitals in poor-regions, adjustments were made for socioeconomic status 
(Glance et al., 2015). In this study, climate was found as another factor in hospital mortality rates 
and therefore I propose the notion that financial adjustments should be made for hospitals within 
their own climate. This would allow hospitals to be meaningfully compared to each other. 
Climate-based adjustments should be considered by policy makers to make meaningful 
comparisons across different hospitals. 
4.6 Limitations  
There are some limitations to this study including the exclusive use of Hospital Compare’s 30-
day mortality metrics. These metrics do not fully represent the quality of a given hospital (Zuger, 
2015). However, these metrics are used to assess hospital quality by policy makers and these 
mortality measures represent a significant burden on the Medicare population (Kahn et al., 
2006). 30-day mortality rates were used because they were readily available from Hospital 
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Compare. However, some researchers suggest that shorter time intervals may be more conducive 
to quality-of-care assessments (Chin et al., 2016), however these shorter time intervals are not 
currently being provided publically. 
4.7 Conclusion 
This study demonstrates that climate-induced impact on hospital performance metrics exists. 
This climate-based variation in mortality rates exists among hospitals even after adjusting for 
socioeconomic confounders. The findings are important for policy makers as climate-based 
adjustments for hospitals could be conducted to enable ‘meaningful comparisons’ of hospitals by 
comparing hospitals within the same climate. Additionally, this study’s findings are important 
for researchers that study hospital performance as the Köppen-Geiger climate class where a 
hospital is located represents an important, yet often overlooked, variable in the equation. 
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Uncovering Genes Underlying Birth 
Season – Disease Effects 
 
5.1 Abstract 
Prenatal and perinatal exposures vary seasonally (e.g., sunlight, allergens) and many diseases are 
linked with variance in exposure. Epidemiologists often measure these changes using birth 
month as a proxy for seasonal variance. Likewise, Genome-Wide Association Studies have 
associated or implicated these same diseases with many genes. Both disparate data types 
(epidemiological and genetic) can provide key insights into the underlying disease biology. In 
this chapter, I developed an algorithm that links 1) epidemiological data from birth month studies 
with 2) genetic data from published gene-disease association studies. My framework uses 
existing data repositories – PubMed, DisGeNET and Gene Ontology – to produce a bipartite 
graph that connects enriched seasonally varying biofactors with birth month dependent diseases 
(BMDDs) through their overlapping developmental gene sets. As a proof-of-concept, I 
investigate 7 known BMDDs and highlight three important biological graphs revealed by my 
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algorithm and explore some interesting genetic mechanisms potentially responsible for the 
seasonal contribution to BMDDs. 
5.2 Introduction  
Dopico et al. demonstrated that gene expression can vary seasonally (Dopico et al., 2015). 
Additionally, many biological compounds are known to vary seasonally in humans (Basu et al., 
1994; Grzybowska et al., 1993; Hao et al., 2003; Woodhouse and Khaw, 2000). To address aim 
three, an algorithm was needed that uses existing data repositories containing genetic 
information for various disease states and Seasonally Varying Biofactors (SVBs) to find genes 
potentially responsible for reported birth month dependent diseases (BMDDs). These genes 
should lend insight into the underlying mechanisms behind birth month-disease relationships. 
One well-studied BMDD is asthma. Several studies have linked asthma risk to birth month 
(Boland et al., 2015b; Korsgaard and Dahl, 1983) where birth month is a proxy for a perinatal 
environmental exposure. Environmental factors play a key role not only in asthma development 
but also in its progression. Others have demonstrated that asthma flare-ups are seasonally 
dependent (Cohen et al., 2014; Randolph, 2014) and that genetic mechanisms are involved in this 
seasonal dependency (Bjornsdottir et al., 2011). Despite all the knowledge behind asthma 
seasonality and the role of perinatal exposures with regards to disease risk, it remains impossible 
to identify a biological mechanism behind the birth month association. In part, the difficulty lies 
in the fact that >1,200 genes have been implicated in asthma disease progression (Piñero et al., 
2015). Because of the plethora of genes implicated in certain diseases, finding the potential 
genetic mechanisms underlying birth seasonality associations is non-trivial. This formed the 
motivation for aim three. 
Aim three focuses on constructing a Month-Of-Birth (MOB) Gene map (MOB-Gene map) that 
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uses publically available data sources including PubMed and DisGeNET. The method builds on 
the traditional Mendelian Randomization (MR) Approach (Figure 20) with several important 
modifications. 
The traditional MR approach (Smith and Ebrahim, 2003) involves studying the relationship 
between an exposure (e.g., lead paint) and a disease (e.g., asthma) through the use of an 
intermediary proxy – namely, genetic polymorphisms. The idea is that if certain gene 
polymorphism changes occur following exposure to a certain substance and those same gene 
polymorphisms changes also occur in the presence of the disease then there may be a link 
between the two entities via the gene polymorphism changes. This can also be statistically 
quantified using enrichment analysis. However, there are several limitations with this approach 
because a disease resulting from an exposure (e.g., colon cancer) can have very different 
properties than the type of colon cancer that is inherited via gene polymorphism changes. 
The MOB-Gene map required a link between a seasonally varying biofactor (e.g., vitamin D) 
and various diseases or BMDDs. The process was similar but instead of gene polymorphism 
changes, any gene link was used (i.e., gene must be connected to the disease and SVB in 
DisGeNET). Additional restrictions were placed on the gene to only include genes that were 
expressed during development. This results in a MOB-Gene Map where BMDDs are linked with 




Figure 20. Differences Between The Traditional Mendelian Randomization Approach And 
My Approach. The Traditional Mendelian Randomization Approach Uses Shared Gene 
Polymorphism Data. My Modified Mendelian Randomization Approach Uses Shared Genes 


















My framework combines data from three public data repositories: PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), DisGeNET (http://www.disgenet.org) (Piñero et al., 
2015) and the Gene Ontology (GO - http://geneontology.org). Figure 21 illustrates the overall 
framework approach. Each step is described in more detail in the sections that follow. 
5.3.1 Assembling Data Sources from Existing Data Repositories 
Using PubMed, my algorithm searched for SVBs in humans (Homo sapiens). All non-humans 
(e.g., rats, geese, and even non-human primates) were excluded and human physiological state 
was ignored (e.g., post/pre menopausal, old/young). Figure 22 contains an example of two SVBs 
extracted from a study by Meier et al. (Meier et al., 2004) demonstrating the seasonality of 
parathyroid hormone (PTH) and vitamin D (specifically calcifediol). In Figure 22, one can see 
that PTH tends to be higher in the winter months (Jan-Mar) while vitamin D is noticeably higher 
in the late spring / summer months (Jun-Aug).  
To develop a list of literature-backed SVBs, I first queried PubMed using the following: 
 (human) AND "seasonal variation" 
which returned 4,091 articles. I then added a species filter (humans) and a language filter 
(English), which reduced the results set down to 3,627 articles. 
This study is primarily interested in SVBs and not disease flare-ups (e.g., asthma exacerbations 
occur seasonally). Therefore, I modified the query to also include the compound. I then ran this 
for a large variety of compounds (e.g., vitamin D, lactic acid, eosinophils, neutrophils, estrogen, 
testosterone) to retrieve articles related to their seasonality or lack thereof. I read through the 
resulting abstracts to determine if the result was correct and to remove any non-human studies 
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that passed through the earlier filter. After these initial checks, I determined if seasonal variation 
was found or not found by the study. 
Previously, a curated reference set of BMDDs was assembled to assess the quality of SeaWAS 
results (Boland et al., 2015b). The details of the assemblage of this set is described in chapter 
two and in the subsequent literature publication (Boland et al., 2015b). Because I wanted a list of 
BMDDs with at least 1 publication supporting the relationship between birth month and disease 
risk, the original list was extended to include the 12 novel findings from my SeaWAS study 
described in chapter two. Supplemental information is available for this study on figshare. I will 
use the phrase ‘see supplement’ throughout this chapter when I am referring to figshare 
accessible via the following link: 
figshare.com/s/b47610ea62d111e5b56406ec4bbcf141 
Each SVB was mapped to a disease involving dysregulation of a SVB because DisGeNET only 
contains genes associated with disease states. For example, vitamin D is an SVB. Hence vitamin 
D deficiency was used as one of the diseases involving the SVB vitamin D. All genes implicated 
via association studies in the disease of vitamin D deficiency were used as vitamin D genes. To 
match SVBs to diseases in DisGeNET, substring matching was performed using the SVB query 
term. In some cases, I had to modify the SVB search term used. This was done to ensure that 
SVBs such as vitamin C (also known as ascorbic acid) were mapped properly. A list of SVBs 
and the exact query terms used for extracting genes from DisGeNET is included with the 
supplement. Examples in Table 9 are included for explanatory purposes along with example 
diseases and example genes implicated in those diseases for each SVB in Table 9. However, 




Figure 21. Overview of My Method Designed to Locate Genes 









































































































Calcifediol − 25(OH) Vitamin D
Figure 22. SVBs (parathyroid hormone and calcifediol) measured by 
Meier et al. 2004. Best-fit lines were applied and slight non-significant 
anti-correlation was observed (r=-0.303, p=0.338). 
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Table 9. Examples of SVBs and DisGeNET query terms used to extract SVB-related diseases and genes potentially 
involved in perturbation of SVBs 
SVB SVB query term used Example Disease Names  Example Genes Implicated  





“Parathyroid” Pseudo-hypoparathyroidism, Parathyroid 
Neoplasms 
GNAS, CDC73 
Vitamin C “ascorbic_acid” Ascorbic Acid Deficiency GSTK1, HP, SLCO6A1 
Vitamin K  “Vitamin_K” Vitamin K Deficiency, Vitamin K Dependent 
Clotting Factors Combined Deficiency  
GGCX, VKORC1, F7 
Neutrophil “Neutrophil” Neutrophil Actin Dysfunction, Hereditary 
Neutrophilia 
PARP1, CYBA, CSF3R 
Eosinophil “Eosinophil” Eosinophilia, Hyper-eosinophilic Syndrome IL5, FIP1L1, PDGFRA 
Hemoglobin “Hemoglobin” Hemoglobinopathies, Methemoglobinemia HBB, CYP1A2, HBA1 
Estrogen “Estrogen” Oestrogen deficiency, Estrogen Resistance  ESR1, RBBP4, BCAR1, PPP2CA 
Additionally, I mapped the list of BMDDs to diseases in DisGeNET. I did this using 
approximate string matching similar to above. For this proof-of-concept, I randomly chose 7 
BMDDs for this analysis provided they spanned the distribution of the number of distinct genes. 
The seven BMDDs and their query terms used in DisGeNET are given in Table 10. I only used 7 
BMDDs because I wanted to test the feasibility of my framework and algorithm. Note the 
number of distinct genes involved in each disease varies largely from 21 genes (reproductive 
performance) to 1253 genes (asthma). I randomly selected the BMDDs with this one constraint. 
Table 10. BMDDs included in proof-of-concept along with query terms, example genes implicated and counts of genes 
involved in BMDD 
BMDD BMDD query term used Example Genes Implicated No. Distinct 
Genes 
Asthma “Asthma” SCGB1A1, TNF, CCL11 1253 
Attention Deficit 
Disorder 
“attention_deficit_disorder” COMT, LPHN3, GRM5 338 
Atrial Fibrillation “Fibrillation” ACE, NOS3, KCNE2, SELE, VWF 318 
Reproductive 
Performance 
“Reproductive” BRCA1, BRCA2, TLR4, ESR1, MBL3P 21 
Cardiovascular 
Disease 
“Cardiovascular” ACE, APOB, LPL, MTHFR 775 
Cardiomyopathy “Cardiomyopathy” CSRP3, TTN, DES, TMPO, VCL 717 
Mitral Valve Disorder “mitral_valve” FBN1, AGTR1, FBN2, NPPB, PLAU, COL3A1 82 
 
5.3.2 BMDD-SVB Pair Enrichment Algorithm 
My algorithm is designed to uncover BMDD-SVB pairs that were enriched using their respective 
gene sets. The first step was the creation of an empirical null distribution for each disease. For 
each BMDD, genes were randomly extracted from DisGeNET (of the same size as the number of 
 108 
genes for that BMDD). Therefore, 1,253 distinct genes would be randomly pulled from 
DisGeNET for the empirical null distribution for asthma. However, for reproductive 
performance only 21 genes would be randomly pulled. The overlap was calculated between the 
SVB and the random gene set. This sampling protocol was iterated for 100 times and then an 
overall average overlap was computed. Fisher’s exact test was performed between the true 
BMDD-SVB pair and the random average overlap computed above (Table 11). Bonferroni 
correction was applied to adjust for multiple comparisons.  
5.3.3 Restrict to Genes Involved in Developmental Processes  
Using the Gene Ontology (GO), the gene set was restricted to only include those genes involved 
in developmental processes. Only genes with at least one GO term containing ‘develop’ in its 
annotation term description were retained. So for example, if a gene contained the term ‘positive 
regulation of hair follicle development’ or ‘embryonic placenta development’ it was retained. 
This further reduced the gene set to about 30% of the size (for asthma, 439 asthma genes were 
enriched in asthma-SVB pairs and only 140 had at least one developmental GO term). 
5.3.4 Construct Bi-Partite Networks 
To visualize the results, I created bi-partite graphs similar to (Lorberbaum et al., 2015) for each 
SVB. BMDDs are included if they are enriched for overlapping genes with the SVB of interest. 
Each SVB (shown on the left side of the graph) is linked to BMDDs (shown on the right side of 
the graph) that are enriched in overlapping genes that are depicted in the middle portion of the 
graph. Only genes with a developmental GO process are included. DAVID was used (Huang et 
al., 2008; 2009) to annotate the genes and identify functional gene modules. Network 
visualization was performed using Cytoscape (Shannon et al., 2003).  
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Table 11. The Structure of the Enrichment Algorithm: Each BMDD-SVB Pair was Compared Against a Randomly 
Generated BMDD-SVB Pair Specific for that BMDD 
 No. of BMDD Genes Per SVB No. Genes Per SVB – No. 
BMDD Genes Per SVB 
Actual BMDD-SVB Pair A B 
Randomly Generated* C D 
* Random was the average across 100 random gene set extractions from DisGeNET using the same number of genes as 
the BMDD 
5.4 Results 
5.4.1 Using Existing Data Repositories to Assemble Key Datasets 
The original search returned 3,627 articles related to seasonal variation in humans. Therefore, I 
included additional query terms for biological compounds such as hormones, vitamins, and 
immune-related cells that are thought to vary seasonally. This allowed for the identification of 22 
SVBs that are known to vary seasonally in humans. It also found 2 compounds (Homocysteine 
and Glutaric acid) that are not known to vary seasonally and one that varies seasonally in animals 
(Corticosterone) but with no human studies currently. I focused on the 22 SVBs that are 
confirmed to vary seasonally in humans by published studies indexed by PubMed. I used these as 
input for the enrichment algorithm. Table 12 contains the references supporting the seasonal 
relationship and references that refute the relationship, if any exist. 
I combined results from my SeaWAS study with a carefully curated set of diseases related to 
birth month that I developed previously. This file is available with the supplement and includes 
the PubMed ID, publication year, disease area (high-level disease category), and a binary 
variable indicating whether the study found or failed to find the association. In this feasibility 
study of the algorithm’s framework, 7 randomly chosen BMDDs were selected with one 
constraint: that the number of distinct disease genes differed largely. For example, 21 genes were 
implicated in reproductive performance while 1253 genes were implicated in asthma.  
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SVBs and BMDDs were mapped to DisGeNET to extract genes associated with each SVB and 
BMDD. Examples of the extraction process are given in methods Table 9 and Table 10. For this 
study, I ran the DisGeNET extraction on 7 random BMDDs with different gene set sizes. I also 
used DisGeNET to extract the genes related to the 22 SVBs given in Table 12 (folate and folic 
acid are counted as separate SVBs but merged under vitamin B9 in Table 12).  
5.4.2 Enrichment Results 
The enrichment algorithm investigates the overlap among gene sets from the BMDD and each 
SVB. It compares this overlap to an average across 100 randomly generated gene sets of the 
same size (i.e., number of genes) as the particular BMDD of interest. The average overlap score 
from the 100 random sets is compared against the actual number to determine significance using 
Fisher’s exact test. P-values were adjusted using the Bonferroni correction method. I then ranked 
each significant BMDD-SVB pair by the ORs. Results are shown in Table 13 with the top three 
associations in bold. 
The top SVBs associated with each BMDD are biologically intuitive. Cardiovascular disease is 
known to involve vitamin K regulation with the anti-coagulant drug warfarin targeting the well-
studied vitamin K gene: VKORC1. The two top SVBs related to asthma (a known immune-
related condition) are also immune related: eosinophils and neutrophils (Kidd et al., 2016). Atrial 
fibrillation’s top hits are calcium related and atrial fibrillation is associated with increased 
calcium release from the sarcoplasmic reticulum (Hove-Madsen et al., 2004). 
5.4.3 Restrict to Genes Involved in Developmental Processes  
Genes were restricted to include only genes involved in at least one developmental process using 
GO annotations. This was primarily because genes that are involved in developmental processes 
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are more likely to play a role in birth month associations. This reduced the number of potential 
genes as shown in Table 14.  
Table 14 illustrates how the algorithm started with 1,253 genes associated with Asthma as 
extracted from DisGeNET. Because asthma is also known to be associated with birth month and 
a BMDD, I ran the algorithm to find overlapping genes between asthma and SVBs where the 
overlapping genes were enriched. This reduced the number of genes potentially involved in a 
seasonally varying process at birth down to 439 genes from 1253. I then restricted these 439 
genes to only include genes known to be involved in some developmental process using GO term 
annotations. This further reduced the number of genes down to 140. Therefore, only 11.2% of 
asthma-related genes are potentially involved in developmental processes related to SVBs that 
could potentially lead to birth month-related effects. 
5.4.4 Developmentally Expressed Genes Link SVBs to BMDDs in Biological Graphs 
My algorithm produces output containing each BMDD, the enriched SVBs and the overlapping 
genes that are developmentally expressed between the BMDD and the SVB. A file containing 
tuples of BMDD, SVB, and gene is available in the supplement. 
For illustrative purposes, I show three SVB graphs from this feasibility study: two immune cells  
(eosinophil and neutrophil) and one hormone (parathyroid hormone). Full resolution images are 
available with supplemental information. The immune cells are shown in Figure 23, the SVB is 
represented by a triangle, the BMDD is represented by a square and circles represent the 
overlapping genes. Cluster annotations from DAVID are shown above or near each cluster. In 
the neutrophil graph (Figure 23A) there are clusters involving blood vessel development, 
response to an organic substance, positive regulation of nitrogen compound metabolic processes, 
regulation of cell proliferation and embryonic development / birthing. In Figure 23B, the largest 
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cluster includes genes related to the immune response (as expected). Other clusters are for 
neuron development, tube development (e.g., neural, endothelial tubes), response to sterol 
hormone synthesis and insulin stimulus. The same five BMDDs are involved in both: attention 
deficit hyperactivity disorder (ADHD), cardiomyopathy, atrial fibrillation, cardiovascular 
disease, and asthma. Eosinophils and neutrophils are in the top three most enriched SVBs for 
both asthma and ADHD (Table 13). Its possible that the genes involved in neuron development 
is responsible for the ADHD – Eosinophil relationship (Figure 23B).  
Figure 24 shows the graph for parathyroid hormone (PTH). There are three main genetic 
processes involved: positive regulation of the development process, receptor linked signal 
transduction, and response to hormone stimulus. Not only is parathyroid hormone a hormone, but 
it also is involved in regulation or other hormones. Both PTH and vitamin D are hormones that 
regulate each other through complex mechanisms. Positive regulation of the development 
process is also enriched in this graph connecting PTH and BMDD this fits with the involvement 





Table 12. Biofactors With Seasonal Dependencies Extracted from the Literature 
  Seasonal Relationship 
Biofactor Notes Reference Supporting Reference 
Refuting 
Hormone    
Parathyroid Hormone (PTH)  PTH and vitamin D are slightly anti-
correlated  
(Meier et al., 2004; 
Steingrimsdottir et al., 
2005) 
 
Estrogen (modulated through Vitamin D) (Lee et al., 2012)  
Estradiol   (Bjørnerem et al., 2006)  
Testosterone  (modulated through Vitamin D) (Lee et al., 2012)  
Progesterone  (modulated through Vitamin D) (Lee et al., 2012)  
Vitamins/Minerals    
Vitamin A (retinol, beta-carotine)  Bitot eye spots are a sign of vitamin a 
deficiency 
(Basu et al., 1994; Khan 
and Khan, 2005; 
Woodhouse and Khaw, 
2000; Xiang et al., 2008) 
 
Vitamin B9: Folate and Folic Acid   (Hao et al., 2003; 
McKinley et al., 2001) 
 
Vitamin B12  (Palva and Salokannel, 
1972) 
 
Vitamin C (Ascorbic acid)   (Hallmann et al., 2013; 
Paalanen et al., 2013; 
Woodhouse and Khaw, 
2000) 
 
Vitamin D   (Douglas, 1993; Meier et 
al., 2004; Steingrimsdottir 
et al., 2005) 
 
Vitamin E  (Woodhouse and Khaw, 
2000) 
 
Vitamin K  Vitamins K and D regulate osteocalcin (Anai et al., 1991; 
Douglas, 1993) 
 
Calcium  (Douglas, 1993; Meier et 
al., 2004; Steingrimsdottir 
et al., 2005) 
 
Phosphate  (Douglas, 1993)  
Immune Cells    
Neutrophil  (Gelardi et al., 2014; 
Klink et al., 2012) 
 
Eosinophil  (Gelardi et al., 2014; 
Henriksen, 1986; Liu, 
1988) 
 
Basophil  (Liu, 1988) (Henriksen, 
1986) 
Other Cells/Metabolites    
Hemoglobin  (Lee et al., 1987)  
Uric Uric acid (Parks et al., 2003)  
Creatine  (Percy et al., 1982)  
















A. Neutrophil Network  B. Eosinophil Network 
Figure 23. Immune Cell Bi-Partite Networks Connecting SVBs to BMDDs Via Overlapping 
Genes Involved in Developmental Processes. Full resolution images are available on figshare 
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Table 13. BMDD-SVB Enriched Overlapping Gene Sets Sorted by OR 
BMDD Disease Enriched SVB OR -log(p) * 
Asthma Eosinophil 23.545308 92.3610942 
 Neutrophil 7.608800 41.7971736 
 Vitamin D 7.597455 4.9508901 
 Phosphate Gene Set 1 (Phosph) 6.787030 36.4156313 
 Hemoglobin 6.684969 19.1382008 
 Uric 5.672420 12.1008132 
 Calcium Gene Set 2 (Calcinosis) 4.085383 5.4623019 
 Calcium Gene Set 1 (Calci) 3.511367 9.7828493 
 Phosphate Gene Set 2 (Phosphate) 5.095905 10.1171083 
 Parathyroid Hormone 4.494405 23.8948578 
ADHD Eosinophil 3.805091 5.2892789 
 Parathyroid Hormone 3.553309 11.9138662 
 Neutrophil 3.308624 9.2041648 
 Phosphate Gene Set 1 (Phosph) 3.302909 9.7728579 
 Calcium Gene Set 1 (Calci) 2.679110 7.5585981 
 Calcium Gene Set 2 (Calcinosis) 2.043983 7.1930726 
Fibrillation Calcium Gene Set 2 (Calcinosis) 12.287454 7.1930726 
 Phosphate Gene Set 1 (Phosph) 6.440454 9.7728579 
 Parathyroid Hormone 6.437664 11.9138662 
 Calcium Gene Set 1 (Calci) 6.380333 7.5585981 
 Neutrophil 6.252987 9.2041648 
 Eosinophil 6.242087 5.2892789 
Reproductive - - - 
Cardiovascular Vitamin K 45.187116 5.8861829 
 Folic Acid 14.548556 6.5377502 
 Vitamin D 13.319860 6.1949509 
 Phosphate Gene Set 2 (Phosphate) 11.560768 23.1079644 
 Phosphate Gene Set 1 (Phosph) 9.246976 39.8563236 
 Uric 9.174204 17.0939677 
 Calcium Gene Set 2 (Calcinosis) 8.543921 13.0824611 
 Calcium Gene Set 1 (Calci) 8.492730 28.6820297 
 Neutrophil 7.892360 28.6839072 
 Eosinophil 6.946996 19.5349288 
 Hemoglobin 6.384460 11.7733926 
 Parathyroid Hormone 4.149517 13.8335245 
Cardiomyopathy Vitamin D 10.145258 3.851662 
 Eosinophil 8.923802 25.690966 
 Lactic 8.159469 6.974233 
 Hemoglobin 7.666338 15.743251 
 Calcium Gene Set 2 (Calcinosis) 7.616024 10.981833 
 Neutrophil 6.468582 21.428566 
 Phosphate Gene Set 1 (Phosph) 6.284259 22.014083 
 Calcium Gene Set 1 (Calci) 6.049040 16.056148 
 Uric 5.784556 6.909913 
 Parathyroid Hormone 4.781197 16.279232 
 Phosphate Gene Set 2 (Phosphate) 4.342993 3.422636 
Mitral Valve Phosphate Gene Set 1 (Phosph) 16.780523 5.1995428 
 Calcium Gene Set 1 (Calci) 13.587347 3.2560223 
* greater than 3.0 is significant after Bonferroni correction 
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Table 14. Number of Genes Involved in BMDD That Are Potentially Involved in Birth Month Contribution to Disease is 
Drastically Reduced After Framework Is Applied 
BMDD No. Distinct 
Genes  (A) 
No. of Overlapping 
Genes from Enriched 
BMDD-SVB Pairs (B) 




% of Genes Potentially Involved 
in Birth Month Contribution Out 
of All BMDD Genes (C / A) 
Asthma 1253 439 140 0.112 
ADHD 338 63 18 0.053 
Fibrillation 318 105 45 0.142 
Reproductive 21 - - - 
Cardiovascular 775 302 109 0.141 
Cardiomyopathy 717 250 89 0.124 
Mitral Valve 82 24 15 0.183 
 
 
Figure 24. Graph Connecting Parathyroid Hormone with BMDDs Via Overlapping 







































































5.5.1 Value of a High-throughput Birth Month-Disease Dependency Genetic Algorithm 
The relationship between genes, environment and disease has been discussed by medical 
researchers since the early days of genetics (Boland et al., 2013b). Because the relationship 
between genes and the environment is complex, researchers originally investigated single 
environmental exposures and how those exposures influenced disease risk via genetic changes 
(Wei et al., 2012). Later the Environment-Wide Association Study (EWAS) was developed, 
which explored a large variety of environmental exposures (not just one as was done previously) 
and then explored how those exposures effected one single disease: Type 2 Diabetes (Patel et al., 
2010). While an improvement over previous work, EWAS was still limited to exploring one 
disease at a time. 
The original SeaWAS study, described in chapter two, revealed multiple birth month-disease 
dependencies (called BMDDs). Additionally, 92 other articles revealed additional information on 
BMDDs. None of these epidemiological studies sheds light on the genetic underpinnings of 
BMDDs. Therefore, a method was required that could investigate diverse environmental triggers 
across a plethora of diseases and disease types. To address this gap, I developed an algorithmic 
framework to uncover enriched SVBs related to BMDDs described in this chapter.  
In addition to finding SVBs enriched in BMDDs, I also explored the overlapping genes 
implicated in both the SVB and the BMDD. I limited my investigation to only those genes that 
are known to be involved in developmental processes to hone in on genes that are potentially 
responsible for birth month disease dependencies.  
5.5.2 Highlighting One Well-Studied Disease: Asthma 
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The top SVBs enriched for asthma were eosinophil (OR=23.545), neutrophil (OR=7.601) and 
vitamin D (OR=7.597) (Table 13). The relationship between eosinophils (key cells in the 
immune response) and asthma is well known and studied (Busse and Sedgwick, 1992). At the 
same time asthma exacerbations and underlying gene expression changes are also known to vary 
seasonally (Bjornsdottir et al., 2011). As revealed by my framework, there is also literature 
support for a relationship between eosinophil changes and season (Gelardi et al., 2014; 
Henriksen, 1986; Liu, 1988). My framework revealed 42 genes in common between asthma and 
eosinophils that are also involved in developmental processes (the entire eosinophil network is 
shown in Figure 23B). The immune response was the key functional process involved along 
with neuron development (which could help to explain the interesting relationship between 
eosinophils and ADHD). 
Table 13 reveals an interesting relationship between asthma and ADHD: they both share 
eosinophils and neutrophils among their top three SVB enrichments (asthma also has vitamin D 
and ADHD has parathyroid hormone—which are also related to each other). When I investigated 
the biological network (Figure 23B), the enrichment in neuron development genes is revealed. 
Importantly, asthma patients are known to be at increased risk for developing ADHD and this 
increased risk was observed even after adjusting for urbanization and comorbid allergic diseases 
suggesting an underlying etiology behind the two diseases (Chen et al., 2013). Others have also 
studied the relationship between asthma and ADHD (Secnik et al., 2005) without uncovering a 
clear genetic/biological mechanism for the relationship. Importantly, my framework enables 
researchers to construct biological networks that connect complex associations between SVBs 
and BMDDs through their shared underlying genetic pathways. This enables researchers to 
formulate and test hypotheses behind disease etiology and progression. 
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5.6 Limitations  
This study is limited by the information contained and available on PubMed regarding biofactors 
that vary seasonally (SVBs) and BMDDs. Therefore, neither of these lists is fully complete as 
there may be other studies not reported in PubMed, studies not translated into English and so 
forth that would prevent utilization of their findings in my framework. My initial query to 
PubMed returned 3,627 articles related to seasonal variation in humans. Because I was primarily 
interested in biological compounds that vary seasonally (such as hormones, vitamins, immune 
cells), I added additional query terms (as specified in the methods section). Manually reviewing 
all 3,627 articles was not feasible; therefore some lesser-known SVBs may be missing. 
Additionally, the fetal-maternal barrier warrants further investigation as the placenta is known to 
be susceptible to environmental effects (Nelissen et al., 2011). Incorporating knowledge on the 
epigenetics of the placenta could help with understanding the underlying disease mechanism 
(Nelissen et al., 2011).  
5.7 Conclusion 
In this chapter, I present a framework that combines existing data repositories (PubMed, GO, and 
DisGeNET) to uncover biological mechanisms underlying birth month – disease dependencies 
(BMDDs) using known Seasonally Varying Biofactors (SVBs). This framework allows me to 
link epidemiological data on birth month-disease relationships and genetic data on gene-disease 
associations recorded in existing public data repositories. My algorithm finds enriched BMDD-
SVB pairs using the genes involved in both the disease and the SVB. I then investigate the 
overlapping genes in these enrichments and trim away genes not known to be involved in 
developmental processes using GO annotations. My framework produces a bipartite graph that 
connects enriched SVBs with BMDDs through their overlapping developmental gene sets. Thus 
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allowing the formation of biological hypotheses around the genetic mechanisms underlying birth 
month-disease dependencies. As a proof-of-concept, results are presented from 7 BMDDs across 
all identified known SVBs.  
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A Phenocopy of the Birth Season – 




Seasonal factors occurring during the prenatal or perinatal period can affect long-term disease 
outcomes. In chapter two, I described the use of clinical data from 1.7 million patients to identify 
55 diseases correlated with birth season. However, this work did not reveal the environmental 
drivers underlying these associations. Vitamin D is a seasonally varying compound synthesized 
in the skin using 7-dehydrocholesterol and ultraviolet B radiation. A competing reaction occurs 
to convert 7-dehydrocholesterol to cholesterol via 7-dehydrocholesterol reductase (DHCR7). 
Deleterious mutations in DHCR7 decrease the ability to produce cholesterol and enhance 
production of vitamin D. Thus making DHCR7 mutations more evolutionarily favored in regions 
of the world with historically low sunlight access.  
Importantly, a rare Mendelian disease - Smith-Lemli-Opitz Syndrome (SLOS [MIM 270400]) is 
characterized by compound heterozygous mutations in DHCR7. SLOS results in severe fetal 
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deformities and malformations. In this study, I discuss the toxicological information gleaned 
from a deep exploration of DHCR7. First, I present a compilation of SLOS-inducing DHCR7 
mutations and the geographic distribution (S. America, Europe, Australia, Asia) of those 
mutations among diseased populations. I describe several hypotheses for DHCR7 mutations that 
would maximize vitamin D production via increased evolutionary pressure. Next, I looked at the 
mutational spectrum of DHCR7 in an ethnically diverse, presumed healthy population from 
ExAC (http://exac.broadinstitute.org/). This study observed that several mutations thought to be 
disease causing occur in healthy populations as well, sometimes with high frequencies, 
indicating an incomplete understanding of SLOS and highlighting new research opportunities. I 
also highlight several DHCR7 variants found in ExAC that could represent SLOS carriers in 
under-represented ethnic groups.  
Knowledge of the importance of vitamin D during the prenatal period coupled with an enhanced 
global understanding of the DHCR7 mutational spectrum allowed me to hypothesize that 
exposure to DHCR7 inhibitors would result in deleterious effects similar to SLOS. I tested this 
hypothesis by investigating the fetal outcomes following prenatal exposure to DHCR7 
modulators. First-trimester exposure to DHCR7 inhibitors resulted in outcomes similar to those 
of known teratogens (50% vs. 48% born-healthy). DHCR7 activity should be considered during 
drug development and prenatal toxicity assessment.  
6.2 Introduction 
Mendelian diseases are genetic conditions that follow a ‘traditional’ pattern of inheritance. 
Previously, researchers utilized information from Mendelian gene mutations to study shared 
underlying disease mechanisms that are common to non-Mendelian diseases in complex diseases 
(Blair et al., 2013) and cancer (Melamed et al., 2015). Mendelian diseases are also useful in 
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studying developmental effects of gene mutations and can help researchers understand the effects 
of a potential pharmaceutical target or off-target effect (Bunnage et al., 2015) increasing the 
impact of their discoveries (Fishman and Porter, 2005). Understanding the underlying 
mechanisms of Mendelian diseases can enable a priori prediction of fetal outcomes following 
prenatal pharmaceutical exposure.  
In this review, I detail one orphan Mendelian disease - Smith-Lemli-Opitz Syndrome (SLOS) 
resulting from mutations in 7-dehydrocholesterol reductase (DHCR7). These mutations affect a 
pathway involving vitamin D and cholesterol production. Mutations affecting vitamin 
metabolism can play an important role in drug response (Carr et al., 2009). In-depth study of this 
biological pathway enables us to explain off-target effects of prenatal drug exposure and 
highlights DHCR7’s importance in drug development for potential prenatal toxicity assessment. 
6.2.1 Clinical Characteristics  
SLOS was first identified in 1964 when physicians described a similar pattern of congenital 
anomalies, including mental retardation, incomplete external genitalia, and abnormalities of face, 
hands, and feet that followed a familial inheritance pattern (Smith et al., 1964). Later it was 
discovered that extremely high 7-dehydrocholesterol levels and surprisingly low serum 
cholesterol levels were common biomarkers of SLOS. This led to the discovery of the exact 
location in the cholesterol synthesis pathway that was defective in SLOS patients, namely the 
conversion of 7-dehyrocholesterol into cholesterol (the last step in cholesterol biosynthesis) (Tint 
et al., 1994). Subsequently, DHCR7 was identified as the culprit gene (Fitzky et al., 1998). 
DHCR7 is the only enzyme that converts 7-dehydrocholesterol to cholesterol (Wilcox et al., 
2007). Cholesterol cannot be produced without DHCR7.  
The physical presentation of SLOS differs widely among individuals, varying by severity, 
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genotype, and other environmental factors (Jira et al., 2003). The most frequently occurring 
feature is 2/3 toe syndactyly (i.e., “webbed toes”) occurring among 97% of patients followed by 
mental retardation with 95% of patients (Jira et al., 2003; Kelley and Hennekam, 2000). Other 
common signs include microcephaly (84%), postnatal growth retardation (82%), anteverted nares 
(78%), ptosis (70%), genital anomalies (65%), and congenital heart defects (among 54% of 
SLOS patients) (Jira et al., 2003; Kelley and Hennekam, 2000). SLOS severity ranges across a 
wide spectrum. Some SLOS patients present with a mild form (Prasad et al., 2002) with minimal 
symptoms and no developmental delay (Nowaczyk and Irons, 2012). Others have a severe form 
that can result in a lack of sexual dismorphism with a functional XY karyotype and female 
internal and external genitalia (Fukazawa et al., 1992).  
The importance of cholesterol in prenatal embryonic and fetal development, and its partial to 
complete absence in SLOS, helps to explain the pleotropic phenotypes within SLOS. In patients 
possessing homozygous null mutations in DHCR7, cholesterol production is absent and prenatal 
lethality results (Lanthaler et al., 2013). Other mutations reduce DHCR7 expression to less than 
5%, dramatically reducing cholesterol production in the body (Fitzky et al., 1998).  
6.2.2 Genetic Characteristics 
SLOS is an inherited autosomal recessive disease with each parent contributing one mutated 
copy of DHCR7. Inheritance follows a compound heterozygosis pattern whereby each parent 
contributes one copy of different mutations in DHCR7. Therefore, the SLOS patient is 
heterozygous for two mutations. Being heterozygous for only one mutation generally does not 
cause the SLOS phenotype, although instances have been reported (De Brasi et al., 1999; Fitzky 
et al., 1998). Being homozygous for a null mutation in DHCR7 typically results in prenatal death 
(Lanthaler et al., 2013). This explains why most full-term viable SLOS patients are compound 
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heterozygotes. Figure 25 depicts the autosomal inheritance of SLOS in children and how 
compound heterozygosity is responsible for the disease phenotype. The discrepancy between the 
DHCR7 mutation carrier rate and SLOS incidence (Nowaczyk et al., 2006) is believed to result 
from prenatal loss of individuals with homozygous null mutations during the first trimester 
(Lanthaler et al., 2013). As in many inherited genetic conditions, de novo mutations have also 
been reported (Waye et al., 2007). 
Importantly, the relationship between null mutations in DHCR7 and SLOS severity is not one-to-
one because variations in the maternal genome can increase the amount of cholesterol passed by 
the placenta to the fetus (Lanthaler et al., 2013) modulating the offspring’s phenotype. Because 
cholesterol is critical during early development, having increased prenatal cholesterol levels 
distributed from the mother via the placenta can mitigate many SLOS symptoms (Lanthaler et 
al., 2013). Diverse factors modulate SLOS severity, therefore it is not possible to completely 
predict the disease phenotype using genotype information alone or vice-versa (Witsch-
Baumgartner et al., 2013). 
6.3 Compendium Containing SLOS-Inducing DHCR7 Mutations 
6.3.1 Development of the DHCR7 SLOS Mutation Compendium  
SLOS patients are compound heterozygotes for diverse mutations in DHCR7 or homozygous for 
non-null mutations. SLOS is a rare disease (~1 in 40,000) and studies typically involve only 
small cohorts of patients. Even with small cohorts, many DHCR7 mutations have been reported. 
Therefore, I reviewed the literature, and developed a compendium of SLOS-inducing DHCR7 
mutations. I collected the reported frequencies for each mutation across all studies, and, when 
available, I extracted the patient genotype (i.e., compound heterozygous mutant alleles) and their 
geographic location or ethnicity. Specifically, I am interested in the ethnicities of SLOS patients 
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and their corresponding genotypes because certain gene variants affect outcomes only within a 
given ethnicity (e.g., ACBCB1 variant in Caucasians) (Megías-Vericat et al., 2015). 
To develop the compendium, I analyzed all publically available DHCR7 mutations contained in 
the Human Gene Mutation Database (HGMD) (HGMD, 2015; Stenson et al., 2014) and their 
corresponding publications (HGMD last accessed in May 2015). I kept track of patients’ DHCR7 
genotype information and their ethnicity/geographic origin when available (described later). The 
aggregated allele frequencies for all DHCR7 mutations across 30 studies are given in Table S1 
of the published paper (Boland and Tatonetti, 2016a). This review focuses only on deleterious 
mutations to DHCR7, and therefore does not include 13 silent DHCR7 mutations (Waterham and 
Hennekam, 2012). Using the HGMD, I found 138 distinct publically available mutations to 
DHCR7 and 165 reported (with the additional 27 mutations being proprietary, and only 
accessible via paid membership).  
This literature review revealed additional DHCR7 mutations (by investigating papers cited in 
those retrieved papers) and overall my compendium contains 147 DHCR7 mutations, 145 of 
these being SLOS-inducing mutations. One mis-sense mutation, W158C, was found in an 
unaffected sibling of a SLOS individual (noted in Table S1), and another mutation, G344D, was 
reported in a patient with holoprosencephaly (noted in Table S1) a different mutation at the same 
position, G344R, was reported in a SLOS patient. Mutations in DHCR7 that result in 

























































Figure 25. Full-Term Smith-Lemli-Opitz Syndrome (SLOS) Patients Are Typically 
Compound Heterozygous for Two Distinct Mutations in DHCR7 (Figure 25A) while 
Homozygous Null Individuals are Detected Less Frequently Due to Prenatal Lethality 
(Figure 25B).  
Figure 25 depicts the autosomal inheritance of SLOS in children and how compound 
heterozygosity is responsible for the disease phenotype. Many SLOS genetic studies focus on 
compound heterozygous patients (Figure 25A) because most homozygous phenotypes result 
in prenatal fatalities, reducing the detection rate (Figure 25B). Both W151X and IVS8-1G>C 
are null mutations in DHCR7 meaning that they reduce DHCR7 expression to almost 0% in 
the homozygous state. Therefore if an individual is homozygous for either of these mutations 
or heterozygous for the combo then little to no DHCR7 expression would result (Correa-Cerro 
et al., 2005). On the other hand, T93M is a non-null mutation in DHCR7 that reduces DHCR7 
expression by 5% when compared to normal (Nowaczyk et al., 2004a). Therefore a compound 
heterozygous patient with one IVS8-1G>C null mutation and one T93M mutation would have 
around 45% functional DHCR7 and SLOS would result, but prenatal fatality would be averted 
(Figure 25A). 
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(RS ID) † 
Intron/Exon Allele  Freq.  












IVS8-1G>C* 71146886 rs138659167 Intron 8 291 (28.4) 386 (4.2 X 10-1) 
T93M 71155082 rs80338853 Exon 4 96 (9.4) 3 (2.7 X 10-3) 
W151X 71152447 rs11555217 Exon 6 86 (8.4) 82 (6.8 X 10-2) 
V326L†† 71146873 rs80338859 Exon 9 52 (5.1) 5 (4.8 X 10-3) 
R404C 71146639 rs61757582 Exon 9 36 (3.5) 4 (3.5 X 10-3) 
R352W†† 71146795 rs80338860 Exon 9 34 (3.3) 2 (1.7 X 10-3) 
E448K 71146507 rs80338864 Exon 9 23 (2.2) 1 (8.5 X 10-4) 
R352Q 71146794 rs121909768 Exon 9 22 (2.2) 4 (3.4 X 10-3) 




- - - 13 (1.3) - 
P51S - - Exon 4 12 (1.2) - 
R242C 71150032 rs80338856 Exon 7 12 (1.2) 
10 (8.3 X 10-3) 
F302L 71148915 rs80338858 Exon 8 12 (1.2) 1 (8.3 X 10-4) 
† Obtained from ExAC output, accessed in November 2015 (http://exac.broadinstitute.org/) 
*Annotated as: c.964-1G>C in some literature articles 
†† SLOS patients with single mutations (true heterozygotes) were found (3 patients), 2 had 
mutations in V326L and 1 had a mutation in R352W (Fitzky et al., 1998). Both mutations were 





Table 16. Top 10 DHCR7-SLOS Inducing Mutations  
Ranked By Frequency in ExAC Population  
 


















IVS8-1G>C* 0.420 0.295 0 0.677 0.177 0.165 0.149 0.007 28.062 
W151X 0.068 0.029 0 0.116 0 0.009 0.111 0 8.39 
V330M 0.036 0.012 0.012 0.044 0.018 0.082 0 0.007 0.096 
T154R 0.008 0.010 0 0.014 0 0 0 0 0.193 
R242C 0.008 0.029 0.023 0.008 0 0 0 0 1.157 
S169L 0.008 0.010 0 0.012 0 0 0.110 0 0.868 
G303R 0.007 0.010 0.046 0.005 0 0.009 0 0 0.579 
R363C 0.007 0 0 0.011 0.015 0 0 0 0.096 
G147D 0.007 0 0 0.012 0 0 0 0 0.675 
L157P 0.007 0 0 0.012 0 0 0 0 0.675 
Ethnicity with Highest Allele Frequency For Each DHCR7 SLOS-Inducing Mutation is Bolded 
  130 
6.3.2 Common SLOS-Inducing DHCR7 Mutations 
I found that 12 mutations (of 145 SLOS-inducing mutations) occurred with allele frequency of at 
least 1% across the 30 reviewed studies (Table 15). The most common of these were IVS8-
1G>C (28.446%), T93M (9.384%), W151X (8.407%) V326L (5.083%), R404C (3.519%), and 
R352W (3.324%). I compared this result to data obtained from 60,706 assumed healthy 
individuals (i.e., non-SLOS) to determine the frequency of various DHCR7 mutations in that 
reference population. I used the ExAC database (Lek et al., 2015) available at 
http://exac.broadinstitute.org/ (accessed November 2015). These results are also given in Table 
15. The majority of frequent DHCR7 mutations in SLOS patients also occur at higher 
frequencies in the ExAC population (this is intuitive). There are two exceptions: T93M that was 
common among SLOS patients (9.4%) but rare in the healthy population (only 3 allele mutations 
observed out of 60,706 individuals). Another counter-intuitive result was that R242C was found 
relatively frequently in the ExAC population (10 allele mutations observed), but was only 
mutated in 1.2% for SLOS. I present the top 10 DHCR7 SLOS-inducing mutations as ranked by 
their incidence in the ExAC population and their corresponding incidence in the SLOS patient 
set in Table 16. All of the SLOS DHCR7 mutations were less than 1% frequency in the ExAC 
population. I compared the entire compendium of DHCR7 mutations to ExAC. The results of 
this comparison including accession numbers and chromosomal locations are given in Table S2 
(of the published paper).  
A SLOS review from 2005, mentioned 11 mutations with at least 1% frequency across SLOS 
patients (Yu and Patel, 2005). I compared my findings to theirs and noticed that the top 8 
mutations remain unchanged. I noted that two additional mutations were on the list, namely 
R352Q (2.151%) and P51S (1.173%) and one mutation on their list was not included in mine, 
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namely S169L (Yu: 1.6%) having a frequency of 0.868% in my compilation of 30 studies (Table 
S1, Table 15).  
The availability of Korean genetic data resulted in the addition of R352Q (Oh et al., 2014) to the 
list of frequent SLOS mutations (>=1%). Importantly, while SLOS occurs more frequently 
among Europeans (Nowaczyk et al., 2001; Nowaczyk et al., 2006), mutations in DHCR7 exhibit 
an evolutionary pressure towards Northern Europeans and Northeast Asians (Kuan et al., 2013), 
indicating that SLOS may be currently under-reported among Northeast Asians. Therefore, as 
more genotype data becomes available from non-European SLOS patients, I would expect the 
common allele frequencies to change somewhat and become less biased towards Northern 
Europeans. 
A couple of DHCR7 mutations were reported to cause SLOS in the heterozygous form (De Brasi 
et al., 1999; Fitzky et al., 1998; Patrono et al., 2002; Waye et al., 2005). However, it is likely that 
an unidentified suspected variant was present in these instances, as SLOS results from two 
defective copies of DHCR7, either in a compound heterozygous state (2 different DHCR7 
mutations) or a homozygous mutated state. Importantly some asymptomatic siblings of SLOS 
patients were heterozygous carriers of the null W151X mutation (they should have around 50% 
expression of DHCR7) and they exhibited no symptoms of SLOS suggesting that the disease 
causing state requires DHCR7 expression to be <50% (Fitzky et al., 1998). This also confirms 
that one copy of a DHCR7 mutation does not result in SLOS. 
6.4 DHCR7 Mutations Vary By Geographical Location 
6.4.1 Specific DHCR7 Mutations Exhibit Geographic Dependency 
SLOS incidence ranges by geographical location and ethnicity because carrier frequencies vary 
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by region (Nowaczyk et al., 2006). Reports range from 1 in 9,000 from Czechoslovakia and 
Central European populations to 1 in 40,000-70,000 in Canada (Nowaczyk et al., 2006; 
Nowaczyk et al., 2004b). The incidence in both the United States of America (USA) and 
Europeans is 1 in 30,000 live births (Nowaczyk et al., 2001; Nowaczyk et al., 2006). Variations 
in reported incidence rates are thought to be due to sampling bias differences. The carrier rate, or 
the proportion of individuals with one copy of a known SLOS-inducing DHCR7 mutation, is 
estimated to be 3% among persons of European ancestry (Nowaczyk et al., 2001) while another 
study found 1-2% among Caucasians (Porter, 2008). In the USA the carrier frequency is 1% 
(Cross et al., 2014; Waye et al., 2002), although in the state of Utah the carrier rate is 4% (Opitz 
et al., 2002).  
Mutation frequencies are known to vary by geographic location / ethnicity (Fricke-Galindo et al., 
2016). Likewise, the spectrum of DHCR7 mutations varies by geographical location. There is 
evidence that T93M is the founder mutation with origins in the Mediterranean basin (Nowaczyk 
et al., 2004a) and is common in Italy, Spain, (Kozák et al., 2000; Witsch-Baumgartner et al., 
2001; Witsch‐Baumgartner et al., 2005) and Portugal (Cardoso et al., 2005). On the other hand, 
Northern Europeans (Austrians, Germans, Dutch) present with the W151X mutation more 
frequently (Lanthaler et al., 2013; Witsch‐Baumgartner et al., 2005). In Korea, three mutations 
account for most of the observed variants (Oh et al., 2014). Persons of African ancestry rarely 
develop SLOS, however some carriers were observed among persons of African ancestry 
(Nowaczyk et al., 2001). One SLOS patient with Spanish-African mixed ancestry was identified, 
this patient had T93M (the common Spanish SLOS allele) and V281M (Nowaczyk et al., 2004a). 
The carrier frequency of DHCR7 mutations among African Canadians was low at 0.79% (Waye 
et al., 2002). 
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The relationship between the specific combinations of DHCR7 mutations and 
ethnicity/geographic location of SLOS patients warranted further exploration. Therefore, I 
extracted all genotype data for SLOS patients that also contained ethnicity details, or where the 
ethnicity could be deduced (e.g., a German study enrolling patients in Germany). Not all studies 
listed in Table S1 reported the genotype and ethnicity information for DHCR7 mutations. The 
aggregated results are shown in Table 17 with genotype data from 21 studies representing 229 
patients from 26 different countries/ethnicities (if mixed ethnicities are included). The exon 
distribution of the 1024 alleles with DHCR7 mutation information available is shown in Figure 
26A. The proportion of DHCR7 mutations that exist in a trans-membrane domain are shown in 
Figure 26B. Three protein structure models are shown in Figure 26B because the 3-dimensional 
structure of DHCR7 has not been solved yet. The three models are: the human protein reference 
database (HPRD) containing trans-membrane exon bound information, the Waterham et al. study 
(Waterham and Wanders, 2000), and the Fitky et al. study (Fitzky et al., 1998). I also analyzed 
the 170 compound heterozygous patients (typical SLOS patients) with geographic/ethnicity data 
from Table 17 in Figure 26C, Figure 26D, Figure S1.  
6.4.2 Exon ‘Hotspots’ Distinguish Among Continents and Between North and South  
Figure 26C illustrates how specific DHCR7 mutations occur commonly among certain 
ethnicities. For example, R352Q and G303R occur almost exclusively among Asian populations 
(Asian: Korean, Japanese, Japanese-Dutch). Other mutations, e.g., G147D, occur among 
Southern Europeans (S. Europe: French, Italian, Spanish, Portuguese, Greek). There are some 
distinctions between Northern and Southern Europeans in terms of DHCR7 mutations. For 
instance, the null mutation IVS8-1G>C occurs more frequently among Southern Europeans 
whereas the null mutation W151X occurs more frequently in Northern Europeans. I also found 
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exon ‘hotspots’ for the pairs of SLOS-inducing DHCR7 mutations. The combination of exons 4 
and 9, and also 6 and 9 tended to occur frequently across the whole cohort (see ‘All’ in Figure 
26D). When I stratified by ethnic group, I found that mutations in exons 4 and 9 or the exon 4-9 
‘hotspot’ were more frequent among Southern Europeans while the exon 6-9 hotspot occurred 
frequently in Northern Europeans. I observed marked differences for the Asian population with 
the exon 8-9 hotspot occurring more frequently. Individuals from South America (S. America: 
Brazil, United States of America-Hispanic) had 3 patterns that were equally frequent, the exon 4-
9 hotspot (also common among S. Europeans), the exon 7-9 hotspot (unique to S. Americans), 
and the exon 8-9 hotspot (common among Asians). Importantly, the frequent N. European 
hotspot (exon 6-9 hotspot) was absent from the S. American result. 
A clear relationship exists between geography/ethnicity and specific DHCR7 mutations (Figure 
26D) and has been described previously (Al‐Owain et al., 2012; Nezarati et al., 2002; Nowaczyk 
et al., 2004a; Oh et al., 2014). In addition, specific exon ‘hotspots’ also vary by geographic 
location/ethnicity (Figure 26D).  
6.5 Pathway Links DHCR7, Vitamin D Synthesis, and Cholesterol Synthesis 
6.5.1 Evolutionary Advantage for DHCR7 Mutations 
Heterozygote advantage among carriers was proposed previously (Nowaczyk et al., 2006) based 
on the relationship between DHCR7 and vitamin D. Heterozygote carriers have lower amounts 
of functional DHCR7 resulting from their carrier state(Fitzky et al., 1998). This would lower the 
amount of available 7-dehydrocholesterol that is converted to cholesterol. Subsequently, levels 
of 7-dehydrocholesterol would increase allowing more available 7-dehydrocholesterol to be 
converted to vitamin D upon exposure to ultraviolet B light.  
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Figure 26. Certain Exons and Functional Regions Are Enriched for SLOS-Inducing Mutations in DHCR7 
and Mutation Spectrum Varies By Region and Ethnicity. The overall exon distribution of alleles is shown in 
Figure 26A for all 1024 alleles. Notice that the intronic null mutation (renders exon 9 non-existent) is the most 
common followed by mutations in exon 9. Exons 4 and 6 also feature prominently in SLOS-inducing mutations. 
Figure 26B depicts the proportion of distinct DHCR7 mutations (left) and overall mutations (right) that occur in 
the trans-membrane region of the protein. The 3D protein structure for DHCR7 has yet to be published. 
However, three different models have been described indicating transmembrane domains including the Human 
Protein Reference Database (HPRD), Waterham et al. (Waterham and Wanders, 2000) and Fitzky et al. (Fitzky 
et al., 1998) Note that the Waterham model (Waterham and Wanders, 2000) results in the largest proportion 
(62.109%) of SLOS-inducing mutations being flagged as occurring in the transmembrane domain. Figure 26C 
shows the allele frequency distribution for patients with ethnicity or country of origin information (170 patients 
had this information available). Some ethnicities only had one patient including, Ashkenazi, Turkish and 
Spanish/African (a patient with mixed ancestry). Figure 26D contains the exon locations for each compound 
heterozygote pair (each patient has 2 mutations in DHCR7). Note that different ethnicities or countries of origin 
have different mutation patterns. For example Asian patients frequently have one mutation in exon 8 and one 
mutation in exon 9; whereas patients from Europe (unspecified lower left-hand corner of Figure 26D) or 
Northern Europe tend to have one mutation in exon 6 and other in exon 9. Patients from Southern Europe 
frequently had two different mutations in exon 9 or one mutation in exon 4 and one in exon 9. Ethnicity 
groupings: Europe (European But Not Otherwise Specified and N-S Europeans); N. Europe (Dutch, Hungarian, 
Polish, German, Austrian, United Kingdom, Irish); S. Europe (French, Italian, Spanish, Portuguese, Greek); S. 
America (Brazil, United States of America-Hispanic); Asia (Korean, Japanese, Japanese-Dutch). 
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Table 17. Compilation of SLOS DHCR7 Genotypes from 229 Patients Extracted from 21 Studies  
Genotype Prenatal 
Lethal?  






IVS8-1G>C* IVS8-1G>C Yes / or shortly 
after birth 
(Evans et al., 2001; Ginat et al., 
2004; Goldenberg et al., 2003; Jira 
et al., 2001; Lanthaler et al., 2013; 
Scalco et al., 2005) 
18 7.860 
W151X W151X Yes (Jezela-Stanek et al., 2010; 
Lanthaler et al., 2013) 
8 3.493 
R352Q R352Q No (Al‐Owain et al., 2012; Matsumoto 
et al., 2005; Oh et al., 2014) 
6 2.620 
T93M T93M No (Cardoso et al., 2005; De Brasi et 
al., 1999; Nowaczyk et al., 2004a) 
4 1.747 
R352W R352W No (Oh et al., 2014) 2 0.873 
P467L P467L No (Nezarati et al., 2002) 2 0.873 
E448K E448K No (Anstey et al., 2005; De Brasi et al., 
1999) 
2 0.873 







(Waterham et al., 1998) 1 0.437 
L109P L109P No (Jezela-Stanek et al., 2010) 1 0.437 
N287K N287K No (Al‐Owain et al., 2012) 1 0.437 
R446Q R446Q NA† (Goldenberg et al., 2003) 1 0.437 
R352L R352L No (Al‐Owain et al., 2012) 1 0.437 
      
      
Total Homozygous 48 20.961 
Compound Heterozygous 
IVS8-1G>C T93M No (Anstey et al., 2005; Cardoso et al., 
2005; Ginat et al., 2004; Nowaczyk 
et al., 2004a; Patrono et al., 2002; 
Scalco et al., 2005) 
21 9.170 
IVS8-1G>C W151X No (Lanthaler et al., 2013) 7 3.057 
IVS8-1G>C G410S No (Goldenberg et al., 2003) 6 2.620 
IVS8-1G>C T154M Died Shortly 
After Birth/No 
(Ginat et al., 2004; Jira et al., 2001) 3 1.310 
G147D F302L Yes for 1, NA 
for 2 
(Goldenberg et al., 2003) 3 1.310 
R352Q  G303R No/Died 
Shortly After 
Birth 
(Matsumoto et al., 2005; Oh et al., 
2014) 
3 1.310 
      
IVS8-1G>C C183Y Died Shortly 
After Birth in 
Some Cases 
(Jira et al., 2001) 2 0.873 
T93M Q98X No (Cardoso et al., 2005; Witsch‐
Baumgartner et al., 2005) 
2 0.873 
W151X V326L No (Fitzky et al., 1998) 2 0.873 
W151X C380S No (Fitzky et al., 1998) 2 0.873 
V326R L68P No (Witsch‐Baumgartner et al., 2005) 2 0.873 
IVS8-1G>C M1V No (Scalco et al., 2005; Witsch‐
Baumgartner et al., 2005) 
2 0.873 
IVS8-1G>C P51S No (Fitzky et al., 1998; Goldenberg et 
al., 2003) 
2 0.873 
IVS8-1G>C L99P No (Anstey et al., 2005; Fitzky et al., 
1998) 
2 0.873 
IVS8-1G>C S169L Died Shortly 
After Birth/No 
(Ginat et al., 2004; Goldenberg et 
al., 2003) 
2 0.873 
IVS8-1G>C A247V No (Ginat et al., 2004) 2 0.873 
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IVS8-1G>C F302L Possibly†† (Goldenberg et al., 2003) 2 0.873 
IVS8-1G>C V326L No (Evans et al., 2001; Goldenberg et 
al., 2003) 
2 0.873 
W151X I145L No (Jezela-Stanek et al., 2010) 2 0.873 
W151X L157P No (Fitzky et al., 1998; Jezela-Stanek 
et al., 2010) 
2 0.873 
W151X V326L No (Jezela-Stanek et al., 2010) 2 0.873 
H119L G244R Died Shortly 
After Birth in 
Some Cases 
(Jira et al., 2001; Waterham et al., 
1998) 
2 0.873 
H301Q R242H No (Goldenberg et al., 2003) 2 0.873 
F302L L470Q No (Ginat et al., 2004) 2 0.873 
G303R R352W No (Oh et al., 2014) 2 0.873 
H405Y G138V No (Waye et al., 2005) 2 0.873 
T93M W151X No (De Brasi et al., 1999; Patrono et 
al., 2002) 
2 0.873 
W151X R352W No (Jezela-Stanek et al., 2010) 2 0.873 
T93M G147D No (Goldenberg et al., 2003) 1 0.437 
T93M T154R No (Scalco et al., 2005) 1 0.437 
T93M S192F No (Witsch‐Baumgartner et al., 2005) 1 0.437 
T93M R228W No (Witsch‐Baumgartner et al., 2005) 1 0.437 
T93M D234Y No (Nowaczyk et al., 2004a) 1 0.437 
T93M R242H Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
T93M G244R No (Patrono et al., 2002) 1 0.437 
T93M N274K No (Cardoso et al., 2005) 1 0.437 
T93M V281M No (Nowaczyk et al., 2004a) 1 0.437 
T93M F302L No (Nowaczyk et al., 2004a) 1 0.437 
T93M G410S No (Scalco et al., 2005) 1 0.437 
T93M 720-735del 
Frameshift 
No (Fitzky et al., 1998) 1 0.437 
T93M IVS5+4 del No (De Brasi et al., 1999) 1 0.437 
IVS8-1G>C A50N No (Witsch‐Baumgartner et al., 2005) 1 0.437 
IVS8-1G>C P51H No (Anstey et al., 2005) 1 0.437 
IVS8-1G>C Q98X No (Lanthaler et al., 2013) 1 0.437 
IVS8-1G>C L109P Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
IVS8-1G>C H119L No (Goldenberg et al., 2003) 1 0.437 
IVS8-1G>C H119fsX8 No (Witsch‐Baumgartner et al., 2005) 1 0.437 
IVS8-1G>C F174S No (Cardoso et al., 2005) 1 0.437 
IVS8-1G>C W182C No (Goldenberg et al., 2003) 1 0.437 
IVS8-1G>C W182L Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
IVS8-1G>C K198E Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
IVS8-1G>C F235S No (Waye et al., 2005) 1 0.437 
IVS8-1G>C R242H NA† (Goldenberg et al., 2003) 1 0.437 
IVS8-1G>C W248C Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
IVS8-1G>C S254A No (Goldenberg et al., 2003) 1 0.437 
IVS8-1G>T F255L Died Shortly 
After Birth 
(Jira et al., 2001) 1 0.437 
IVS8-1G>C I297T No (Waye et al., 2005) 1 0.437 
IVS8-1G>C H301R No (Cardoso et al., 2005) 1 0.437 
IVS8-1G>C P329L No (Patrono et al., 2002) 1 0.437 
IVS8-1G>C 356delH No (Evans et al., 2001) 1 0.437 
IVS8-1G>C G366V No (Szabó et al., 2010) 1 0.437 
IVS8-1G>C C380Y No (Ginat et al., 2004) 1 0.437 
IVS8-1G>C R404C Died Shortly 
After Birth 
(Goldenberg et al., 2003) 1 0.437 
IVS8-1G>C Y432C No (Witsch‐Baumgartner et al., 2005) 1 0.437 
IVS8-1G>C R446Q No (Patrono et al., 2002) 1 0.437 
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IVS8-1G>C E448K No (Evans et al., 2001) 1 0.437 
IVS8-1G>C R450L No (Anstey et al., 2005) 1 0.437 
IVS8-1G>C F475S No (Witsch‐Baumgartner et al., 2005) 1 0.437 
IVS8-1G>C Unidentified 
Suspected Variant 
No (Cardoso et al., 2005) 1 0.437 
W151X L109P Died Shortly 
After Birth 
(Jezela-Stanek et al., 2010) 1 0.437 
W151X N146K No (Jezela-Stanek et al., 2010) 1 0.437 
W151X I178F No (Witsch‐Baumgartner et al., 2005) 1 0.437 
W151X W248C No (Jezela-Stanek et al., 2010) 1 0.437 
W151X G347S No (Witsch‐Baumgartner et al., 2005) 1 0.437 
     0.437 
W151X R352Q No (Jezela-Stanek et al., 2010) 1 0.437 
W151X L360P No (Witsch‐Baumgartner et al., 2005) 1 0.437 
W151X R446Q Died Shortly 
After Birth 
(Jezela-Stanek et al., 2010) 1 0.437 
W151X Unidentified 
Suspected Variant 
Yes (Jezela-Stanek et al., 2010) 1 0.437 
W151X G322 frameshift No (Jezela-Stanek et al., 2010) 1 0.437 
P51S N274K Died Shortly 
After Birth 
(Goldenberg et al., 2003) 1 0.437 
G322 frameshift Unidentified 
Suspected Variant 
No (Jezela-Stanek et al., 2010) 1 0.437 
V326R L360P No (Witsch‐Baumgartner et al., 2005) 1 0.437 
Q98X  Unidentified 
Suspected Variant 
No (Witsch‐Baumgartner et al., 2005) 1 0.437 
L99P G410S No (Fitzky et al., 1998) 1 0.437 
T154M Y219D No (Jezela-Stanek et al., 2010) 1 0.437 
I178F R242H No (Witsch‐Baumgartner et al., 2005) 1 0.437 
W182L E224K No (Witsch‐Baumgartner et al., 2005) 1 0.437 
P243R Y408H Died Shortly 
After Birth 
(Goldenberg et al., 2003) 1 0.437 
A247V R404C No (Fitzky et al., 1998) 1 0.437 
V273G Y432C No (Witsch‐Baumgartner et al., 2005) 1 0.437 
     0.437 
H301R W182L No (Cardoso et al., 2005) 1 0.437 
     0.437 
V326L G244R No (Goldenberg et al., 2003) 1 0.437 
V326L R352W No (Fitzky et al., 1998) 1 0.437 




W248C No (Waterham et al., 1998) 1 0.437 
T93M N407Y No (De Brasi et al., 1999) 1 0.437 
R352W N407Y Died Shortly 
After Birth 
(Goldenberg et al., 2003) 1 0.437 
R352W K376R fs*37 No (Oh et al., 2014) 1 0.437 
R352W  L317R No (Scalco et al., 2005) 1 0.437 
G322 Frameshift L109P Yes (Jezela-Stanek et al., 2010) 1 0.437 
V330M R363C No (Patrono et al., 2002) 1 0.437 
R352Q R242H No (Matsumoto et al., 2005) 1 0.437 
R352Q X476Q No (Matsumoto et al., 2005) 1 0.437 
R352Q S192F No (Matsumoto et al., 2005) 1 0.437 
P227S G303R No (Oh et al., 2014) 1 0.437 
L68P R404C No (Waye et al., 2005) 1 0.437 
Q107H C444Y No (Ginat et al., 2004) 1 0.437 
I145L Y408H No (Waye et al., 2005) 1 0.437 
N274K V466A No (Scalco et al., 2005) 1 0.437 
N274K G410S No (Scalco et al., 2005) 1 0.437 
R242C G344R No (Waye et al., 2005) 1 0.437 
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R242C W177R No (Ginat et al., 2004) 1 0.437 
R242C H426P No (Waye et al., 2005) 1 0.437 
E288K I215N No (Romano et al., 2005) 1 0.437 
682-683 insert-C 98-184 deletion No (Ginat et al., 2004) 1 0.437 
Total Compound Heterozygous 172 75.109 
True Heterozygous 
R352W None No (De Brasi et al., 1999; Fitzky et al., 
1998) 
3 1.310 
T93M None No (De Brasi et al., 1999) 2 0.873 
V326L None No (Fitzky et al., 1998) 2 0.873 
S113C None No (Waye et al., 2005) 1 0.437 
E448K None No (Patrono et al., 2002) 1 0.437 
Total True Heterozygous 9 3.930 
*Annotated as: c.964-1G>C in some literature articles 
† Not Applicable, medical termination of pregnancy occurred (Goldenberg et al., 2003) 
†† In one case natural miscarriage occurred, in second case medical termination of pregnancy occurred (Goldenberg et al., 2003)  
Died Shortly After Birth= Less than 1 year old  
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This would protect individuals from developing rickets (a vitamin D deficiency condition that 
results in bone softening and malformations) and osteomalacia (an adult form of rickets) 
(Nowaczyk et al., 2006). 
Certain DHCR7 variants were found to be evolutionarily favored in Northern climates, including 
Europe and Asia (Kuan et al., 2013) suggesting a selective pressure and a plausible heterozygote 
advantage for those variants. Researchers found certain DHCR7 variants were associated with 
lower vitamin D levels in the general population (Wang et al., 2010) and among individuals with 
polycystic ovary syndrome (Wehr et al., 2011). This further links vitamin D levels with DHCR7 
variants. 
Historically, there would have been an evolutionary pressure to maximize the small amount of 
sunlight available for vitamin D production in Northern climates due to lower sunlight exposure. 
Additionally, benefits from prenatal vitamin D supplementation are also modulated by 
geographic location and other factors (Karras et al., 2015). Therefore biological mechanisms that 
maximize vitamin D production and absorption would be selected for in the North. A 
heterozygote advantage for individuals with one DHCR7 mutation would therefore exist to allow 
most of the body’s 7-dehydrocholesterol to be converted into vitamin D (and not cholesterol). 
This has been used to explain why Northern populations have a higher prevalence of SLOS 
(Kelley and Hennekam, 2000).  
Carriers also are hypothesized to have a reproductive advantage because of the reduced fetal 
death due to rachitic cephalopelvic disproportion (Kelley and Hennekam, 2000; Opitz et al., 
2002). This is again related to increased vitamin D production causing improved bone formation. 
Improved hip formation is thought to enable females to produce more offspring and thereby 
provide another carrier advantage (Kelley and Hennekam, 2000; Opitz et al., 2002). 
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Additionally, vitamin D has been shown to increase chances of pregnancy for infertile women 
receiving in vitro fertilization (Ozkan et al., 2010). Vitamin D has many pleiotropic roles in 
reproductive outcomes and can affect both male and female fertility (Lerchbaum and 
Obermayer-Pietsch, 2012). Therefore, there could be multiple mechanisms that could explain 
why evolution favors vitamin D production in Northern climates through mutations in DHCR7 
(and other genes).  
6.5.2 Biological Mechanism: DHCR7’s Effect on Vitamin D and Cholesterol Synthesis 
The biological mechanism that connects DHCR7 mutations (SLOS carriers) and Northern 
climate involves regulation of 7-dehydrocholesterol, vitamin D, and cholesterol. Typically, 7-
dehydrocholesterol can be converted into either cholesterol or vitamin D (cholecalciferol). The 
conversion of 7-dehydrocholesterol to vitamin D occurs in the skin upon exposure to ultraviolet 
B light (290-320 nm) (Deeb et al., 2007). Under normal sunlight conditions, only around 15% of 
available 7-dehydrocholesterol will be converted to vitamin D while excess 7-dehydrocholesterol 
in the skin will be converted to inert compounds for degradation (Norman, 1998; Webb et al., 
1988). DHCR7 is the sole enzyme used to convert 7-dehydrocholesterol to cholesterol (Moebius 
et al., 1998). A shortage of DHCR7 would decrease the body’s ability to convert 7-
dehydrocholesterol into cholesterol thereby causing a buildup of 7-dehydrocholesterol, which 
could be converted into vitamin D in the skin. Each piece of this mechanistic pathway is depicted 
in Figure 27 along with the corresponding literature references. 
An indirect negative feedback loop, established in laboratory studies, allows vitamin D levels to 
regulate DHCR7 activity and prevent hypervitaminosis D (i.e., toxically high vitamin D levels) 
(Zou and Porter). SLOS patients have high 7-dehydrocholesterol levels. Therefore, from Figure 
27 and the literature, one would expect them to have high vitamin D levels. However, vitamin D 
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levels in SLOS patients are reported to be low (Rossi et al., 2005). This could be due to many 
lifestyle factors that occur when a patient is seriously ill with SLOS. One possible biological 
explanation that fits with the literature-derived mechanism (Figure 27) is that SLOS patients 
spent less time outdoors thereby reducing their ultraviolet B exposure (another critical 
requirement for vitamin D synthesis) (Rossi et al., 2005).  
6.6 Genetic Understanding of SLOS-Inducing DHCR7 Mutations: Implications for Future 
Work 
6.6.1 Changing The Understanding of SLOS Genetics Using Large-Scale Genomics Studies  
Using ExAC (Lek et al., 2015), I was able to compare the frequencies of DHCR7 SLOS-
inducing mutations in the SLOS population (extracted from the literature) and the assumed-
healthy ExAC population. I found that there were many differences. To illustrate some of these 
differences, I plotted the overall incidence of DHCR7 mutations in SLOS against the incidence 
in the healthy population (ordered by healthy population). Several DHCR7 mutations are much 
more frequent among SLOS individuals then expected given the background population rate 
(Figure 28).  For example, T93M is the second most frequent DHCR7 mutation in SLOS 
patients, but it is comparatively rare among the ExAC population (Figure 28) (Lek et al., 2015). 
This could be due to sampling bias differences between the SLOS cohort and the ExAC 
population. For example, T93M is thought to be the founder SLOS mutation and is common in 
Italy, Spain and Portugal (Cardoso et al., 2005; Kozák et al., 2000; Nowaczyk et al., 2004a; 
Witsch-Baumgartner et al., 2001; Witsch‐Baumgartner et al., 2005). The ExAC population may 
be under-represented for Southern Europeans. In ExAC they distinguish a ‘Finnish’ European 
cohort from a non-Finnish European cohort (representing Northern American peoples and other 
Europeans), but it is unclear how many Southern Europeans are represented in that cohort. 
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Figure 27. Literature-Derived Pathway Illustrates How 7-DeHydroCholesterol 
Reductase Effects Vitamin D Production By Removing 7-Dehydrocholesterol and the 
Effects of Drugs on this Pathway. Drugs that enhance DHCR7 (7-DehydroCholesterol 
Reductase) function result in reduction in vitamin D production. This occurs because 
DHCR7 causes more 7-dehydrocholesterol to be converted to cholesterol. This indirectly 
inhibits vitamin D production by reducing the amount of 7-dehydrocholesterol that can be 
converted into cholecalciferol in the skin. Homozygous null mutations in DHCR7 
completely inhibit functionality and result in patients with Smith-Lemli-Opitz Syndrome 
(SLOS) with heterozygous patients showing increased protection against rickets and 
osteomalacia. The dashed line indicates a feedback inhibition loop. 
Reference Legend: 
1 (Moebius et al., 1998);  2 (Wang et al., 2010);  3 (Ahn et al., 2010);  4 (Tint et al., 1994);  
5 (Lauth et al., 2010);  6 (Fernø et al., 2005);  7 (Raeder et al., 2006);  8 (Zou and Porter);  9 







































Figure 28. DHCR7 SLOS-Inducing Mutation Frequency in SLOS Patients vs. 
Frequency from ExAC Population. Some mutations occurred more frequently in the 
SLOS population given their frequency in the healthy population (e.g., T93M, V326L, 
R404C, R352W). A possible explanation for this could be that these mutations occur in 
certain ethnic populations and those populations are under-represented in the ExAC 
population. 
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Table 18. DHCR7 Mutations Predicted to Be Damaging from ExAC Cohort (60,706 Individuals) 
Includes Both Known SLOS-Inducing Mutations and Unknown Mutations 
 
Implicated 




Yes 71146886 rs138659167  c.964-1G>C 
splice 
acceptor 
386 (4.2 X 10-
1) 
Yes 71152447 rs11555217 p.Trp151Ter c.452G>A stop gained 82 (6.8 X 10-2) 
No 71146229 rs115338563 p.Arg207Ter c.619C>T stop gained 6 (5.4 X 10-2) 




donor 8 (6.8 X 10-3) 
Yes 71146886 rs138659167 - c.964-1G>T 
splice 
acceptor 6 (6.5 X 10-3) 
Yes 71155249 . p.Trp37Ter c.111G>A stop gained 3 (5.7 X 10-3) 
Yes 71155068 rs104886039 p.Gln98Ter c.292C>T stop gained 5 (4.8 X 10-3) 
AA* 71152354 . p.Trp182Ter c.545G>A stop gained 5 (4.1 X 10-3) 




upACCC frameshift 2 (2.7 X 10-3) 
No 71152488 . - c.413-2A>G 
splice 
acceptor 2 (2.3 X 10-3) 
AA 71146937 . 
p.Leu138Cys
fsTer10 c.412delC frameshift 1 (2.0 X 10-3) 
No 71146790 . p.Trp187Ter c.560G>A stop gained 2 (1.7 X 10-3) 
AA 71146782 . 
p.His356Thrf
sTer57 c.1066delC frameshift 2 (1.7 X 10-3) 
No 71155195 . p.Tyr55Ter c.165C>G stop gained 1 (1.1 X 10-3) 





CTinsT frameshift 1 (9.3 X 10-4) 






TACinsC frameshift 1 (8.7 X 10-4) 




lCAinsA frameshift 1 (8.6 X 10-4) 
AA 71146791 . 
p.Val353Trpf
sTer60 c.1057delG frameshift 1 (8.5 X 10-4) 
No 71146559 rs140791666 p.Tyr430Ter c.1290C>G stop gained 1 (8.5 X 10-4) 
AA 71146709 . p.Cys380Ter c.1140C>A stop gained 1 (8.4 X 10-4) 
Yes 71150105 . p.Tyr217Ter c.651C>A stop gained 1 (8.3 X 10-4) 
No 71148951 . p.Trp290Ter c.870G>A stop gained 1 (8.3 X 10-4) 
No 71155917 . p.Gln28Ter c.82C>T stop gained 1 (8.3 X 10-4) 
No 71155938 . 
p.Asp21Argf
sTer42 c.60_61insA frameshift 1 (8.3 X 10-4) 
* AA: Indicates that another mutation at that same amino acid (AA) position number has been implicated 
in SLOS. However, the mutation is different from the one found by ExAC.  
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Therefore, some of these differences are likely due to sampling bias. 
Additionally, I was able to identify DHCR7 mutations that were predicted to be damaging using 
ExAC. This revealed 24 mutations (Table 18). Eight of those mutations were already known to 
be implicated in SLOS and were contained in the compendium. Six more mutations occurred at 
the same amino acid position of another mutation that has been implicated in SLOS 
(demonstrating the importance of that amino acid position in SLOS). However, 12 mutations 
were never reported as being found in SLOS patients. There are two potential reasons for this: 1) 
the mutation is not disease causing (this is difficult to ascertain without the protein structure); 
and 2) the mutation only exists in an under-studied research population. For example, one 
mutation (R207X) was found to have 2.2% frequency among the healthy African population 
from ExAC. This means that R207X is polymorphic among Africans. However, this mutation 
has never been implicated in SLOS. Its possible that Africans are not often diagnosed with SLOS 
and then sequenced because they often come from resource-poor environments. The 12 
mutations in Table 18 that have never been implicated in SLOS are worthy of further 
investigation by researchers to ascertain whether they are deleterious. If these mutations were 
deleterious, the next research question would be why African populations are under-diagnosed 
for SLOS. 
6.6.2 Implications for Causality 
Hill established a set of nine criteria for determining whether an association was causal or not 
(Hill, 1965). I will focus discussion on three of these criteria with regards to DHCR7: strength, 
plausibility and coherence. Strength is difficult to assess in SLOS because the DHCR7 mutations 
are often only found among SLOS patients (and researchers are biased to look specifically for 
mutations in DHCR7). As can be seen from Table 18 the incidence of these mutations in the 
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ExAC population is very low. This helps to strengthen the belief in the relationship between 
DHCR7 mutations and SLOS, especially for mutations that are disproportionately high among 
SLOS patients (e.g., T93M in Figure 28). However, the fact that some mutations are very high 
among SLOS patients and very low among the ExAC population could be due to sampling bias 
between the two populations. Some DHCR7 mutations were found in the ExAC population that 
is predicted to be functionally deleterious. However, not all of these have been reported to be 
SLOS-Inducing. This could be due to ethnic differences between the two datasets (i.e., certain 
groups are under-studied and therefore some of the predicted damaging mutations are actually 
un-reported SLOS-Inducing mutations) or it could be because some predicted damaging 
mutations are not functionally damaging (this would be easier to determine if the structure of 
DHCR7 were known). Because the protein structure of DHCR7 remains unknown it is difficult 
to predict for certain whether a mutation is deleterious or not.  
A paper by Lanthaler et al. (Lanthaler et al., 2013) found that certain maternal genetic signatures 
could help rescue the SLOS phenotype by increasing the amount of cholesterol passed to the 
offspring via the placenta. This variation in the maternal genome could perhaps explain some of 
the discrepancies between the literature-derived SLOS compendium and the ExAC population. 
For example, in addition to the requirement that two DHCR7 mutations be inherited, it may also 
be necessary to have a certain placenta state (or placental gene mutation) to acquire the disease. 
This could perhaps explain why some common DHCR7 mutations from ExAC are not found to 
be SLOS-inducing (even though they are predicted to be damaging). However, it is too early to 
state yet because of sampling bias issues and under-reporting among certain ethnicities. Further 
investigation could help provide additional coherence to reported DHCR7 mutations in the 
literature. Therefore, this remains an open area of research. 
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6.7 Pharmacological Effects of DHCR7 Modulators 
Importantly, pharmaceutical drugs have been shown to modulate DHCR7 activity in various 
ways. Several anti-psychotic drugs were found to enhance DHCR7 activity (Fernø et al., 2005; 
Lauth et al., 2010; Raeder et al., 2006). Other drugs, not otherwise known to modulate DHCR7, 
can cause high 7-dehydrocholesterol in the absence of SLOS (Hall et al., 2013). Currently, 
pharmaceuticals are being designed to inhibit DHCR7 as a suggested treatment for hepatitis C 
(Rodgers et al., 2012). However, diverse therapeutic uses exist for targeting DHCR7. In this 
section, I review all known pharmaceuticals, compounds, chemicals, and toxins known to 
modulate DHCR7. 
6.7.1 DHCR7 Modulators 
6.7.1.1 Expression 
I used the Comparative Toxicogenomics Database (CTD) (CTD, 2015; Davis et al., 2015) to 
retrieve articles describing compounds that modulate DHCR7 expression (data retrieved 
February 2015). I then manually reviewed the resulting literature references and only retained 
compounds with direct evidence of modulating DHCR7 expression in studies using human 
tissue. Table 19 contains the list of modulators with corresponding references. Several other 
compounds were found in CTD to modulate DHCR7, but failed the requirements listed above 
these are presented as potential DHCR7 modulators in Table S3 (of the published paper). 
Overall I found 5 pharmaceuticals and 2 inorganic compounds increased DHCR7 expression and 
3 toxins decreased DHCR7 expression. Antipsychotic drugs, such as haloperidol, clozapine, and 
chlorpromazine, are known to alter expression in cardiovascular genes (Foley and Mackinnon, 
2014) in addition to DHCR7 (increased DHCR7 activity would increase the rate of cholesterol 
synthesis see Figure 27).  
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Table 19. Chemicals Known to Modulate DHCR7 with Literature References 





Reference(s) Source Structure 
Increases Expression (up-regulates)    
Pharmaceutical Drugs      
Antipsychotic 
[Dibenzazepine] 
Clozapine B (Fernø et al., 
2005; Ferno et al., 
2006; Lauth et al., 







Chlorpromazine C (Fernø et al., 
2005; Lauth et al., 







Haloperidol C (Fernø et al., 
2005; Lauth et al., 




Statin [Naphthalene] Simvastatin X (Correa-Cerro et 
al., 2006; Wassif 










Inorganic Compounds      
Inorganic Element 
[Fullerene] 










Decreases Expression (down-regulates)    
Toxins      
























Decreases Protein Activity     
Poisonous steroidal 
jerveratrum alkaloid  
Cyclopamine (11-
deoxojervine) 
Poison (Zou and Porter) Literature 
Review 
 
Direct Inhibitors      
Approved Chemotherapeutics     
Chemotherapeutic, 





D (Bignon et al., 
1989; Jordan, 
2003; Ruenitz et 














Investigational Chemotherapeutics     
Clinical Trials      
Selective Estrogen 
Receptor Modulator 



















(Teo et al., 1992) Chembl 
 


















Ormeloxifene is a SERM  
Rel-Ormeloxifene - (Teo et al., 1992) Chembl 
   
Inhibitor of Cytochrome 
P450 [Fatty Acid, 
Valerate] 
Proadifen - (Teo et al., 1992) Chembl 
 


















LY-117018 - (Sharma et al., 




† Chemical Type Determined Using the Anatomical Therapeutic Chemical Classification Browser: 
http://mor.nlm.nih.gov/RxClass/ 
†† Fetal Risk Categories are based on Food Drug Administration’s Criteria for the United States of America 
NA: Not Available 
Note: Structure diagrams are from Chembl and/or Wikipedia 
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6.7.1.2 Inhibition 
I used ChEMBL, a freely-available semi-curated database of bioactive molecules (Bento et al., 
2014), to find all pharmacological compounds that directly inhibit DHCR7 (Table 19). This 
includes approved chemotherapeutics, and investigational chemotherapeutics either in clinical or 
preclinical trials. When available I report IC-50 values (Table 19). Drugs with IC-50 values less 
than 10,000nM or 10 uM are considered potentially pharmacologically relevant inhibitors 
(Hopkins and Groom, 2002; Keller et al., 2006). I included tamoxifen (IC50=12nM) and 
doxorubicin (IC50=150nM) as FDA-approved DHCR7 inhibitors. 
DHCR7 inhibitors are used to treat cancer, typically breast cancer. For example, nafoxidine 
inhibits DHCR7 (Teo et al., 1992) and is a known oestrogen antagonist. Several clinical trials 
were performed in the 1970s for nafoxidine (Engelsman et al., 1975; Group, 1972; Jain et al., 
1977; Steinbaum et al., 1978). The major reaction to the drug consisted of dermatitis (55% of 
patients) exacerbated by sunlight (Steinbaum et al., 1978). This indicates that the drug effected 
patients’ dermal response to sunlight exposure (which could be related to its inhibition of 
DHCR7 and dysregulation of vitamin D synthesis pathways).  
6.7.1.3 Summary Modulators 
Overall I found that five approved pharmaceuticals increase DHCR7 expression while 2 inhibit 
DHCR7. Two inorganic compounds increase DHCR7 expression, while 3 toxins (including a 
metabolite of arsenic) decrease DHCR7 expression and one toxin decreases protein activity. Ten 
pharmaceutical inhibitors of DHCR7 are in various stages of clinical development. This includes 
7 inhibitors in the pre-clinical stage and 3 inhibitors in the clinical trials stage (Table S4, 
published paper). DHCR7 Inhibitors are used or will be used (if approved) for cancer treatment.  
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6.7.2 Investigating Fetal Outcomes Following Prenatal Exposure to DHCR7 Modulators 
6.7.2.1 Overview 
The biological mechanisms underlying pharmacological teratogenicity and adverse fetal 
outcomes are complex involving many genetic and environmental factors. In the United States of 
America, major developmental defects occur in approximately 3-5% of live-born children 
(Finnell, 1999). Among these defects between 2-3% are classifiable as teratogen-induced 
meaning that the defect occurred due to a known or suspected prenatal environmental exposure 
(Finnell, 1999). It is further estimated that <1% of teratogenic effects have a pharmacological 
origin (Beckman and Brent, 1984).  
Interactions between pharmaceutical drugs and genetics could result in increased teratogenicity 
among certain individuals. For example, holoprosencephaly clusters in families (Roach et al., 
1974), can result from mutations in DHCR7 (Shim et al., 2004), and can also occur after 
exposure to certain drugs, namely lovastatin (Edison and Muenke, 2004a; 2005). It is reasonable 
to assume that various combinations of those factors (e.g., drug exposure, DHCR7 mutations, 
familial risk factors) could result in increased likelihood for teratogenic effects. However, for the 
purposes of this review, I focus on fetal outcomes resulting from prenatal drug exposure to 
DHCR7 modulators. 
Because of the importance of functioning DHCR7 during fetal development, I decided to 
investigate the outcomes of prenatal exposure to two approved pharmaceutical DHCR7 
inhibitors (Table S4, published paper) and compare them against five approved pharmaceutical 
drugs that increase DHCR7 expression. I was interested in the fetal outcomes of both DHCR7 
inhibitors and those that increase expression to determine if DHCR7 inhibitors resulted in 
increased detrimental fetal outcomes. I made this hypothesis because DHCR7 inhibition results 
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in a pharmaceutically induced SLOS-like fetal development environment and therefore prenatal 
exposure to these inhibitors should result in SLOS like adverse outcomes.  
6.7.2.2 PubMed Literature Review on Fetal Toxicity 
Using PubMed, I retrieved all relevant observational studies on fetal outcomes due to prenatal 
exposure of each drug. The full details regarding the semi-automated query and retrieval process 
for included articles are described in the Supplemental of the published paper. I reviewed each 
observational study carefully recording the number of pregnancy outcomes per drug treatment. 
Seven main pregnancy outcomes were used: born healthy, spontaneous abortion (or miscarriage), 
elective termination (or induced abortion), neonatal death (died within 1st week of birth), still 
birth (or intrauterine death), ectopic pregnancy, and major/minor fetal malformations or defects 
or congenital anomalies. Whenever possible I included information regarding the trimester of 
drug exposure, as this is critical information for understanding teratogenic effects, realizing that 
SLOS-like symptoms would result mainly from first-trimester exposure (when cholesterol 
production is critical for proper structural formation). As controls, I included one known 
teratogen and one known pregnancy-safe drug. I selected isotretinoin (trade name: Accutane) as 
the known teratogen and levothyroxine as the known pregnancy-safe drug (FDA category A).  
My method uses data gleaned from literature reports on fetal outcomes following prenatal drug 
exposure. Therefore, this data suffers from reporting bias. This occurs because reports on a 
drug’s effects may be more likely if the effect is deleterious or severe. To address this issue, I 
included two ‘control’ drugs and followed the same procedure (i.e., literature review and 
extraction of outcomes). One ‘control’ drug was a known pregnancy safe drug – levothyroxine 
and the other ‘control’ drug was a known teratogenic drug – isotretinoin. I compared the findings 
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of drugs that modulate DHCR7 to these two ‘controls’ to determine if any effect I observe is 
significant and worthy of further investigation. 
A certain number of adverse fetal outcomes occur in the general population. For additional 
comparison purposes, I also included data from the Centers of Disease Prevention and Control 
(CDC) on pregnancy outcomes (i.e., live born, spontaneous abortion, elective termination) 
collected across all races from both 1990 and 2008 for reference (CDC et al., 2012; Ventura et 
al., 2012). I coupled this with data stating that 3% of live-born babies (1 in 33) have a birth 
defect (CDC, 2008). Table 20 displays the findings along with their corresponding references. 
6.7.2.3 Fetal Outcomes from Prenatal Exposure to DHCR7 Modulators  
Figure 29 contains the overall results for each of the 7 FDA approved DHCR7-modulating 
pharmaceuticals. For comparison purposes, known pregnancy-safe levothyroxine and known 
teratogen isotretinoin (or Accutane) are also included. The breakdown of these drugs across the 7 
pregnancy outcomes is shown in Figure 29A. The number of deformations (possible teratogenic 
effects) vs. number of healthy babies is shown in Figure 29B. Drugs that inhibit DHCR7 
resulted in deformities among 10.9% of babies born while drugs that increase DHCR7 
expression resulted in deformities among 5.5%. This can be compared to the CDC background of 
3.0% and levothyroxine’s rate of 0.0% (the known pregnancy-safe drug). While DHCR7 
inhibitors result in increased risk of deformities, the rate was still much lower than the well-
known teratogen – Accutane or isotretinoin – at 47.7%. I also statistically compared how 
DHCR7 activity affected fetal outcomes. Using the CDC background rate from 2008 (CDC et 
al., 2012; Ventura et al., 2012) (accessed in January 2016), I performed a fisher’s exact test for 
healthy vs. non-healthy (this includes born with birth defect/deformity, spontaneous abortion, 
elective terminations). As expected, levothyroxine (pregnancy safe drug) was not statistically 
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different from the background rate (p-value = 0.197). I found that DHCR7 inhibitors were highly 
enriched for adverse fetal outcomes (OR= 6.0, p-value < 0.001) with DHCR7 promoters showing 
less enrichment (OR=3.3, p-value < 0.001). Neither came close to the known teratogen 
isotretinoin (OR= 34.8, p-value < 0.001). 
I also investigated the relationship between first-trimester exposure to DHCR7 modulators and 
increased risk of teratogenic effects (Figure 29C and Figure 29D). First-trimester effects were 
especially interesting because reduction in cholesterol during the first-trimester has been shown 
to cause severe teratogenic effects (Edison and Muenke, 2004a). By inhibiting DHCR7 during 
the first-trimester, cholesterol production is also inhibited, therefore, I would expect severe 
teratogenic effects (Edison and Muenke, 2004a). Additionally, studies have shown that exposure 
to chemotherapeutic drugs, e.g., doxorubicin and tamoxifen, during the first-trimester is 
associated with increased risk of fetal complications (Germann et al., 2004). First-trimester 
results for all pregnancy outcomes are shown in Figure 29C. I grouped drugs by their DHCR7 
effect in Figure 29D. Counts and percentages of pregnancy outcomes for first-trimester exposure 
to DHCR7 modulating drugs are provided in Table 21.  
First-trimester exposure to drugs that increase DHCR7 expression (73.5% born healthy) was 
comparable to first-trimester exposure of a pregnancy-safe drug (72.7% born healthy). Even 
more importantly, first-trimester exposure to DHCR7 inhibitors was comparable to the known 
teratogen with 50.0% born healthy among drugs that inhibit DHCR7 vs. 48.3% for the teratogen. 
However, the sample size for first-trimester exposures was small (N=40 for known DHCR7 
inhibitors) indicating that caution must be taken when interpreting these results. 






Figure 29. Fetal Outcomes of Prenatal Exposure to DHCR7 Modulators Compared to CDC Prevalence 
and a Known Teratogenic Drug (i.e., Isotretinoin or Accutane) and a Known Pregnancy Safe Drug (i.e., 
Levothyroxine). Figure 29A contains aggregated results across all trimesters for regarding pregnancy 
outcomes. Figure 29B contains only born healthy and born with fetal malformations, defects or congenital 
anomalies. Therefore, I excluded spontaneous abortions, elective terminations, stillbirths, ectopic pregnancies 
and neonatal deaths. Notice that in Figure 29A the number of fetal malformations/anomalies is higher among 
DHCR7 modulators including those that increase expression of DHCR7 (5.5%). However, drugs that inhibit 
DHCR7 have an increase in fetal malformations (10.9%). None of these levels comes close to the known 
teratogen, isotretinoin or Accutane, with 47.7% born with malformations (out of total born). Many patients that 
are pregnant elect to terminate their pregnancy (Figure 29A), which may be due to detected anomalies, however 
data on malformations among aborted fetuses is typically not available. I took all reported results where first-
trimester exposure occurred (even if exposure persisted throughout the pregnancy) or where the exposure was 
listed as ‘early pregnancy’ as this appeared to indicate first-trimester exposure and these are shown in Figure 
29C. Many known first-trimester Accutane or isotretinoin exposures resulted in elective terminations or induced 
abortions. Therefore, I included elective terminations and spontaneous abortions in Figure 29D along with live 
births (healthy or malformed).  
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Table 20. Reported Fetal Outcomes Following Prenatal Exposure to DHCR7 Modulating Drugs 




Fetal Pregnancy Outcome 
(N=No. of Patients) 
Reference(s) on Fetal Outcome 
Levothyroxine  None A Born Healthy (612) 
Spontaneous Abortion (151) 
Elective Termination (79) 
Fetal Malformation/Congenital 
Anomaly (0) 
Stillbirth/IntraUterine Death (0) 
Ectopic Pregnancy (0) 
Neonatal Death§ (0) 
Unspecified Outcome (249) 
(Neto et al., 2007; Pomorski et al., 
1999; Rotondi et al., 1999; Taylor et 
al., 2014; Zamperini et al., 2009) 
Clozapine  Increases 
Expression 
B Born Healthy (113) 
Spontaneous Abortion (15) 
Elective Termination (27) 
Fetal Malformation/Congenital 
Anomaly (20) 
Stillbirth/IntraUterine Death (0) 
Ectopic Pregnancy (0) 
Neonatal Death§ (0) 
Unspecified Outcome (28) 
(Gentile, 2004; Karakuła et al., 
2004; McKenna et al., 2005; Reis 




B Born Healthy (531) 
Spontaneous Abortion (8) 
Elective Termination (13) 
Fetal Malformation/Congenital 
Anomaly (11) 
Stillbirth/Intrauterine Death (0) 
Ectopic Pregnancy (0) 
Neonatal Death§ (0) 
Unspecified Outcome (0) 
(Aarskog, 1979; Ahn et al., 2008; 
Hayles and Nolan, 1958) 
Haloperidol Increases 
Expression 
C Born Healthy (268) 
Spontaneous Abortion (19) 
Elective Termination (19) 
Fetal Malformation/Congenital 
Anomaly (12) 
Stillbirth/Intrauterine Death (0) 
Ectopic Pregnancy (1) 
Neonatal Death§ (0) 
Unspecified Outcome (0) 
(Diav-Citrin et al., 2005; 
Mendhekar and Andrade, 2011; 
Newport et al., 2007; Reis and 
Källén, 2008; Yaris et al., 2004) 
Chlorpromazine Increases 
Expression 
C Born Healthy (65) 
Spontaneous Abortion (0) 
Elective Termination (0) 
Fetal Malformation/Congenital 
Anomaly (0) 
Stillbirth/Intrauterine Death (42) 
Ectopic Pregnancy (0) 
Neonatal Death§ (1) 
Unspecified Outcome (0) 
(Chatterjee and Mukheree, 1997; 




X Born Healthy (184) 
Spontaneous Abortion (30) 
Elective Termination (87) 
Fetal Malformation/Congenital 
Anomaly (24) 
Stillbirth/Intrauterine Death (7) 
Ectopic Pregnancy (0) 
Neonatal Death§ (1) 
Unspecified Outcome (70) 
(Edison and Muenke, 2004b; 
Manson et al., 1996; Pollack et al., 






D Born Healthy (146) 
Spontaneous Abortion (12) 
Elective Termination (31) 
Fetal Malformation/Congenital 
Anomaly (26) 
(Andreadis et al., 2004; Barthelmes 
and Gateley, 2004; Berger and 
Clericuzio, 2008; Braems et al., 
2011; Clark, 1993; Cullins et al., 
1994; Isaacs et al., 2001; Koizumi 
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Stillbirth/Intrauterine Death (3) 
Ectopic Pregnancy (1) 
Neonatal Death§ (0) 
Unspecified Outcome (70) 
and Aono, 1986; Öksüzoglu and 






D Born Healthy (140) 
Spontaneous Abortion (20) 
Elective Termination (0) 
Fetal Malformation/Congenital 
Anomaly (9) 
Stillbirth/Intrauterine Death (1) 
Ectopic Pregnancy (0) 
Neonatal Death§ (1) 
Unspecified Outcome (0) 
(Barni et al., 1992; Cardonick et al., 
2012; de Wildt et al., 2009; Hahn et 
al., 2006; Karp et al., 1983; Kerr, 
2005; Meyer-Wittkopf et al., 2001; 
Mir et al., 2012; Morris et al., 2009; 
Murray et al., 1984; Nieto et al., 
2006; Peccatori et al., 2004; Potluri 
et al., 2006; Soliman et al., 2007; 
Willemse et al., 1990) 
Isotretinoin None X Born Healthy (91) 
Spontaneous Abortion (38) 
Elective Termination (296) 
Fetal Malformation/Congenital 
Anomaly (83) 
Stillbirth/Intrauterine Death (0) 
Ectopic Pregnancy (0) 
Neonatal Death§ (0) 
Unspecified Outcome (0) 
(Dai et al., 1992; Honein et al., 
2001; Schaefer et al., 2010) 
* Fetal Risk Categories are based on Food Drug Administration’s Criteria for the United States of America 
§  Died within 1st week of life 
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Table 21. First-Trimester Fetal Outcomes of DHCR7 Modulating Drugs 
 









Healthy 612 (72.684) 194 (73.485) 20 (50.000) 72 (48.322) 
Spontaneous 
abortion 151 (17.933) 21 (7.955) 6 (15.000) 5 (3.356) 
Elective termination/ 
Induced abortion 79 (9.382) 14 (5.303) 7 (17.50) 69 (46.309) 
Fetal malformation/ 
Defect 0 (0.000) 35 (13.258) 7 (17.50) 3 (2.013) 
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6.7.2.4 Interpretation of Fetal Results 
I found that tamoxifen has an IC-50 of 12nM indicating that it inhibits DHCR7 at a 
pharmacologically potent level (Hopkins and Groom, 2002; Keller et al., 2006). I also found that 
tamoxifen exposure (especially during 1st trimester) resulted in increased fetal malformation risk. 
When compared to tamoxifen, doxorubicin had a lower ability to inhibit DHCR7 (IC-50 =150-
10000nM) and likewise a lower risk of adverse fetal outcomes.  
In total, five pregnancies resulted in fetal malformations/defects or congenital anomalies from 
first-trimester tamoxifen exposure while two pregnancies resulted from first-trimester 
doxorubicin exposure. The anomalies resulting from first-trimester tamoxifen exposure appeared 
to have phenotypes similar to SLOS. These included, two cases of genital deformities including 
ambiguous genitalia (Barthelmes and Gateley, 2004; Braems et al., 2011; Tewari et al., 1997), 
cleft palate (a form of holoprosencephaly) (Berger and Clericuzio, 2008; Braems et al., 2011) 
and Goldenhar’s syndrome, which is characterized by facial deformities (Barthelmes and 
Gateley, 2004; Cullins et al., 1994), and one hand deformation (Braems et al., 2011). Note that 
facial deformities and cleft palate (a form of holoprosencephaly) can occur in SLOS patients. 
Genital anomalies occur frequently among SLOS patients (Fukazawa et al., 1992; Jira et al., 
2003; Kelley and Hennekam, 2000). Hand deformations are rare among SLOS patients, however 
toe anomalies (e.g., toe syndactyly) are common (Jira et al., 2003; Kelley and Hennekam, 2000). 
Two deformed babies reported in the literature were born after first-trimester doxorubicin 
exposure. One had genitalia issues (Murray et al., 1984) while the other had hydrocephalus 
(Potluri et al., 2006). These congenital defects are highly related to the pleiotropic effects of 
SLOS (and defective functioning of DHCR7) indicating the distinct possibility that 
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pharmacological inhibition of DHCR7 during the first-trimester of pregnancy results in 
teratogenic effects similar to the physical manifestations of SLOS. 
6.7.2.5 Comment on Vitamin D3’s In-Direct Inhibition of DHCR7  
Of note, vitamin D (cholecalciferol) decreases the DHCR7 activity through an indirect 
mechanism (Zou and Porter). There has been some speculation on the possibility of teratogenic 
affects resulting from high doses of vitamin D when taken as a prenatal supplement (Roth, 
2011). However, a recent review of vitamin D supplementation among pregnant women found 
that vitamin D supplementation may reduce the risk of pre-eclampsia, low birth weight, preterm 
birth (De-Regil et al., 2012; De-Regil et al., 2016) and adverse kidney outcomes in offspring 
(Miliku et al., 2015). Because the mechanism of vitamin D3’s inhibition of DHCR7 is indirect 
(unlike the studied pharmacological DHCR7 inhibitors) it is likely to be mediated through a 
complex pathway with many interacting feedback loops. Studies involving moderate prenatal 
vitamin D supplementation have reported no adverse effects (Roth, 2011). Therefore, I would not 
expect vitamin D to result in SLOS-related teratogenic effects, although additional studies would 
be needed to ascertain the effects of large doses of prenatal vitamin D supplementation. 
6.8 Limitations 
There are several limitations for this literature review. First, information on what drugs target 
DHCR7 (either through inhibition or increasing gene expression) is limited by the current 
knowledge of drugs contained within Chembl. Not all drugs have been tested to determine the 
IC50 for its effect on DHCR7. Therefore it is possible that many more drugs inhibit DHCR7 as 
an off-target effect (i.e., not the main target of the drug). Second, the information on prenatal 
exposures to different compounds (both those that increase gene expression and those that inhibit 
the protein product) is limited by reported case studies in the literature. There is recall bias in 
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studies comparing the reported experiences of women during pregnancy versus after pregnancy 
(Bryant et al., 1989). These studies may also be afflicted with some of these biases. Further there 
may be under-reporting of miscarriage and fetal loss rates as these are often difficult to capture 
accurately in case studies.  
6.9 Future Directions and Conclusion 
In this review, I demonstrate the utility of an in-depth exploration of one Mendelian orphan 
disease: SLOS. I contribute a compendium of SLOS-inducing DHCR7 mutations, their 
incidence, and geographic distribution. I also include the incidence of these mutations in a large 
population from ExAC. This helped to illustrate important differences between mutation 
frequencies in SLOS vs. an assumed healthy population. It is believed that the ExAC population 
are non-SLOS individuals, however it is likely that they have other conditions. Comparing my 
SLOS mutation compendium to ExAC allele frequencies allows me to raise some important 
research questions both for studying under-represented ethnic groups, such as Africans (found to 
exhibit theoretically damaging DHCR7 mutations in ExAC), and for understanding genetic drift 
of DHCR7 mutations. 
I went one step further and explored the prenatal effects of pharmaceuticals that target DHCR7. I 
posited that pharmaceutically induced DHCR7 inhibition would result in fetal outcomes similar 
to those seen in SLOS (miscarriage, fetal malformations, ambiguous genitalia). I reviewed the 
literature for observational studies on fetal outcomes due to drug exposure. I found that exposure 
to DHCR7 inhibitors during the first-trimester of pregnancy resulted in fetal 
deformities/malformations or anomalies in 50% of conceptions born healthy vs. 48% for a 
known teratogen control. Contrastingly, 73% were born healthy to those on drugs that increased 
DHCR7 expression compared to 73% for a known pregnancy-safe control. These results indicate 
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that screening for DHCR7 inhibition during the pre-clinical phase of drug toxicity may be 
helpful in identifying drugs with potential to induce adverse fetal outcomes before the drug is 
released to the market.  
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Development of a Machine Learning 




Many drugs commonly prescribed during pregnancy lack a fetal safety recommendation – called 
FDA ‘category C’ drugs. I present a data-driven approach to determine a drug’s likelihood for 
inducing fetal harm, focusing on fetal loss and congenital anomalies. The fetal loss cohort 
contains 14,922 affected and 33,043 unaffected pregnancies and the congenital anomalies cohort 
contains 5,658 affected and 31,240 unaffected infants. I trained a random forest to classify drugs 
of unknown pregnancy class. Models achieved an out-of-bag accuracy of 91% for fetal loss and 
87% for congenital anomalies outperforming null models. Fifty-seven ‘category C’ medications 
were classified as harmful for fetal loss and eleven for congenital anomalies. This includes 
medications with documented harmful effects, including naproxen, ibuprofen and rubella live 
vaccine. I also identified several novel drugs, e.g., haloperidol, that increased the risk of fetal 
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loss. My approach provides important information for pharmacologists and prescribers interested 
in drugs’ fetal effects. 
7.2 Introduction 
In the late 1950s a great medical tragedy began with the promotion of thalidomide, an approved 
sedative, as a new modern treatment for morning sickness (Dally, 1998). Thousands of pregnant 
women began taking the drug, which resulted in a dramatic increase in spontaneous abortion 
(i.e., ‘miscarriage’), and congenital abnormalities most notably shortened legs (Kim and Scialli, 
2011). By mid-1961 it became clear that thalidomide was the culprit behind the increase in 
malformations leading to the drug’s removal from the market (Smithells, 1962) and banned 
among women who may become pregnant. This experience led to the implementation of more 
stringent guidelines for drugs targeted at pregnant females.  
Over the years the number of medications taken by pregnant women has grown. Concern over 
this ‘epidemic of prescribing’ among pregnant women began in the 1970s (Hill, 1973). A study 
of Danish women found that 44.2% of women received prescriptions for at least one medication 
during pregnancy (Olesen et al., 1999). Anti-inflammatory drugs are commonly prescribed 
medications in pregnancy, which have been shown to increase the risk of miscarriage or fetal 
loss (Nielsen et al., 2001). However, in many cases the effects that specific pharmacologics have 
on fetal outcomes remains unknown. The Food and Drug Administration (FDA) lists 
pharmacological drugs with unknown fetal outcomes as category C (‘risk not ruled out’) drugs 
while those with known teratogenic properties (such as thalidomide) are listed as category X 
(‘contraindicated in pregnancy’). An estimated 37.8% of pregnant women receiving medications 
during pregnancy received an FDA category C drug (Andrade et al., 2004). Therefore, detailed 
study of these enigmatic drugs is greatly needed. 
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The purpose of this study is to systematically investigate the fetal outcomes, both fetal loss and 
congenital anomalies, following pharmacological exposure to category C drugs. This will 
provide both pharmacologists and physicians much needed information on the potential harms 
and benefits of these ‘unknown fetal effect’ drugs when they are considering prescribing them 
for pregnant women. Because fetal loss and congenital anomalies are two very different 
outcomes, I perform two separate cohort studies. In addition, I will focus some discussion on 
FDA category C drugs that target DHCR7, which are known to affect fetal outcomes (Boland 
and Tatonetti, 2016a). 
7.3 Methods 
7.3.1 Clinical Cohorts 
7.3.1.1 Maternal Prescription Exposure and Fetal Outcome: Live Birth  
Records were obtained on all infants born at the Columbia University Medical Center (CUMC) - 
New York Presbyterian Hospital (NYPH) healthcare system who had mothers listed in the 
Electronic Health Record (EHR) system. These links were created in the EHR system upon 
delivery to facilitate maternal-fetal care post-delivery. All mother-infant pairs with at least one 
medication prescribed before birth and up to 15 months prior were retained. I excluded all 
multiple infant pregnancies (e.g., twins, triplets), as these pregnancies are high-risk and subject 
to complications. I also excluded all pregnancies with any chromosomal abnormality diagnosed 
within the first three months of life (0-90 days of life). Presence of chromosomal abnormality 
was determined using the International Classification of Diseases, 9th edition (ICD-9) range 758-
758.9.  
Infants with congenital anomalies were identified as those having a congenital anomaly ICD-9 
diagnosis, i.e., 740-759 (with 758-758.9 excluded) occurring within the first 90 days of life. Only 
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one anomaly diagnosis was necessary for identification although some infants had multiple 
anomalies. Minor anomalies were identified using criteria established set by the New York State 
Department of Health. Only minor anomalies within the 740-759 range were used (NYSDOH, 
2007).  
7.3.1.2 Maternal Prescription Exposure and Fetal Outcome: Fetal Loss 
All pregnancies ending in fetal loss were identified as recorded at CUMC-NYPH. Fetal loss was 
defined as an ICD-9 code within the range: 630-639. Because I am interested in fetal outcomes 
following pharmacological exposure, I only included females with at least one medication 
prescribed up to 15 months prior to fetal loss. Fetal loss is this study includes spontaneous 
abortion (i.e. ‘miscarriages’), legal/elective termination and any other forms of fetal loss/death 
recorded within the ICD-9 range 630-639. Because a female may have more than one fetal loss 
code occurring on two separate dates (often during the course of a single hospital visit), I 
collapsed dates to the month level. For the control population, I used women with a successful 
fetal outcome (i.e., single live birth) recorded at CUMC-NYPH with at least one medication 
prescribed up to 15 months prior to birth and who had no diagnosis of fetal loss recorded at the 
hospital and whose infant was without chromosomal abnormality.  
7.3.2 Pharmacological Drug Information 
The Food and Drug Administration (FDA) pregnancy categories for all drugs included in the 
study were extracted from uptodate.com and drugs.com. While the FDA has recently updated 
this labeling system and moved away from the A-X categorization schema (Boothby and 
Doering, 2001), I chose to use it in this study because it allows researchers and physicians to 
easily identify drugs with unknown fetal effects (i.e., the category C drugs). If a particular drug-
combo was not listed with its own FDA pregnancy category designation then I used the most 
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severe pregnancy category from each drug in the combo. I also mapped each drug to its first-
level Anatomical Therapeutic Chemical (ATC) classification system, which classifies drugs 
based on the effects of the drug’s active ingredients on various organ systems. I also extracted 
the Mendelian genes either inhibited or affected (regardless of mechanism) for each drug using 
information from the Online Mendelian Inheritance in Man (OMIM) (URL: 
https://www.omim.org/). Because drugs targeting genes involved in vitamin processes may 
affect fetal risk (either protective or injurious), I also identified drugs that target at least one 
‘vitamin’ gene as noted on DisGeNET – a disease-gene association network (URL: 
http://www.disgenet.org/). 
The primary goal of this study is to find drugs that increase or decrease the risk of fetal loss 
following prenatal exposure. However, some prescription drugs / medications are used to induce 
legal termination or to treat subsequent conditions (e.g., hemorrhage, excessive bleeding, pain) 
and these drugs could bias the analyses. Therefore, I identified drugs given to women where the 
first prescription of the drug was the same day that the woman’s legal termination was 
performed. I calculated the proportion of legal terminations where a given prescription drug was 
first prescribed out of those terminations where prescription information was available. All drugs 
with at least 2% frequency were labeled as ‘drugs typically prescribed with legal termination’.  
7.3.3 Statistical Analysis 
7.3.3.1 Identifying Trimester of Drug Exposure 
For pregnancies that resulted in a single live birth, I used the average gestation period (i.e., 38 
weeks) as reported by the Centers for Disease Prevention and Control (CDC) (CDC, 2015). I 
then divided the 38-week pregnancy into three equal-sized periods (12.67 weeks each) as 
‘trimesters’. For pregnancies that resulted in fetal loss, I used the average time to fetal loss. CDC 
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reported that 91.6% of legal terminations occur within 13 weeks gestation with many other forms 
of fetal loss occurring prior to 13 weeks as well (CDC, 2017). Therefore, an exposure could have 
only occurred during the first trimester (i.e., one 12.67 week period). I also investigated two pre-
conception periods (each 3 months in size) where exposures could occur both for the fetal loss 
and congenital anomaly cohorts. This was to investigate the presence or absence of a drug’s pre-
conception effect. 
7.3.3.2 Classifying Category C Drugs Into Harmful and Non-Harmful Pregnancy Categories 
I only investigated drugs having at least 50 pregnancies across all exposure periods (e.g., first 
trimester, second trimester) to minimize statistical anomalies due to low data. I also excluded all 
drugs classified as FDA pregnancy category N (i.e., Not Classified) or drugs that were ‘Not 
Listed’.  
A logistic regression model was constructed to predict a binary pregnancy category either 
‘Detrimental to Fetus – D or X’ or ‘Not Harmful to Fetus – A or B’. Three models were built – 
one model for fetal loss, a second for congenital anomalies and a third for minor congenital 
anomalies only. This allowed me to determine Odds Ratios (OR) and significance in a full 
model. The full model includes 29 features: one for each of 14 ATC classifications, 5 features 
indicating the number exposed during each trimester category (3 trimesters plus two 3-month 
periods for the pre-conception period), 5 features indicated the proportion of exposed with an 
anomaly per trimester category, 1 binary indicator variable for whether Mendelian genes were 
inhibited (from OMIM), 1 binary indicator variable whether Mendelian genes were affected 
(from OMIM), one binary indicator variable for whether vitamin genes are affected (from 
DisGeNET), one binary indicator variable for whether or not the drug could be used as a prenatal 
supplement (e.g., vitamin, mineral, glucose), and one binary indicator variable for whether or not 
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the drug was a treatment for nicotine abuse (since exposure to smoking during the prenatal 
period is a known risk factor for fetal loss and anomalies). For the fetal loss model, I only had 25 
features because the majority of fetal losses occur during the first trimester and therefore I did 
not have variables for second and third trimester (either proportion of anomalies or exposed). 
Next, a random forest model was constructed for both fetal loss and congenital anomalies 
(separately) with 2000 trees using all possible features. Out-Of-Bag (OOB) error rates were 
estimated to assess the quality of each model. Features were ranked using the Mean Decrease in 
Accuracy (MDA) with more informative features having higher MDAs. I compared a drug’s 
probability of being harmful from each model for drugs with known FDA status and those with 
no recommendation (i.e., FDA category C drugs). Component analysis was performed using the 
proportion of fetal loss or the proportion with congenital anomaly per trimester of exposure to 
illustrate the relationship between adverse fetal outcomes and FDA pregnancy category. Code 
was implemented using R version 3.3.0. 
7.4 Results 
7.4.1 Clinical Cohort 
Females with live-born births at NYPH were extracted where data on maternal drug exposure 
was captured in the EHR (i.e., the female had at least one prescription recorded in the EHR 
within a 1.3-year period prior to the child’s birthdate). Infants with congenital anomalies were 
identified as those having a diagnosis within 90 days of life.  The resulting dataset contained 
31,240 pregnancies resulting in a live birth without a congenital anomaly and 5,658 pregnancies 
with a congenital anomaly (either major or minor). This indicated a baseline incidence of 15.33% 
for congenital anomalies. Of pregnancies with a recorded anomaly, 1,588 pregnancies had a 
minor anomaly. This cohort is referred to as the ‘congenital anomaly’ cohort while the cohort 
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containing the subset with minor anomalies is referred to as the ‘minor congenital anomaly’ 
cohort. Demographics of all pregnant females in both cohorts (i.e., congenital anomalies and 
fetal loss) that were included in this study are displayed in Table 22. 
For the ‘fetal loss’ cohort, patients were extracted with any recorded fetal loss/death as indicated 
by a diagnosis within the ICD-9 range 630-639. For controls, patients with no prior fetal loss in 
their EHRs were selected having at least one single live birth recorded at NYPH. This resulted in 
a dataset of 14,922 pregnancies with fetal loss and 33,043 pregnancies without fetal loss and 
satisfying the above criteria. Fetal loss in this study includes any form of fetal loss/death 
recorded within the ICD-9 range 630-639.  
7.4.2 Pharmacological Drug Dataset 
The FDA pregnancy categories for all drugs included in this study were obtained from 
uptodate.com and drugs.com. The categories and their descriptions are provided in Table 23 
along with the number of distinct drugs belonging to each category in both cohorts. Drugs 
labeled as ‘N: Not Classified’ or ‘Not Listed’ were excluded from all analyses. The most popular 
category was category ‘C: Risk Not Ruled Out’ followed by the lower risk category ‘B: No Risk 
in Other Studies’. Interestingly more distinct drugs belonged to category ‘D: Positive Evidence 
of Risk’ then category ‘A: No Risk in Controlled Human Studies’. I extracted the ATC first-level 
categories for all distinct drugs included in the analysis. The most popular categories were ‘A: 
Alimentary Tract and Metabolism’ followed by ‘D: Dermatologicals’ indicating that a wide 
diversity of drugs belonging to these two categories are prescribed to pregnant females (Table 
24). I also extracted information on genes listed in OMIM that the drugs in the dataset target, 
along with drugs that target vitamin-related genes from DisGeNET. Drugs were identified that 
were commonly prescribed with legal termination at NYPH as these could bias the fetal loss 
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results. Two drugs identified were common drugs used in chemical abortions: Mifepristone (200 
MG) and Misoprostol (0.2MG) (Schaff et al., 1999) and these were commonly prescribed at 
NYPH with legal termination (15.1% and 14.6% respectively). 
7.4.3 Classifying FDA Category C Drugs As ‘Harmful or ‘Not-Known-To-Be-Harmful’  
I constructed a logistic regression model with a binary outcome variable representing a non-
harmful pregnancy classification (i.e., FDA pregnancy category A or B) versus a severe 
pregnancy classification (i.e., FDA pregnancy category D or X). For both congenital anomaly 
models (i.e., all anomalies, and minor anomalies), I added all possible features that could inform 
the model to predict the accurate FDA pregnancy category. The odds ratios along with their 95% 
confidence intervals (CIs) are shown in Figure 30.  
In the fetal loss model, a drug belonging to the respiratory system category (ATC: R) increased 
the probability that the drug was either an A or B drug whereas, a drug belonging to the systemic 
hormonal preparations category (ATC: H) increased the probability that the drug was a harmful 
drug – either D or X. In the congenital anomalies model, drugs were more likely to be classified 
as A or B when a high proportion of anomalies was observed following exposure during the third 
trimester (t3).  
A simple random forest model was built using only the proportion with anomaly (for the 
congenital anomaly cohort) or the proportion with fetal loss (for the fetal loss cohort) at each 
trimester of exposure. The model was run with 1000 trees and I constructed a multi-dimensional 
scaling (MDS) component plot to illustrate the separation among drugs that can be achieved 
using only the proportion with anomaly/fetal loss. Fifty-eight medications were classified as 
harmful and 206 safe in the fetal loss cohort. Eleven medications were classified as harmful and 
181 safe in the congenital anomalies cohort. Figure 31 shows the separation between the known-
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harmful drugs (category D or X) in bright red from the not-known-to-be-harmful drugs in light 
blue (category A or B). The separation between the harmful and non-harmful drugs is most 
evident for the fetal loss cohort. I also separated out drugs that are used in legal termination to 
show where in the various plots those drugs appear (right-hand portion of Figure 31). In most 
cases drugs prescribe during legal terminations are harmful categories (category D or X) or 
cluster with known harmful drugs. 
A clear relationship was observed between the first MDS component and the proportion of 
women experiencing fetal loss following first trimester exposure to the drug (Figure 32). 
Because some of this effect could be due to legal termination, I separated out drugs empirically 
determined to be involved in legal termination procedures. This showed that the relationship was 
not fully due to drugs involved in legal termination. I also investigated the relationship between 
the proportions of women experiencing an offspring with a congenital anomaly following 
exposure across the three trimesters, but these results were not as stark.  
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Table 22.  Demographics of Pregnant Females Included in Study 
 
 Fetal Loss Dataset Congenital Anomaly Dataset 















Ethnicity       
Hispanic 13060 (39.5%) 6558 (43.9%) 0.215 12721 (40.7%) 2055 (36.3%) 0.123 
Not-Reported as 
Hispanic 
19983 (60.5%) 8364 (56.1%)  18519 (59.3%) 3603 (63.7%)  
Race   0.226    
Asian 877 (2.65%) 147 (0.99%)  755 (2.42%) 148 (2.62%) 0.076 
Black 3131 (9.48%) 1448 (9.70%)  2871 (9.19%) 539 (9.53%)  
Indian 59     (0.18%) 5 (0.03%)  52 (0.17%) 10 (0.18%)  
Other 9594 (29.0%) 3962 (26.6%)  8858 (28.4%) 1776 (31.4%)  
Pacific Islander 123   (0.37%) 87 (0.58%)  131 (0.42%) 24 (0.42%)  
Unidentified/Decli
ned/Unknown 
8580 (26.0%) 5775 (38.7%)  8672 (27.8%) 1634 (28.9%)  
White 10679 (32.3%) 3498 (23.4%)  9901 (31.7%) 1527 (27.0%)  
Age at birth/fetal 
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Table 23. FDA Pregnancy Categories and Descriptions 
FDA 
Category 




No. of Drugs 









A No Risk in Controlled 
Human Studies 
    
  No Risk To 
Fetus 
No Risk To 
Fetus 
20 15 
B No Risk in Other Studies     
  No Adequate 
Studies 
No Risk To 
Fetus 
  
  OR 147 125 
  No Risk To 
Fetus 
Risk To Fetus   
C Risk Not Ruled Out     
  No Adequate 
Studies 
Risk To Fetus 264 192 
D Positive Evidence of Risk     
  Risk To Fetus Risk To Fetus 37 26 
X Contraindicated in Pregnancy     
  Risk To Fetus – 
Including 
Anomalies 
Risk To Fetus 31 20 
N Not Yet Classified Into A 
Pregnancy Category 
    
  - - -  
Not Listed      
  - - -  
*Distinct Drug-Dosage Combos – A drug only has 1 FDA Pregnancy Classification 
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Table 24. ATC Classifications and Descriptions 
ATC 
Category 
Description No. of Drugs in Fetal 
Loss Dataset* 
No. of Drugs in Congenital 
Anomaly Dataset* 
A Alimentary Tract and Metabolism 131 113 
B Blood and Blood-Forming Organs 44 38 
C Cardiovascular System 53 41 
D Dermatologicals 81 65 
G Genito-Urinary System and Sex 
Hormones 
81 61 
H  Systemic Hormonal Preparations, 
excluding sex hormones and insulins 
21 18 
J Anti-infectives for Systemic Use 69 58 
L Anti-neoplastic and Immuno-
modulating agents 
15 10 
M Musculo-skeletal System 17 11 
N Nervous system 72 44 
P Anti-parasitic products, insecticides and 
repellents 
6 6 
R Respiratory System 76 53 
S Sensory Organs 60 49 
V Various 12 12 














































































































































































































































































































































































































































Figure 30. Odds Ratios from Logistic Regression Models: Fetal Loss, Congenital Anomaly and Minor Congenital 
Anomaly. ORs less than 1 indicate that the model predicts that feature to indicate that a drug is more likely to be a FDA 
Category D or X Drug. ORs greater than 1 indicate that the model predicts that feature to indicate that a drug is more 
likely to be a FDA Category A or B drug. In the fetal loss model, a drug having an ATC category of R (Respiratory 
System drug) increases the probability that the drug is an FDA Category A or B drug (i.e., a ‘good’ drug) while an ATC 
category of H (Systemic Hormonal Preparations excluding sex hormones and insulins) increases the probability that the 
drug is FDA Category D or X (i.e., a ‘harmful’ drug). 
 













































































































































































































































































































































































































































































































































Figure 31. Multi-Dimensional Scaling (MDS) Component Plots for: Fetal Loss, Congenital Anomaly and 
Minor Congenital Anomaly. The three subplots on the left hand side of the figure contain all drugs while on 
the right hand side of the figure contain only drugs typically prescribed with legal termination. Red drugs are 
those shown as category D or X, blue drugs are category A or B while category C drugs are shown as grey. For 
congenital anomalies, the proportion with an anomaly for each of the 5 exposure periods (2 pre-conception and 
3 trimesters) were included as features in this principal component analysis. For fetal loss, only the 2 pre-
conception periods and the first trimester were included. 
 
















































































































































































































































































































































































































































































Figure 32. Component vs. Proportion with Fetal Loss. There is a clear relationship between the first 
component and the proportion of individuals experiencing fetal loss following prenatal exposure to the drug. 
This effect is not entirely due to drugs prescribed for legal termination, which are shown separately in the right 
most subplots. 
 


















































































































































































































































































Figure 33. Mean Decrease in Accuracy (MDA) Plots for: Fetal Loss, Congenital Anomaly and Minor 
Congenital Anomaly. The higher the MDA score, the more informative the feature is to the model’s 
performance. This means that features towards the top of each subplot are the most indicative of whether a drug 
is known to be harmful (D or X) versus not-known-to-be-harmful (A or B). The number of individuals exposed 
to a drug at each trimester was highly informative of the drug’s pregnancy class (i.e., harmful (D or X) or not-
known-to-be-harmful (A or B)). This is intuitive as physicians often modify their behavior when they identify a 
woman as being pregnant and are less likely to give them a known harmful drug (i.e., D or X). ATC drug class N 
is also very predictive in all 3 models, but was more predictive for the congenital anomalies models then the fetal 
loss model. 
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Next I ran the model containing all potentially informative features in the random forest model 
with 2000 trees. Each feature’s contribution to the model’s performance was assessed using 
Mean Decrease in Accuracy (MDA). Features with high MDA are more important in 
contributing to the model’s performance. I found that the number of individuals exposed to a 
drug at a given trimester was highly informative in predicting whether a drug was harmful (i.e., 
D or X) versus not-known-to-be-harmful (A or B) as shown in Figure 33. This is intuitive as 
physicians often changing their prescribing behavior upon recognizing that a woman is pregnant. 
Therefore, they are not as likely to prescribe a new medication that is known to be harmful to a 
woman who is pregnant (D or X drug) making this feature to be very informative in all three 
outcome models. Interestingly, the proportion of those born with an anomaly following exposure 
to a drug for a given trimester was not as informative in the model indicating that FDA class 
affects the exposure pattern, but is not necessarily based on the overall fetal toxicity (as this is 
often unknown at the time the FDA class is assigned).  
Certain ATC drug classes were also found to be very informative in the model (Figure 33). The 
top five most informative ATC classes in predicting a drug’s FDA pregnancy category across all 
fetal outcome models were nervous system drugs (ATC: N), systemic hormonal preparations 
excluding sex hormones (ATC: H), anti-neoplastic and immune-modulating agents (ATC: L), 
genito-urinary system and sex hormones (ATC: G) and respiratory system (ATC: R). The 
ordering of the specific categories importance varied by model with ATC category N being the 
most informative feature overall in both the congenital anomalies (major and minor) and the 
minor anomalies only models.  
Importantly, a binary indicator variable for whether or not vitamin genes (from DisGeNET) were 
affected by a given drug was consistently more informative then whether or not a drug was 
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actually a prenatal supplement/mineral/vitamin (Figure 33). Additionally, whether or not 
Mendelian genes were affected or inhibited was more informative then whether or not a vitamin 
gene was affected indicating the importance of Mendelian genes in developmental processes. 
The out-of-bag (OOB) estimated error rate was 9.36% for the fetal loss model (containing 235 / 
499 drugs with known non-C FDA class), and 12.90% for both the congenital anomalies model 
(containing 186 / 378 drugs with known non-C FDA class) and the minor anomalies model (also 
containing 186 / 378 drugs with known non-C FDA class). This indicates that the estimated 
accuracy was 90.64% for the fetal loss model, and 87.10% for both anomalies models.  
Drugs predicted by the models to be similar to harmful drugs (D or X) in the fetal loss model are 
displayed in Table 25 (Overall OOB accuracy: 90.64%) and Table 26 shows drugs predicted to 
be harmful in the congenital anomaly model (Overall OOB accuracy: 87.10%). All known 
harmful drugs (D or X) had a model probabilityharmful above 50% while all not-known-to-be-
harmful (or safe) drugs (A or B) had a model probabilityharmful below 50% (Figure 34). Category 
C drugs, where no recommendation for pregnancy status is given, had probabilities of being 
harmful across the entire spectrum (Figure 34). All 192 category C drugs included in the 
congenital anomalies model were also included in the fetal loss model (fetal loss model 
contained 264 category C drugs). This allowed for the comparison of the probability that a drug 
was harmful in increasing the risk of fetal loss and congenital anomalies. These two probabilities 
were highly correlated (r=0.63, p<0.001). Drugs like rubella virus vaccine were predicted 
harmful in increasing the risk of fetal loss and also congenital anomalies (Figure 35). Some 
drugs, like Fentanyl and Benzocaine were only predicted harmful in one model. These drugs are 
likely to require further investigation to determine if there is a mechanistic reason for this 
difference. 
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Two drugs were predicted by the congenital anomalies model to be similar to harmful drugs that 
had very few exposures during the entire pregnancy (first through third trimesters) these drugs 
are Hydromorphone Hydrochloride (2MG) and Benzocaine (200MG/ML mucosal spray). 
Typically, physicians reduce pregnant females exposure to drugs that are labeled as category D 
or X drugs resulting in very few exposures during the first through third trimesters. The model 
detects drugs based on similar patterns. Since these two drugs had very low exposures during 
pregnancy they were detected as being potentially harmful drugs because their pattern of usage 
was similar. Other drugs, such as naproxen (2 different dosages) had a high rate of anomalies 
among exposed infants (even though the exposures were reduced during pregnancy versus pre-
conception period), which was another hallmark of category D or X drugs. The advantage of a 
machine learning approach is the ability to detect these patterns in prescribing (i.e., number of 
exposed) and also fetal severity of the drug (i.e., proportion with anomalies) in determining the 
predicted pregnancy class for category C drugs. 
7.5 Discussion 
The models successfully identified category C drugs that are likely to be harmful (D or X) and 
not-likely-to-be-harmful (A or B) across either fetal loss or congenital anomalies. This 
information is critical for pharmacologists seeking to understand placental and trans-placental 
effects and for physicians who may be considering prescribing a category C drug to a pregnant 
female. 
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Loss t1  
Alimentary Tract and Metabolism (ATC: A)    
Sodium Chloride 0.0769 MEQ/ML Injectable Solution 36.8 50 73.9 
3 ML Sodium Chloride 9 MG/ML Prefilled Syringe 68.8 90.5 74.1 
Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / Potassium 
Chloride 0.004 MEQ/ML / Sodium Chloride 0.103 MEQ/ML / Sodium 
Lactate 0.028 MEQ/ML Injectable Solution 39.8 57 87.4 
Magnesium Oxide 400 MG Oral Tablet 58.3 50 81.3 
Calcium Gluconate 100 MG/ML Injectable Solution 54.5 52.2 82.5 
Potassium Chloride 0.4 MEQ/ML Injectable Solution 41.7 46.7 88.1 
Potassium Chloride 10 MEQ Extended Release Oral Tablet 36.4 55.6 86.4 
Magnesium Hydroxide 80 MG/ML Oral Suspension 38.8 53.5 92.3 
Calcium Chloride 0.0014 MEQ/ML / Potassium Chloride 0.004 MEQ/ML / 
Sodium Chloride 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML 
Injectable Solution 43.6 47.6 87.2 
Cardiovascular System (ATC: C)    
Dexamethasone 4 MG Oral Tablet 50 81.8 91.3 
Hydrocortisone 25 MG/ML Topical Cream 50 72.7 70 
Ibuprofen 800 MG Oral Tablet 59.3 71.8 99 
Nifedipine 10 MG Oral Capsule 36.7 72.7 96.2 
24 HR Nifedipine 30 MG Extended Release Oral Tablet 36.7 60 86.2 
24 HR Nifedipine 60 MG Extended Release Oral Tablet 50 40 89.5 
Furosemide 20 MG Oral Tablet 50 33.3 85.2 
Labetalol hydrochloride 5 MG/ML Injectable Solution 23.5 28.6 88.5 
Genitourinary System and Sex Hormones (ATC: G)    
Naproxen 500 MG Delayed Release Oral Tablet 47.8 43.8 84.6 
Naproxen 500 MG Oral Tablet 46 49.1 83.3 
Dinoprostone 10 MG Drug Implant [Cervidil] 43.9 73.1 100 
1 ML Carboprost 0.25 MG/ML Injection [Hemabate] 56.3 85.7 100 
Methylergonovine Maleate 0.2 MG Oral Tablet 53.3 75 99.1 
Methylergonovine Maleate 0.2 MG Oral Tablet [Methergine] 45.9 75 100 
Methylergonovine Maleate 0.2 MG/ML Injectable Solution [Methergine] 45.2 57.1 97.9 
Pain-Reliever Combination Drugs (ATC: N)    
Acetaminophen 300 MG / Hydrocodone Bitartrate 10 MG Oral Tablet 77.8 100 99.2 
Acetaminophen 325 MG / Codeine Phosphate 30 MG Oral Capsule 51.9 60.9 98.6 
Acetaminophen 325 MG / Oxycodone Hydrochloride 5 MG Oral Tablet 36.6 45.3 90.4 
Acetaminophen 650 MG Rectal Suppository [Acephen] 60.3 61.4 85.8 
Anti-Depressant or Anti-Psychotic (ATC: N)    
Sertraline 100 MG Oral Tablet 60 41.7 68.4 
Sertraline 25 MG Oral Tablet 71.4 50 75 
Sertraline 50 MG Oral Tablet 53.3 41.7 76.2 
Prochlorperazine 10 MG Oral Tablet 76.9 85.7 73.7 
Prochlorperazine 5 MG Oral Tablet 75 64.3 84.6 
Citalopram 20 MG Oral Tablet 27.3 29.4 71.4 
Haloperidol 5 MG Oral Tablet 40 70 78.3 
Haloperidol 5 MG/ML Injectable Solution 22.2 50 78.6 
Fluoxetine 20 MG Oral Capsule 41.7 50 91.7 
Trazodone Hydrochloride 50 MG Oral Tablet 57.1 38.9 45 
Migraines or Anti-Seizure (ATC: N)    
Sumatriptan 25 MG Oral Tablet 62.5 65 75 
Gabapentin 300 MG Oral Capsule 40 44.4 57.1 
Sedative (ATC: N)    
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Zolpidem tartrate 10 MG Oral Tablet 37.5 62.5 84.1 
Zolpidem tartrate 5 MG Oral Tablet 39.8 49.8 90.3 
Opioid (ATC: N)    
Butorphanol Tartrate 2 MG/ML Injectable Solution 62.2 75 83.3 
Hydromorphone Hydrochloride 2 MG Oral Tablet [Dilaudid] 45 53.8 69.6 
Hydromorphone Hydrochloride 2 MG/ML Injectable Solution 55.4 48.6 88 
1 ML Hydromorphone Hydrochloride 1 MG/ML Injection 47.1 42.5 91.6 
Morphine Sulfate 10 MG/ML Injectable Solution 14.3 61.5 90 
Morphine Sulfate 2 MG/ML Injectable Solution 41.7 48.5 84.9 
Morphine Sulfate 4 MG/ML Injectable Solution 50.9 54.7 90.9 
12 HR Oxycodone Hydrochloride 10 MG Extended Release Oral Tablet 27.3 50 100 
Oxycodone Hydrochloride 5 MG Oral Tablet 57.4 49.5 85 
Tramadol hydrochloride 50 MG Oral Tablet 28.6 33.3 75 
Fentanyl 0.05 MG/ML Injectable Solution 70.6 62.1 98.7 
Respiratory System (ATC: R)    
Promethazine Hydrochloride 25 MG Oral Tablet 96.2 89.4 97.7 
Musculoskeletal / Sensory System (ATC: M and S)    
1 ML Ketorolac Tromethamine 30 MG/ML Prefilled Syringe 46.4 47.9 91 
Various Systems (ATC: V)    
Naloxone Hydrochloride 0.4 MG/ML Injectable Solution 55.6 57.1 96.1 
Vaccine    
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML 
Injectable Solution 37 47.5 96.4 
Bold italics indicates that drug was implicated in adverse fetal outcomes for both the fetal loss model and the 
congenital anomaly model. 
t-2: Pre-conception effect: -6 to -3 months before conception 
t-1: Pre-conception effect: -3 to 0 months before conception 
t1: First Trimester 
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Table 26. Category C Drugs Predicted to be Harmful (D or X): Congenital Anomalies Cohort  






















Pain Reliever       
Benzocaine 200 MG/ML 
Mucosal Spray 13.4 10.7 0 0 0 
RGDP 
NSAID       
Ibuprofen 200 MG Oral Tablet 12.2 18.6 29.2 0 0 1st 
Ibuprofen 800 MG Oral Tablet 16.9 14.1 20 12.5 0 1st -2nd  
Naproxen 250 MG Oral Tablet 14.3 8 50 0 0 1st  
Naproxen 500 MG Oral Tablet 12.9 13.2 7.7 20 0 1st -2nd 
Opioid       
Butorphanol Tartrate 2 
MG/ML Injectable Solution 
5 14.3 0 0 10.4 3rd 
Hydromorphone Hydrochloride 
2 MG Oral Tablet [Dilaudid] 
9.1 14.3 0 0 0 RGDP 
Hydromorphone Hydrochloride 
2 MG/ML Injectable Solution 
10.7 9.5 0 6.1 12.8 2nd – 3rd 
Steroid       
Hydrocortisone 25 MG/ML 
Topical Cream 57.1 12.5 0 5.6 3.9 
2nd – 3rd  
Cervical Implant       
Dinoprostone 10 MG Drug 
Implant [Cervidil] 9.2 16.7 0 0 13.5 
3rd 
Vaccine       
Rubella Virus Vaccine Live 
(Wistar RA 27-3 Strain) 2000 
UNT/ML Injectable Solution 12.6 8.5 20 0 15 
1st or 3rd  
 
* RGDP: Rarely Given During Pregnancies Ending in Liveborn Infants. The dramatic drop off in prescribing 
throughout the entire pregnancy (t1-t3) is why these drugs were labeled as likely to be harmful during pregnancy (D 
or X) due to similar patterns being observed for drugs that are known to be harmful.  
 
Bold italics indicates that drug was implicated in adverse fetal outcomes for both the fetal loss model and the 
congenital anomaly model. 
t-2: Pre-conception effect: -6 to -3 months before conception 
t-1: Pre-conception effect: -3 to 0 months before conception 
t1: First Trimester 
t2: Second Trimester 
t3: Third Trimester 
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Figure 34. Model Probability of Being a Harmful Drug (D or X). The top portion of the graph shows drugs 
with known FDA pregnancy class. All drugs above the 50% probability threshold were predicted to be harmful 
and were harmful (three top graphs) across all models including fetal loss, congenital anomaly and minor 
congenital anomalies alone. In the lower three graphs FDA category C drugs are included (depicted in light 
grey). These drugs have no FDA recommendation regarding their safety during pregnancy. The majority of these 
drugs were predicted to be pregnancy safe (less than 50% probability of being harmful). While some drugs were 
above the 50% threshold and were more similar to known harmful drugs. 
 
 









































































































































































































































Figure 35. Model Probability of Being a Harmful Drug (D or X) in Congenital Anomaly Model vs. Fetal 
Loss Model for Category C Drugs (i.e., those with no FDA recommendation). The model probabilities for a 
drug’s harmful status were highly correlated (r=0.63, p<0.001) between both congenital anomaly and fetal loss 
models. NSAIDs like naproxen were predicted harmful by both models. Also live rubella vaccination was 
harmful in both models. Other drugs were predicted harmful in increasing the risk of either fetal loss only (lower 
right hand quadrant) or congenital anomalies only (upper left hand quadrant). These may require further 
investigation to determine the mechanistic rationale for their predicted harm in one fetal outcome over the other. 
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7.5.1 Drugs Predicted Harmful in Congenital Anomaly Model 
Eleven distinct medications or eight distinct drugs were predicted to be harmful (D or X) in the 
congenital anomalies model. I developed a machine-learning algorithm to predict drugs that were 
harmful based on anomaly rates and usage patterns for drugs with known FDA pregnancy 
classifications. This machine learning approach predicts a drug to be harmful if one of the 
following conditions is met: a.) drug exposure results in a high proportion of anomalies; b.) the 
drug’s usage was greatly restricted during pregnancy (i.e., females were exposed during pre-
conception period at much higher rates then during pregnancy; and c.) drug was similar to known 
harmful drugs in terms of mechanism (e.g., ATC classification, drug targets proteins involved in 
Mendelian diseases, drug targets known vitamin-related proteins).  
7.5.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
Two predicted harmful drugs (and 4 distinct medications) were Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs), namely ibuprofen and naproxen. Several studies report an 
increased risk of anomalies, specifically cardiac anomalies among infants exposed to either 
naproxen, ibuprofen, NSAIDs generally or combinations of those drugs (Ericson and Källén, 
2001; Ofori et al., 2006). In most cases studying the effects of NSAIDs on fetal anomalies, the 
drugs - naproxen and/or ibuprofen - were often associated with the most number of congenital 
anomalies (Ericson and Källén, 2001; Hernandez et al., 2012). For both drugs, this study 
observed the highest risk among first and second trimester exposures, with higher risk among 
naproxen users than ibuprofen users (Table 26). 
7.5.1.2 Live Rubella Vaccine 
Maternal exposure to ‘Rubella Virus Vaccine Live’ was predicted to be harmful by my algorithm 
(D or X). It should be noted that live rubella vaccine is not indicated in pregnancy and often 
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occurred in the pre-conception and first-trimester period of the pregnancy. The proportion of 
females exposed to the vaccine whose infant was born with a congenital anomaly was high. For 
the pre-conception period 6-3 months prior to conception the rate of anomaly following exposure 
to live rubella vaccine was 12.58%, and 8.47% in the period 3-0 months prior to conception and 
a rate of 20% with anomalies for first trimester exposure. A very low number of females were 
exposed during the second trimester (most likely because live rubella vaccine is contra-indicated 
during pregnancy) and therefore no anomalies were reported among those first exposed during 
the second trimester. However, a rate of 15% with anomalies was observed for those exposed 
during the third trimester (Table 26). 
The relationship between rubella virus and fetal anomalies is well known and described in the 
literature (Cooper and Krugman, 1967) (Swan et al., 1943; Webster, 1998). In fact, a single 
epidemic of rubella caused more birth defects in the United States then thalidomide during the 
entire time that it was on the global market (Webster, 1998). Increases in both anomalies and 
fetal loss were observed in women infected with rubella during pregnancy (Naeye and Blanc, 
1965; Rudolph et al., 1965). Exposure to live rubella vaccine was considered harmful (D or X) in 
both the congenital anomaly models and also the fetal loss model (Table 25) indicating an 
increased risk of fetal loss as well as an increased risk of anomalies. This is consistent with the 
literature on the harms of inadvertent exposure to rubella during the early stages of pregnancy. 
This study also shows some evidence of a pre-conception effect at least 6 months prior to 
conception. Pre-conception effects of maternal rubella have been reported in past epidemics 
(Wolff, 1972), but not in the vaccination context. One study from Turkey found seventeen 
infants inadvertently exposed to the rubella vaccine either in the first month of pregnancy or just 
prior to conception and all 17 showed no signs of congenital rubella syndrome (Ergenoglu et al., 
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2012). Evidence from the epidemics shows that third trimester exposure to rubella was 
associated with more ocular issues while preconception rubella was associated with severe 
outcomes, but no reported ocular issues (five pregnancies reported in literature: two spontaneous 
abortions, two neonatal deaths, and one live-born without ocular issues) (Wolff, 1972). From the 
fetal loss cohort, 96.4% of those receiving rubella vaccination in the first trimester (83 exposed 
during first-trimester in fetal loss cohort) resulted in a fetal loss (Table 25). This indicates the 
severity of first-trimester rubella exposure on fetal outcomes underscoring the importance of 
avoiding rubella vaccination prior to conception. 
7.5.1.3 Two Drugs Rarely Given During Pregnancy – Predicted Harmful in Congenital 
Anomaly Model 
Two drugs were rarely prescribed during pregnancy – Benzocaine mucosal spray and 
Hydromorphone Hydrochloride (Dilaudid), but were prescribed during the pre-conception 
period. This sudden drop-off in prescribing resulted in my algorithm detecting these two drugs as 
harmful (D or X) given that a similar drop-off in prescribing is often observed in known harmful 
(e.g., category X) drugs. Hydromorphone Hydrochloride (Dilaudid) is an opioid and therefore 
would typically not be prescribed during pregnancy given the harm that opioids are known to 
have on developing fetuses (Brennan and Rayburn, 2012). The other medication – benzocaine 
mucosal spray – is somewhat interesting. While a category C drug, benzocaine has been linked 
to development of methemoglobinemia in infants and because of the availability of safer 
category B medications is considered by many physicians to be contra-indicated during 
pregnancy according to several research papers (Lee et al., 2013; Peterson, 1960). My machine 
learning approach did not know this information a priori, but it was able to learn this from the 
physicians’ usage pattern of the drug (i.e., dramatic drop-off of prescribing during pregnancy), 
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which is indicative of a category D or X drug. The ability to detect these types of potential D or 
X drugs is also of value to the pharmacology community since these drugs are treated as harmful 
by traditional standards of care. 
7.5.2 Drugs Predicted Harmful in Fetal Loss Model 
7.5.2.1 Drugs Treating Symptoms of Fetal Loss 
Some drugs predicted to be harmful in the fetal loss cohort could have been prescribed to treat 
conditions leading up to a spontaneous abortion. For example, excessive bleeding often occurs 
during a spontaneous abortion, but this can take several days depending on the type of 
miscarriage. A drug used to treat severe bleeding following childbirth, or miscarriage, is 
Methylergonovine Maleate. All forms of Methylergonovine Maleate (3 different types listed in 
Table 25) had high rates of miscarriage following first trimester exposure – ranging from 97.9 – 
100% of those exposed during that trimester. Typically, Methylergonovine Maleate would not be 
prescribed during the first trimester, unless something was wrong (e.g., excessive bleeding, 
which is indicative of a miscarriage). Therefore, this is likely a treatment-of-the-fetal-loss type of 
result. 
7.5.2.2 Drugs That May Inadvertently Induce Fetal Loss: Diuretics 
Furosemide is a potent diuretic with evidence of fetal-lethality among animals especially rabbits 
(FDA, 2012). Human studies involving fetal exposure to furosemide are sparse (i.e., indicative of 
a true FDA ‘category C’ drug). I found that 85.2% of pregnancies exposed during the first 
trimester resulted in fetal loss among the cohort. In general, diuretics are discouraged during 
pregnancy even as a treatment for hypertension when benefits may outweigh risks (Cunningham 
and Lindheimer, 1992), indicating the potential fetal harm of diuretic exposure, in general, on a 
developing fetus. 
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7.5.2.3 Drugs That May Inadvertently Induce Fetal Loss: DHCR7 Mechanism 
Haloperidol was found to increase the risk of fetal loss following first trimester exposure. 
Haloperidol injection increased risk of fetal loss from 22.2% in the 3-6 months prior to 
conception to 78.6% if the exposure was in the first trimester. Nine pregnancies were exposed in 
the 3-6 month period pre-conception while 28 pregnancies were exposed during the first 
trimester – 22 resulted in fetal loss. Haloperidol is important as it is known to increase the 
expression of 7-dehydrocholesterol reductase (DHCR7) - an enzyme important in the conversion 
of 7-dehydrocholesterol to cholesterol (Boland and Tatonetti, 2016a). While exposure to 
pharmacological inhibitors of DHCR7 is known to result in fetal anomalies, the effects of drugs 
that merely increase the expression of the gene are less-well known. Drugs increasing expression 
of DHCR7 are not known to increase fetal loss (Boland and Tatonetti, 2016a). However, early 
fetal loss can be difficult to capture in many situations, whereas congenital anomalies in live-
born babies is often easier to measure in case studies. DHCR7 is known to be important in 
regulating two very important processes for fetal development – cholesterol and vitamin D and 
perturbation of either of these important hormones is likely to adversely affect a fetus. 
Some research suggests that neural toxicity of haloperidol can be rescued through a vitamin E 
mechanism (Behl et al., 1995). Variations in female’s vitamin E concentrations could potentially 
explain variability observed in case studies and reported here with regards to fetal toxicity of 
haloperidol exposures. Therefore, increases in risk of fetal loss among first trimester exposure to 
haloperidol injections may be due to these underlying biochemical mechanisms. 
7.5.3 Genetic Targets of Drugs More Predictive Than Classification 
Prenatal vitamin supplementation is extremely important in reducing the overall disease risk of 
the offspring. For example, research has linked prenatal vitamin supplementation with lower 
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rates of leukemia, pediatric brain tumors and neuroblastoma (Goh et al., 2007). I restricted the 
analyses to identification of congenital anomalies diagnosed within the first 90 days of life. 
Therefore, I did not investigate complex outcomes such as childhood cancers or autism. 
However, vitamin-exposure during the prenatal period is widely considered to be an important 
variable in predicting fetal outcome. Hence, I included information on whether a drug was a 
vitamin or not in the models. In addition, I added information on whether a drug affected any 
vitamin-related protein. All models showed that knowing whether or not a drug affected a 
vitamin-related protein was more important then just knowing that a drug was a prenatal 
supplement (Figure 33). This is critical because it shows that a drug’s mechanism of action and 
how it interfaces with vitamin-related mechanisms is extremely important in determine the fetal 
outcomes following drug exposure. This was known for certain drugs (Boland and Tatonetti, 
2016a), but not across a larger cohort of fetal drug exposures. This has important clinical and 
pharmacological applications for future fetal toxicity studies. 
7.6 Limitations 
One drug predicted as harmful in the congenital anomalies model, was a cervical ripener - the 
drug implant Dinoprostone (or Cervidil). Cervical ripeners are drug-devices that are inserted into 
the vagina-cervix area for the induction of labor. It is possible that it was predicted as harmful 
because high-risk pregnancies are at increased risk of complications during delivery, which may 
lead to a higher-risk of congenital anomalies (Sunitha et al., 2017). My method identifies drugs 
predicted to be harmful given their prescribing patterns (e.g., low exposure during pregnancy), 
anomaly rates (e.g., proportion of exposed with an anomaly) and other factors often important in 
determining fetal effect (e.g., affecting proteins involved in vitamin-related processes). Further 
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study is needed to confirm that drugs predicted to be ‘not-known-to-be-harmful’ (i.e., similar to 
A or B category drugs) are in fact not harmful to the developing fetus. 
7.7 Conclusion 
In conclusion, I developed a machine learning approach that predicts drugs to be either harmful 
(D or X) or not-known-to-be-harmful (A or B) in two outcome models – fetal loss and congenital 
anomalies. Some drugs were predicted to be harmful because physicians stopped prescribing 
them upon pregnancy diagnosis – this dramatic drop-off in exposure rates triggered the algorithm 
to detect the drug as harmful (since a similar pattern is observed among drugs that are known to 
be harmful). Other drugs were predicted to be harmful because of the increase in anomalies 
observed following exposure - and many of these were validated in the literature, e.g., first 
trimester exposure to rubella live vaccine. Additionally, I found that first trimester exposure to 
haloperidol – a drug that interferes with the DHCR7 – cholesterol – vitamin D pathway increased 
the risk of fetal loss. The models achieved an OOB estimated accuracy of 90.6% for fetal loss 
and 87.1% for congenital anomalies. The model confirmed that NSAIDs – naproxen and 
ibuprofen – increased the risk of congenital anomalies, a finding reported in the literature. My 
approach provides much needed information for pharmacologists and prescribers interested in 
understanding the fetal effects of drugs.  
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In this dissertation, I have set out to explore the relationship between the seasonal factors of early 
development (both prenatal and perinatal) and how those seasonal factors affect later risk of 
disease. The goal of my work was to be applicable to both clinicians and pharmacologists by 
increasing the understanding of how these factors affect human health and disease. 
While many birth month or birth season studies have been conducted throughout the world, no 
one previously has established whether or not birth season is causal in later risk of disease in a 
general sense. To that end, I have utilized nine criteria set forth by Dr. Hill to determine whether 
there is enough evidence underlying an association to suggest if it is causal or not (Hill, 1965). 
These nine criteria are known as Hill’s criteria for causality. Various aims, described in separate 
chapters, address seven of nine of the Hill’s criteria to establish that enough evidence does exist 
for a causal relationship between birth season and later risk of disease in a general sense. 
The criteria addressed by this dissertation include: strength, consistency, specificity, biological 
gradient, plausibility, coherence and experiment. Analogy and temporality were not addressed. 
Testing for analogy was not necessary because phenocopies of the birth season – disease effect 
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can be directly tested using pharmacological inhibitors (typically analogy is used in lieu of other 
criteria). Additionally, I did not directly address temporality. Associations were tested using 
exposures taken at different sites to determine if the birth month – disease risk covaried along 
with the exposure. Table 27 outlines the seven of nine Hill criteria addressed in this dissertation 
and how a link between birth month/seasonality and lifetime disease risk appears solid across 
many studies of diverse types conducted as a result of this dissertation. 
Through this work, I identified several climate (e.g., rainfall, sunlight) and pollutant drivers (e.g., 
carbon monoxide) that were correlated with the birth season – disease effect across multiple sites 
throughout the world. These associations represent strong proof for the existence of birth season 
– disease relationships. In the second section of this dissertation, I explore mechanistic 
explanations for the population-level insights gained in the first half of the dissertation.  
To that end, I first explored connections between genes involved in seasonal processes (e.g., 
vitamin D, folate regulation) and genes involved in diseases where risk is modulated by birth 
season (e.g., diabetes, hypertension). Then, I investigated the use of proxies (pharmacological 
inhibitors) to test retrospectively if the fetal outcomes mimicked what was observed in adults 
albeit more severe (Boland and Tatonetti, 2016a). 
Drugs that target genes involved in vitamin D processes (specifically DHCR7) resulted in 
adverse fetal effects upon prenatal exposure. A deep exploration of drugs that inhibit DHCR7 
showed increased fetal malformations and anomalies (Boland and Tatonetti, 2016a). Drugs that 
increased DHCR7 expression were shown to increase the risk of fetal loss (‘miscarriage’) 
following the development of a machine learning algorithm used on EHRs at CUMC (Boland et 
al., 2017d). 
In addition, I was able to provide much needed information on the fetal toxicity or the lack 
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thereof for many drugs with no prior FDA recommendation with regards to their pregnancy 
status (i.e., FDA category C drugs). This information is very useful for clinicians, 
pharmacologists and women considering taking a medication during pregnancy that is 
determined to be category C. This included category C drugs that did not necessarily target a 
known seasonal gene/protein. This is also important because the pharmacological action of drugs 
is still in the nascent stage. Many of these drugs identified to be harmful through my machine 
learning approach may in fact target vitamin – related processes that have yet to be identified at 
this early stage. This dissertation establishes that birth month / season is an important factor in 
later risk of disease. Further, pharmacological perturbation of proteins undergoing seasonal 
regulation increases the risk of fetal harm. Informatics-methods can be used to combine both 
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Table 27. This Dissertation In the Context of Hill’s Nine Criteria:  
Determining Causality for the Birth Month – Health Relationship 
Criterion 
 
Desc. Desc. As Related to Birth Season 
Effect 
Aim  Ch. Reference 
Strength How strong is the 
association? 
What is the Relative Risk by birth 
month for disease associations? 
1 2 (Boland et al., 
2015b) 
Consistency Is the association repeatedly 
observed by different 
persons, places, and times 
Are findings replicated at other 
sites? 
1 2,3  (Li et al., 2016)  
(Boland et al., 
2017b) 
Specificity Is the association between 
occupation x and disease y 
specific? Or is a plethora of 
diseases associated with 
occupation x? 
Do disease categories cluster 
around certain birth seasons? 
1 2 (Boland et al., 
2015b) 
Temporality Does the cart come before 
the horse? Or the horse 
before the cart? What items 
are the cart and what is the 
horse 
Does sunlight exposure (or other 
climate variable) precede disease 
risk curve?  





Does increasing the particular 
climate variable (e.g., sunlight) 
correspondingly affect the birth 
season – disease effect?  
2 3 (Boland et al., 
2017b) 
Plausibility Biological plausibility – is 
there a known mechanism 
that can explain the 
observation? 
Does the effect we observe fit with 
what is known about the particular 
climate variable (e.g., sunlight) 
and its effect on the body and 
prenatal gene expression 
3 5 (Boland and 
Tatonetti, 
2016c) 
Coherence All findings related to the 
association should 
contribute to the overall 
mechanism involved (adds 
weight to the mechanism 
being correct) 
When associations are found or 
failed to be found at certain sites – 
does it fit with what we know 
about the climate drivers 
underlying the relationship? 
2 3 (Boland et al., 
2017c);  
(Boland et al., 
2015a) 
Experiment Direct experimental 
evidence (gene knockout, 
phenocopy of birth season 
effect) 
Using drugs as a phenocopy for 
the birth season – disease effect, 
can we mimic the climate driver’s 
effect on prenatal outcomes 
through the use of a 
pharmacological inhibitor? 
4 6, 7 (Boland and 
Tatonetti, 
2016a) 
(Boland et al., 
2017d) 
Analogy We can learn from 
thalidomide and rubella and 
through the use of analogy 
accept slighter but similar 
evidence with another drug 
or viral disease when 
exposed during pregnancy. 
Perhaps compare birth season 
effect to drug exposures during 
pregnancy through use of the 
phenocopy approach – however 
this can be done directly (see 
Experiment) and use of Analogy is 
not necessary 
-  - 
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